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1 ABSTRACT	
	
	
Numb	was	originally	 identified	as	a	determinant	of	cell	 fate	 in	Drosophila,	and	more	re-
cently	as	a	tumor	suppressor	in	different	human	cancers.	Our	lab,	in	particular,	has	contrib-
uted	 to	 the	 characterization	 of	 Numb	 as	 a	 tumor	 suppressor.	 Indeed,	we	 showed	 that	
Numb	protein	expression	 is	 lost	 in	~30%	of	breast	cancers	 (BCs)	and	associates	with	an	
adverse	prognostic	outcome.	At	the	cellular	level,	Numb	loss	results	in	uncontrolled	prolif-
eration,	impaired	response	to	genotoxic	treatments	and	emergence	and	amplification	of	
the	cancer	stem	cell	pool,	while	at	the	molecular	level,	it	leads	to	enhanced	Notch	onco-
genic	signaling	and	reduced	expression	of	the	tumor	suppressor	protein	p53.	
Under	physiological	conditions,	Numb	acts	to	stabilize	p53	protein	by	binding	to	and	inhib-
iting	the	activity	of	Mdm2,	the	E3	ligase	that	mediates	p53	ubiquitination	and	subsequent	
degradation.	A	detailed	structural	characterization	of	the	Numb:Mdm2	binding	interface,	
recently	performed	in	our	lab,	has	revealed	that	a	short	Numb	region	encoded	by	the	al-
ternatively	spliced	exon	3	was	necessary	and	sufficient	to	bind	to	Mdm2	and	prevent	p53	
degradation.	This	region	is	only	present	in	two	out	of	the	four	main	Numb	isoforms	(Numb	
1	and	2,	hereafter	referred	to	as	Numb	1/2).		
Based	on	these	findings,	we	hypothesized	that	the	tumor	suppressor	role	of	Numb	might	
be	mediated	specifically	by	isoforms	1	and	2,	and	that	altered	splicing	could	represent	a	
novel	mechanism	responsible	for	the	functional	loss	of	Numb	in	tumors.		
To	test	these	possibilities,	we	performed	a	series	of	experiments	aimed	at	elucidating	the	
specific	roles	of	Numb	isoforms	in	cancer	and	their	contribution	to	tumorigenesis.	In	par-
ticular,	we	 characterized	Numb	 isoforms	expression	 in	BC	 cells	 and	 investigated	 the	 in-
volvement	of	 the	expressed	 isoforms	 in	 the	 regulation	of	 the	p53	pathway.	Our	 results	
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point	to	the	exclusive	role	of	Numb	1/2	isoforms	in	the	regulation	of	the	Mdm2-p53	cir-
cuitry.	Loss	of	Numb	1/2	in	p53-WT	BCs	 leads	to	reduced	p53	levels	and	activity	and	an	
accumulation	of	DNA	damage	upon	genotoxic	stress.	Accordingly,	primary	BC	cells,	display-
ing	 reduced	 levels	 of	 Numb	 1/2,	 exhibited	 increased	 chemoresistance,	 indicating	 that	
Numb	splicing	patterns	could	influence	therapy	response	in	BC	patients.	
Moreover,	we	performed	a	large-scale	RT-qPCR-based	screening	of	a	case-cohort	of	890	
breast	tumors	to	uncover	the	impact	of	the	different	Numb	isoforms	on	clinical	outcome.	
We	unmasked	an	increased	risk	of	distance	metastasis	in	patients	expressing	low	levels	of	
Numb	1/2,	which	was	more	evident	in	the	p53-WT	BCs,	in	accordance	with	our	results	on	
the	role	of	Numb	1/2	in	p53	regulation.	A	similar	prognostic	effect	was	also	observed	in	BCs	
displaying	low	levels	of	total	Numb	mRNA,	revealing	that,	alongside	the	well-characterized	
mechanism	of	Numb	hyperdegradation,	also	pre-translational	mechanisms	contribute	to	
Numb	loss	in	BC.	Our	analysis	also	revealed	worse	prognosis	in	BC	patients	displaying	low	
levels	of	Numb	isoforms	1/3	and	2/4	(with	or	without	the	exon	9	coded-region,	respec-
tively),	suggesting	a	more	complex	scenario,	in	which	the	differential	role	of	Numb	isoforms	
in	pathways	other	than	p53,	such	as	the	Notch	pathway,	might	contribute	to	tumorigenesis.	
Together,	our	results	indicate	that	the	aberrant	alternative	splicing	of	Numb	towards	exon	
3	 skipping	 events	 (leading	 to	 a	 reduction	 in	 Numb	 1/2	 levels),	 could	 increase	 chemo-
resistance	and	contribute	to	tumor	progression	in	p53-WT	BCs.	Moreover,	additional	layers	
of	Numb	deregulation,	independent	of	hyperdegradation,	could	account	for	loss	of	Numb	
in	BCs.	These	findings	offer	new	strategies	for	stratifying	BC	patients	according	to	Numb	
status,	and	possibly	new	therapeutic	options	to	re-establish	the	Numb-p53	physiological	
circuitry	in	breast	tumors.	
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2 INTRODUCTION	
This	thesis	explores	the	role	played	by	the	different	isoforms	of	the	protein	Numb	and,	in	
particular,	 their	 involvement	 in	 tumorigenesis.	 In	 this	 introduction,	 I	 will	 provide	 an	
overview	 of	 the	 different	 Numb	 functions,	 starting	 from	 its	 discovery	 as	 a	 cell	 fate	
determinant	in	Drosophila	(Section	2.1)	and	ending	with	its	well-characterized	role	as	an	
endocytic	 adaptor	 protein	 and,	 more	 recently,	 as	 a	 tumor	 suppressor	 (section	 2.4).	 A	
particular	 focus	 will	 be	 placed	 on	 the	 latter	 point	 and	 the	 Numb-Mdm2-p53	 circuitry	
(section	 2.3.4),	 considering	 the	 key	 role	 that	 this	 circuitry	 plays	 in	 the	 cell	 and	 how	 its	
deregulation	has	a	profound	impact	on	tumorigenesis	(section	2.3.4.5).	Finally,	the	last	part	
of	 the	 introduction	will	 be	 focused	 on	 the	 consequences	 of	 loss	 of	 Numb	 in	 cancer	 to	
provide	 the	 rationale	 for	 possible	 therapeutic	 interventions	 in	 Numb-deficient	 tumors	
(section	2.3.4.6).	
	
2.1 NUMB	 FROM	 ITS	 DISCOVERY…THE	 LESSON	 FROM	
DROSOPHILA		
Numb	was	originally	 identified	as	a	cell	 fate	determinant	during	Drosophila	nervous	and	
muscle	system	development	1.	Loss	of	functional	protein	in	Drosophila	mutants	causes	flies	
to	 become	 “numb”,	 since	 it	 dramatically	 affects	 sensory	 neuron	 maturation	 during	
peripheral	 nervous	 system	 (PNS)	 development	 2.	 The	 complex	 molecular	 mechanisms	
involved	in	the	generation	of	the	bristle	sensory	organ	is	organized	as	a	hierarchical	pattern	
of	asymmetric	cell	divisions	(ACD)	from	a	sensory	organ	precursor	(SOP)	cell	to	give	rise	to	
all	the	differentiated	cells	that	constitute	the	architecture	of	the	external	sensory	organ,	a	
component	of	the	PNS	3.	
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Numb	is	uniformly	distributed	in	the	cytosol	of	the	SOP	cell	during	interphase	and	then	is	
asymmetrically	distributed	towards	one	of	the	spindle	poles	during	cytokinesis.	This	event	
drives	the	acquisition	of	alternative	developmental	fates	in	the	daughter	cells	(DCs)	4	(Fig.	
1).	 Alteration	 of	 this	 asymmetry,	 by	 either	 overexpression	 or	 depletion	 of	 Numb	 in	
Drosophila	results	in	cells	acquiring	the	same	cell	identity.	
Also	 at	 the	 level	 of	 the	 stem	 cell	 (SC)	 compartment,	 it	 has	 been	 shown	 that	 Numb	
segregates	asymmetrically	during	cell	mitosis	and	this	event	ultimately	has	an	impact	on	
the	DC	fates,	both	in	Drosophila	5,6	and	in	mammal	neuroblasts	7	(see	paragraph	2.4.1)	(Fig.	
1).	
Fig.	1	Numb	asymmetric	division	in	Drosophila	SOP	and	neuroblasts	
The	 figure	 shows	 Numb	 asymmetric	 partition	 in	 Drosophila	 SOP	 cell	 (left)	 and	 central	
nervous	system	(CNS)	neuroblast	(right)	cell	division.	The	orientation	of	the	plane	of	division	
is	 indicated.	 Numb	 is	 depicted	 in	 green,	 as	 a	 crescent	 in	 the	 dividing	 SOP	 and	 in	 the	
neuroblast,	or	as	spheres	in	the	pIIb	cell	(one	of	the	daughter	cells	derived	from	SOP	division)	
and	in	the	ganglion	mother	cell	(GMC)	where	it	accumulates	after	the	first	asymmetric	cell	
division	 (ACD).	 For	 simplicity,	 only	 the	 first	 ACD	 in	 both	 lineages	 is	 depicted	 in	 detail.	
However,	 all	 other	 divisions	 are	 asymmetric	 and,	 at	 least	 in	 the	 SOP	 lineage,	 involve	
asymmetric	partitioning	of	Numb.	Details	are	in	the	main	text.	Figure	from	2.	
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Despite	the	initial	focus	on	the	role	of	Numb	in	neurogenesis	and	in	SC	regulation,	another	
aspect	that	emerged	early	in	Numb	studies	in	Drosophila	is	its	molecular	counteraction	of	
Notch	(see	paragraph	2.3.2)	that	affects	the	differentiative-proliferative	balance	in	nervous	
system	and	partially	justifies	Numb	being	labeled	as	a	tumor	suppressor	gene.		
In	conclusion,	the	extensive	research	on	the	neurogenic	function	of	Numb	highlighted	the	
critical	role	of	Numb	in	the	regulation	of	cell	fate	in	SC	compartments,	and	its	inhibition	
over	Notch,	two	roles	that	also	open	important	questions:	i)	how	is	the	asymmetric	locali-
zation	of	Numb	determined,	and	ii)	how	does	Numb	work	at	the	molecular	level?	
	
Concerning	 the	 first	point,	great	 interest	was	placed	 in	clarifying	how	Numb	partition	 is	
generated.	The	major	components	of	the	polarity	machinery	 involved	in	the	asymmetric	
partition	 of	 Numb	 at	 mitosis,	 during	 ACD,	 were	 intensively	 studied	 and	 are	 conserved	
between	flies	and	mammals.	The	process	seems	to	be	orchestrated	by	PAR	(par-titioning	–
defective)	 proteins.	 In	Drosophila,	 as	 in	mammalian	 neurons,	 this	 complex	 includes	 the	
proteins	Par3	(Bazooka	in	Drosophila)	Par6	and	aPKC	(atypical	protein	kinase	C)	that	localize	
asymmetrically	in	correspondence	with	one	of	the	spindle	poles:	posteriorly	in	SOP	cells,	
apically	in	neuroblasts	of	the	Drosophila	central	nervous	system	(CNS)	(Fig.	1),	and	basally	
in	neuroblasts	of	mammals	CNS	 2.	At	 the	onset	of	mitosis,	Aurora	A	 is	 activated,	which	
triggers	a	kinetic	cascade	that	leads	to	the	phosphorylation	of	Numb	by	aPKC	8,9	(Fig.	2A).	
Direct	phosphorylation	of	Numb	by	aPKC	is	sufficient	to	displace	Numb	from	the	pole	where	
aPKC	is	localized	10.	In	this	way	Numb	accumulates	at	the	opposite	pole	together	with	other	
intrinsic	 cell	 fate	 determinants,	 such	 as	 Mira,	 Prospero	 and	 Pon	 11,12,13,14	 (Fig.	 2B).	
Phosphorylation	 of	 Pon	 by	 Polo	 kinase	 is	 also	 involved	 in	 Numb	 localization,	 but	 the	
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mechanisms	need	to	be	better	elucidated	15.	
	
	
Fig.	2	PAR	complex	orchestrates	Numb	asymmetric	partition	at	mitosis.	
A)	At	mitosis,	Aurora-A	 (AurA)–mediated	phosphorylation	of	Par-6	 leads	 to	activation	of	
aPKC	kinase	activity	on	Lethal	giant	 larvae	(Lgl).	Phosphorylated	Lgl	 is	excluded	from	the	
complex	 ,	which	allows	entry	of	Par-3	 into	 the	Par	complex.	This	complex	 remodeling	 is	
associated	with	an	alteration	of	the	aPKC	substrate	specificity	towards	Numb	and	Miranda,	
which	are	phosphorylated	by	aPKC.	B)	 In	neuroblasts,	phosphorylated	Numb	is	excluded	
from	the	cell	side	occupied	by	aPKC	(red	crescent)	and	accumulates	on	the	opposite	site	of	
the	 plasma	membrane	 (green	 crescent)	 with	 other	 cell	 fate	 determinants.	 The	 ratio	 of	
apical/basal	 determinants	 specifies	 identity	 in	 each	 daughter	 cell	 (DNA,	 blue).	 Figure	
adapted	from	12.	
	
Deregulation	 of	 the	 expression	 of	 PAR	 complex	 components	 can	 alter	 physiologic	
developmental	decisions	and	tissue	morphogenesis	by	compromising	Numb	segregation	at	
cell	mitosis	and	consequently	the	fates	in	stem/progenitor	cells.	The	exact	elucidation	of	
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these	mechanisms	and	the	molecular	players	that	crosstalk	with	Numb	to	trigger	the	cell	
fate	choice	requires	further	studies.	Nevertheless,	it	is	clear	that	a	number	of	pathways	that	
control	stem/progenitor	cell	development	have	been	described	to	involve	Numb	and	they	
will	be	the	object	of	an	in-depth	analysis	in	paragraphs	2.3.2,	2.3.3,2.3.4.7.		
	
2.2 NUMB	STRUCTURE	
The	vertebrate	homologues	of	Drosophila	Numb	(dNumb)	are	represented	by	Numb	and	
Numb-like	proteins	16.	These	proteins	belong	to	an	evolutionary	conserved	protein	family	
and	 show	 some	 redundant	 roles	 during	 early	 neurogenesis	 17.	 The	 structural	 similarity	
between	Numb	and	Numb-like	is	present	throughout	the	protein,	with	a	strong	sequence	
similarity,	particularly,	in	the	N-terminal		region,	which	displays	also	strong	similarity	with	
the	N-terminal	portion	of	dNumb.		
The	structure	of	Numb	resembles	a	scaffold	protein	composed	of	different	protein-protein	
interactor	domains.	Mammalian	Numb	protein	is	composed	of	an	N-term	phosphotyrosine	
binding	(PTB)	domain,	followed	by	a	proline-rich	region	(PRR)	containing	different	putative	
Src	 homology	 3	 (SH3)	 domain-binding	 sites,	 along	 with	 an	 NPF	 (asparagine-proline-
phenylalanine)		and	two	DPF	(aspartic	acid-proline-phenylalanine)	motifs	at	the	C-terminal	
responsible	for	binding	to	the	EH	(Eps	homology)	domain	of	endocytic	proteins	16.		
In	general,	looking	at	Numb	domain	composition,	Numb	displays	a	structural	similarity	to	
the	bona	fide	cargo	selective	adaptors,	DAB2	and	ARH.	In	particular,	these	proteins	share	a	
highly	related	PTB	domain	supporting	the	concept	that	Numb	belongs	to	the	same	protein	
functional	family	2.	The	PTB	domain	is	highly	represented	in	protein	domain	structures,	has	
a	globular	folding	and	is	highly	conserved	in	the	two	mammalian	homologue	proteins.	In	
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particular,	Numb	PTB	 is	able	 to	 interact	 in	vivo	with	multiple	 target	proteins	 involved	 in	
several	biochemical	roles.	Moreover,	Numb	PTB	is	able	to	recognize	ligand	peptides	that	
differ	in	primary	amino	acid	sequence	and	secondary	structure	18.		
Differently	from	other	PTB	domains,	such	as	those	of	Shc	and	IRS-1,	Numb	PTB	does	not	
require	tyrosine	phosphorylation	for	high	affinity	peptide	binding	and	seems	to	display	a	
wide	 interaction	 specificity	mediated	 by	 a	 flexible	 hydrophobic	 groove.	 This	 allows	 the	
backbone	structure	of	PTB	to	be	able	to	adopt	different	tertiary	conformations	adapted	by	
a	wide	range	of	intermolecular	binding	partners	18.	
These	structural	considerations	provide	 insights	 into	the	broad	 involvement	of	Numb	 in	
signaling	regulation	and	in	coordination	of	the	biochemical	network	of	protein-protein	in-
teractions.	
	
An	additional	layer	of	complexity	in	Numb	structure	is	related	to	the	different	lengths	of	the	
Numb	PTB	displayed	in	the	four	most	abundantly	expressed	Numb	splice	variants	expressed	
in	mammals	as	a	result	of	alternative	splicing	events.	Although	nine	Numb	isoforms	have	
been	described,	only	the	four	main	isoforms	are	well-characterized	since	they	are	expressed	
in	different	tissue	models.	These	four	isoforms	differ	in	their	retention	or	skipping	of	exon	
3,	comprised	of	33	nucleotides	(11	amino	acids),	in	the	N-terminal	PTB	domain-encoding	
region	of	Numb,	and	of	exon	9,	comprised	of	144-nucleotides	(48	amino	acids),	in	the	C-
terminal	PRR-encoding	region	19,20	(see	paragraph	2.3.6	and	Fig.	3).		
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Fig.	3	Schematic	diagrams	showing	Numb	isoforms	structure 
Human	Numb	 isoforms	1/2/3/4	 (p72,	p71,	p66,	p65	 respectively)	 structure	showing	 the	
main	 protein-protein	 interactor	 domains:	 phosphotyrosine	 binding	 domain	 (PTB,	 light	
orange),	the	proline-rich	region	(PRR,	light	blue),	and	the	DPF1,	DPF2,	and	NPF	motifs.	Exon	
numbering	 starts	 from	 the	 first	 Numb	 codifying	 exon.	 In	 dark	 orange,	 the	 alternatively	
spliced	exon	3	within	PTB	domain.	In	dark	blue,	the	alternatively	spliced	exon	9	within	PRR	
domain.	 DPF1	 and	 DPF2:	 aspartic	 acid-proline-phenylalanine	 motifs.	 NPF:	 asparagine-
proline-phenylalanine	motif.		
	
2.3 THE	MULTIPLE	NUMB	FUNCTIONS	
	
	
2.3.1 NUMB	AND	ENDOCYTOSIS	
Although	the	majority	of	research	on	Numb	has	focused	on	its	role	in	cell	fate	specification	
and	signaling	regulation	(see	paragraphs	2.3.2,	2.3.3,	2.3.4.7),	the	wide	pattern	of	Numb	
expression	in	almost	all	tissues	suggests	a	general	role	of	Numb	in	cell	homeostasis.	Clues	
about	a	more	general	role	of	Numb	in	basic	cellular	processes	come	from	observations	on	
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i)	 the	 Numb	 protein	modular	 domain	 structure	 and	 ii)	 Numb	 subcellular	 localization	 in	
endocytic	organelles,	described	in	detail	below.	Both	observations	suggest	the	possibility	
that	Numb	acts	as	an	endocytic	adaptor	protein	interacting	with	several	components	of	the	
endocytic	machinery.	
			
i)	Numb	protein	modular	domain	structure.	The	Numb	motifs,	DPF	and	NPF	(Fig.	3),	have	
been	shown	to	mediate	interactions	with	endocytic	proteins.	Specifically,	Numb	DPF	motifs	
at	the	C-termal	of	the	protein	mediate	the	interaction	with	the	main	clathrin	adaptor	AP2	
(specifically,	the	α-adaptin	subunit)	in	endocytic	clathrin-coated	pits	21,	while	the	NPF	motif	
is	important	for	binding	to	Epsin15	homology	domain	(EHD)	containing	proteins,	Eps15	and	
Eps15R,	which	act	as	adaptors	in	clathrin-dependent	and	-independent	endocytosis,	as	well	
as	in	vesicle	transport	22,23.	The	Numb	NPF	motif	is	also	required	for	the	interaction	with	the	
endocytic	proteins,	Epsin	15	homology	domain	1	and	Epsin	15	homology	domain	2	(EHD1	
and	EHD4),	which	are	involved	in	recycling	vesicles	back	to	the	plasma	membrane,	in	order	
to	return	their	cargo	(membrane	proteins	or	receptors)	to	the	cell	surface	24.	By	affecting	
vesicles	recycle,	Numb	is	involved	in	spatial	regulation	of	signaling	25.	Moreover,	the	Numb	
PTB	domain	has	been	shown,	both	in	Drosophila	and	mammalian	proteins,	to	bind	to	the	
intracellular	domains	of	 transmembrane	proteins,	promoting	receptor	recruitment	2.	Via	
these	 domains/motifs,	 Numb	 has	 been	 shown	 to	 interact	 with,	 and	 be	 involved	 in	 the	
regulation	 of	 transferrin	 receptor	 26,	 LDLR	 (low	 density	 lipoprotein	 receptor)	 26,	 cell	
adhesion	molecules	(e.g.,	L1	in	neurons)	27,	integrins	(B1	and	B2)	28,	and	Notch	29,30,	being	
co-trafficked	with	these	internalized	receptors	and	membrane	proteins	2	(Fig.	4).	
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ii)	Numb	subcellular	localization	in	endocytic	organelles.	The	role	of	Numb	at	various	stages	
of	 endocytosis	 is	 suggested	 by	 its	 temporally	 coordinated	 co-localization	 with	 AP2	 and	
Eps15	in	clathrin-coated	pits	and	early	endosomes	21,	and	by	its	localization	in	Arf6	GTPase-
containing	 vesicles,	 which	 are	 known	 to	 represent	 recycling	 endosomes	 24.	 These	
subcellular	localizations	have	suggested	a	role	of	Numb	as	a	cargo	selective	adaptor,	acting	
at	the	internalization	step	of	endocytosis	and	in	endosomal	trafficking	of	transmembrane	
receptors	 2.	Moreover,	 Numb	 has	 been	 characterized	 as	 a	 negative	modulator	 of	 Arf6-
dependent	endocytic	recycling	24,25	
	
The	first	indications	of	an	endocytic	function	of	Numb	were	linked	to	its	role	as	a	cell	fate	
determinant	in	the	SOP	system.	The	identified	mechanism	also	explains	Numb-mediated	
inhibition	of	Notch	signaling	(see	paragraph	2.3.2).	Similarly	to	Numb,	the	AP2	subunit,	α-
adaptin,	was	demonstrated	to	be	asymmetrically	segregated	in	the	SOP	lineage	31.	Mutation	
of	 α-adaptin	 phenocopies	 loss	 of	 Numb,	 similarly	 affecting	 the	 bristle	 morphology	 in	
Drosophila	31.	Moreover,	in	the	SOP	system,	Numb	was	required	for	the	internalization	of	
Sanpodo,	 a	 membrane	 protein	 important	 for	 Notch	 activity	 32,16(Fig.	 4).	 These	 results	
suggested	that	the	retention	of	the	Numb/α-adaptin	axis	could	have	an	impact	on	Notch	
polarized	endocytosis	and	on	its	signaling	asymmetry	in	DCs.	
Of	note,	also	Numb	negative	regulation	of	receptor	and	ligands	recycling	might	also	explain	
Numb-mediated	counteraction	of	Notch	33.	It	has	been	shown	that	in	myoblast	cells,	Numb	
seems	to	promote	the	sorting	of	Notch	receptor	to	late	endosomes	for	degradation,	thus,	
inhibiting	its	signaling.	The	downmodulation	of	Numb,	instead,	directs	Notch	to	recycling	
vesicles,	thus,	enhancing	Notch	signaling	34	(see	paragraph	2.3.2	and	Fig.	4).	
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Fig.	4	Numb	in	endocytosis	and	recycling.	
The	figure	shows	examples	of	cellular	phenotypes	controlled	by	Numb	endocytic	functions	
(in	 red:	 migration,	 adhesion,	 proliferation/differentiation,	 metabolism).	 Internalization	
(violet	arrows),	degradative	(red	arrows)	and	recycling	routes	(green	arrows)	highlight	the	
multiple	roles	of	Numb	in	vesicular	intracellular	traffic.	AJs,	adherens	junctions;	FAs,	focal	
adhesions;	ECM,	extracellular	matrix;	LDLR,	low-density	lipoprotein	receptor.	Figure	from	2.	
	
	
To	summarize,	Numb	function	in	the	endocytic	machinery	seems	to	be	at	the	basis	of	its	
role	in	signaling,	especially	in	Notch	regulation	(see	paragraph	2.3.2),	and	to	explain	several	
Numb-related	 phenotypes	 affecting	 cell	 fate	 specification,	 proliferation,	 differentiation,	
survival	and	stem	cell	homeostasis.	
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2.3.2 NUMB	AND	THE	NOTCH	PATHWAY	
The	Notch	signaling	pathway	is	a	highly	conserved	developmental	network	involved	in	cell	
fate	 determination,	 homeostasis	 of	 the	 SC	 compartment,	 and	 regulation	 of	 the	
proliferative/differentiative	balance	during	development	and	in	adult	tissue	homeostasis	35.	
Notch	 signaling	 functions	 as	 an	 essential	 mechanism	 to	 direct	 cell	 fate	 decisions	 of	
neighboring	 cells	 through	 cell-cell	 physical	 interactions.	 Trans-interaction	 between	
receptors	and	ligands,	present	on	opposing	cells,	represent	activating	events	of	the	Notch	
signaling	pathway.	
Notch	 is	 an	 evolutionary	 conserved	 transmembrane	 receptor	 localized	 on	 the	 signal-
receiving	cell.	It	binds	directly	to	ligands	of	the	DSL	family	(Delta,	Serrate,	Lag-2	in	mouse;	
DLL1,	DLL2,	DLL3,	 Jagged	1/2	 in	human)	 located,	as	 integral	membrane	proteins,	on	the	
opposing	 signal-sending	 cell	 2.	 Receptor-ligand	 engagement	 triggers	 a	 cascade	 of	
proteolytic	cleavage	events	that	concludes	with	the	cleavage	of	Notch	itself	by	y-secretase.	
These	steps	are	critical	for	Notch	maturation	and	signal	transmission,	and	culminate	in	the	
cleavage	of	the	entire	Notch	intracellular	domain	(NICD)	from	the	cell	membrane	and	its	
translocation	into	the	nucleus,	where	it	acts	with	the	CSL	transcription	complex	composed	
by	C	promoter	binding	factor	1	(CBF-1)/Suppressor	of	Hairless/Longevity	assurance	gene-1	
(LAG-1),	Mastermind	and	other	 coactivators	 to	drive	 the	expression	of	 the	Notch	 target	
genes	36	(Fig.	5).	The	biological	outcome	of	Notch	signaling	is	far	from	being	fully	understood	
and	results	from	different	model	systems	are	often	contradictory.	
In	the	regulation	of	Notch	signaling,	a	central	role	has	been	assigned	to	Notch	endosomal	
processing	and	trafficking	at	different	stages	of	the	signaling	pathway.	Of	the	proteins	that	
guide	endocytic	trafficking	of	Notch	receptor	upon	activation	in	signal-receiving	cells,	Numb	
and	Sanpodo	interplay	to	directly	regulate	Notch	availability	and	activity.	
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Numb	was	 originally	 identified	 as	 an	 inhibitor	 of	Notch	 signaling	 in	Drosophila.	 Indeed,	
Numb	loss-of-function	phenocopies	Notch	gain-of-function	and	this	confirms	their	epistatic	
relationship	37.	The	Numb-Notch	axis	is	important	in	both	Drosophila	and	mammals,	in	CNS	
development	and	in	ACD	of	SCs.	During	ACD	of	SCs,	Numb	is	asymmetrically	partitioned	at	
mitosis:	the	DC	that	receives	Numb	is	unresponsive	to	Notch	signaling,	while	the	DC	that	
loses	Numb	retains	responsiveness	to	Notch	and	adopts	the	cell	fate	associated	with	Notch	
activation.	A	broad	model	of	 the	molecular	mechanisms	governing	 this	Numb-mediated	
inhibition	of	Notch	has	been	deduced.	
The	first	clues	to	the	mechanism	came	from	the	characterization	of	the	SOP	system	in	which	
the	 endocytic	 function	 of	 Numb	 accounts	 for	 its	 biological	 antagonism	 of	 Notch	 (see	
paragraphs	 2.3.1).	 Numb	 can	 indeed	 suppress	 Notch	 function	 by	 controlling	 Notch	
intracellular	trafficking	and	consequently	its	potential	activation.	In	the	Drosophila	neural	
system,	this	effect	is	mediated	by	Sanpodo.	Sanpodo	is	a	transmembrane	protein	expressed	
only	in	asymmetrically	dividing	cells	38.	It	is	required	for	Notch	signaling	activation,	and	it	
interacts	 with	 both	 Notch	 and	 Numb.	 Numb,	 on	 the	 other	 hand,	 interacts	 with	 the	
endocytic	 proteins,	 AP2	 and	 Eps15,	 and	 by	 doing	 so	 it	 works	 as	 an	 adaptor	 protein	
mediating	endocytosis	of	Sanpodo	39.	Numb	asymmetrically	distributes	at	cytokinesis	of	the	
SOP	cell.	This	results	in	Sanpodo	removal	from	plasma	membrane,	through	internalization,	
in	the	SOP	daughter	cell	that	retains	Numb	(Fig.4)	38,29,	causing	inhibition	of	Notch	signaling,	
and	preventing	the	acquisition	of	a	neuroblast	cell	fate	2.	In	contrast,	in	the	stem	daughter	
cell,	Numb	is	excluded	and,	consequently,	Sanpodo	is	stabilized	at	the	level	of	the	plasma	
membrane	and	Notch	is	highly	expressed,	leading	to	the	acquisition	of	a	neuroblast	cell	fate.	
Inhibition	of	Notch	signaling	 in	 the	SOP	system	results	 in	neuroblast	depletion,	while	 its	
overexpression	 in	 progenitor	 daughter	 cells	 leads	 to	 their	 de-differentiation	 back	 to	 a	
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neuroblast	fate.	Thus,	in	this	system,	the	Numb/Notch	axis	is	decisive	in	committing	cells	to	
specific	fates.	
	
Although	mammalian	 cells	 do	 not	 express	 Sanpodo,	 the	 general	 mechanism	 of	 Numb-
mediated	inhibition	of	Notch	is	conserved.	Mammalian	Notch	is	constitutively	internalized	
and	 either	 recycled	 back	 to	 the	 plasma	membrane	 or	 trafficked	 to	 the	 late	 endosomal	
compartment	for	degradation	40	(Fig.5).	It	has	been	demonstrated	that	changes	in	Numb	
expression	 alter	 the	 dynamics	 of	 late	 endocytic	 trafficking	 of	 Notch.	 Overexpression	 of	
Numb	promotes	Notch	sorting	to	late	endosomes/lysosomes	for	degradation,	whereas	its	
depletion	facilitates	its	recycling	to	plasma	membrane	34.	These	observations	suggest	that	
Numb	behaves	like	a	molecular	sensor	that	modulates	the	responsiveness	of	cells	to	Notch	
ligand.	 Thus,	 under	 pathological	 conditions,	 loss	 of	 Numb	 could	 impose	 Notch	 hyper-
activation	due	to	increased	receptor	recycling	and	enhanced	cell	responsiveness	to	Notch	
activating	signals	(see	paragraph	2.4)	
In	mammals,	Numb	antagonizes	Notch	also	by	controlling	the	intracellular	trafficking	and	
stability	of	the	Notch	ligand,	Delta-like	4	(Dll4).	It	acts	as	a	post-endocytic	sorting	switch,	
negatively	 controlling	 recycling	 to	 the	 plasma	 membrane	 through	 AP1	 and,	 instead,	
increasing	Dll4	delivery	 to	 lysosomes	 for	degradation	 33.	 In	 this	way,	Numb	 limits	Notch	
signal	transmission	from	the	signal-sending	cell.	In	this	complex	scenario,	the	endocytic	role	
of	Numb	is	fundamental	to	remove	or	recycle	molecules	from	specific	plasma	membrane	
domains	 for	 the	execution	of	polarized	 functions.	Numb	 is	 involved	 in	 creating	multiple	
levels	of	asymmetry	relevant	for	directional	signaling	(in	the	case	of	Notch	signaling,	at	the	
level	of	cell-cell	interface)	or	for	asymmetric	activation	of	cell	fate	determinants	following	
ACD.	
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These	findings	about	the	endocytic	function	of	Numb	in	Notch	signaling	regulation	have	
been	complemented	by	 several	 lines	of	evidence	 suggesting	an	additional	 tier	of	Numb	
regulation	on	Notch	signaling	via	 the	ubiquitin-proteasome	degradation	pathway.	Numb	
interacts	with	NICD	and	promotes	its	ubiquitination	driving	its	proteasomal	degradation,	
thus,	 resulting	 in	 attenuation	 of	 Notch	 signaling	 41	 (Fig.	 5).	 Numb	 recruits	 Itch	 (HECT	
domain-containing	 E3	 ligase),	 a	 component	 of	 the	 ubiquitination	machinery	 to	 the	 cell	
membrane-tethered	 Notch	 1	 receptor,	 thereby	 cooperatively	 enhancing	 Notch	
ubiquitination	 and	 degradation,	 ultimately,	 leading	 to	 downregulation	 of	 Notch	 signal	
transduction	41.	
Inappropriate	activation	of	Notch	has	been	reported	as	oncogenic	signal	associated	with	
various	types	of	cancer,	including	colon,	pancreatic,	lung	and	breast	cancer,	acute	myeloid	
leukemia	and	glioblastoma	42,43,44,45.	Of	note,	the	role	of	Notch	as	an	oncogene	conceptually	
underlines	 that,	 at	 the	 molecular	 level,	 its	 upstream	 regulator	 Numb,	 has	 a	 tumor	
suppressor	role	in	different	cancer	contexts	(see	paragraph	2.4).		
In	conclusion,	tight	regulation	of	the	Numb-Notch	axis	is	essential	for	preventing	potential	
pro-tumorigenic	 events	 that	 could	 result	 from	 its	 deregulation.	 Although	 the	 main	
mechanisms	of	Numb	inhibition	of	Notch	have	been	depicted	here,	the	overall,	context-
dependent	scenario	is	still	far	from	being	completely	unraveled.	
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Fig.	5	Two,	not	alternative,	models	of	Notch	inhibition	by	Numb.	
Numb	interacts	with	AP-2	and	Eps15	to	downregulate	Notch	receptor	signaling	by	clearing	
Notch	 from	 the	 surface	 of	 receptor-expressing	 cells.	 In	 the	 same	 way,	 Numb	 targets	
Sanpodo,	required	for	Notch	activation,	for	endocytic	removal	from	the	plasma	membrane	
(not	shown)(1).	Notch	signaling	activation	is	initiated	by	the	binding	of	Notch	ligands	(Delta-
like	1-3-4,	Jagged	[JAG1,	JAG2])	to	Notch	transmembrane	receptors	1–4,	which	undergo	a	
series	of	proteolytic	cleavages,	by	ADAM	family	proteins	(ADAM	10,	ADAM	17)	and	a	γ–
secretase	complex,	which	lead	to	the	release	of	the	Notch	intracellular	domain	(NICD)	(2).	
The	NICD	translocates	to	the	nucleus,	where	it	interacts	with	CSL	and	converts	the	complex	
from	a	repressor	(Co-R	CSL)	to	an	activator	of	Notch	target	genes	(Co-A	CSL),	such	as	Hes-1	
and	Hey-1	 (3).	Numb	prevents	translocation	of	NCID	 into	the	nucleus	targeting	NICD	for	
Itch-mediated	ubiquitination	and	consequent	proteasomal	degradation	(4).	Figure	adapted	
from	46.	
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2.3.3 NUMB	AND	HEDGEHOG	PATHWAY	
The	Hedgehog	(Hh)	signaling	pathway	(which	takes	its	name	from	the	Hh	ligand,	rather	than	
the	receptor)	plays	an	important	role	in	tissue	patterning,	SC	regulation	and	cancer	47.	Hh	
is	a	morphogenic	molecule	that	is	necessary	for	the	development	of	different	tissue	types,	
including	 bone,	 brain,	 skin,	 gonads,	 and	 lungs.	 Consequently,	 its	 cell	 distribution	 and	
pathway	activation	need	to	be	strictly	regulated	48,49,50.	In	Drosophila,	Hh	mutants	display	
an	abnormal	development	and	give	rise	to	unusually	hairy	and	stumpy	larvae	compared	to	
wild-type,	resembling	the	hedgehog	animal	from	which	it	derives	its	name	51,47.	In	mammals,	
Hh	exists	as	3	variants:	Sonic	(SHH),	Indian	and	Desert	51.	Despite	some	differences	in	the	
signaling	effectors	between	Drosophila	and	mammals,	the	main	core	components	of	the	Hh	
pathway	remain	quite	conserved.	
Hedgehog	ligand	are	composed	by	two	main	domains:	the	N-terminal	"Hedge"	domain	that	
functions	 as	 a	 signal-transmitting	 domain	 and	 a	 processing	 C-terminal	 "Hog”	 domain,	
involved	in	the	autocatalytic	intramolecular	cleavage	of	the	Hedgehog	ligand.	The	Hedge	
domain	 	 is	modified	 by	 the	 addition	of	 a	 cholesterol	moiety	 at	 its	 C-terminal	 52	 and	by	
palmitate	addition	to	the	N-terminal	by	an	acetyl	transferase	enzyme.	These	modifications	
allow	the	interaction	of	Hedge	with	lipoproteins.	The	modified	fully	active	“Hedge”	domain	
is	 then	 released	 from	 cell	 membrane	 of	 signal	 producing	 cell	 thanks	 to	 the	 activity	 of	
Dispatched	(Disp)	and	acts	as	signaling	molecule	(Hh,	from	hereafter)	in	the	extracellular	
space	50.		
Hh	interaction	with	its	membrane	receptor,	Patch,	in	signal	receiving	cell,	abrogates	Patch	
inhibition	of	Smoothened	(Smo),	a	G-coupled	protein	receptor.	Smo,	in	turn,	undergoes	a	
conformational	change	that	allows	the	activation	of	a	signaling	cascade	that	converges	on	
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increasing	transcription	factor	activity	of	Ci,	in	Drosophila,	or	of	its	mammalian	homologues,	
Gli	proteins	(Gli1,	Gli2,	Gli3).	Gli	activity	is	regulated	in	a	very	similar	way	to	that	observed	
in	Drosophila.	In	absence	of	Hh	ligand,	Gli	proteins	are	phosphorylated	and	processed,	and	
in	their	truncated	form	result	inactive.	Addition	of	Hh	leads	to	inhibition	of	processing	of	
Gli	proteins	and	their	accumulation	as	full-length	active	form	of	proteins.	Of	note,	Gli1	e	
Gli2,	upon	activation,	act	as	transcriptional	activators	of	Hh	target	genes,	while	Gli	3	acts	as	
a	 transcriptional	 repressor	 50,53.	 The	 strength	 and	 duration	 of	 Hh	 signaling	 is	 strictly	
regulated	 by	 the	 ubiquitin-dependent	 proteolytic	 processing	 of	 Gli	 proteins.	 The	 Hh	
cascade	induces	different	set	of	target	genes	encoding	secreted	signaling	protein	involved	
in	 cell	 growth	 and	 division	 and	 many	 transcription	 factors	 that	 are	 essential	 for	
developmental	processes.	
The	role	of	Numb	in	this	context	is	to	suppress	Hh	signaling,	thereby	arresting	cell	growth	
and	 promoting	 cell	 differentiation.	 Numb	 interacts	 with	 the	 E3-ubiquitin	 ligase,	 Itch,	
promoting	 its	 ubiquitination	 of	 Gli1	 54,55	 (Fig.	 6A).	 This	 results	 in	 Gli1	 degradation	 and	
consequently	decreased	 transcriptional	activity	 leading	 to	downregulation	of	Gli1	 target	
genes,	 such	 as	 cyclin	 D2,	 IGF-2,	 N-Myc	 and	 Bmi-1	 54,55	 (Fig.	 6A).	 This	 mechanism	 is	
reminiscent	of	that	already	discussed	for	the	inhibition	of	Notch	signaling	in	mammals	(see	
paragraph	2.3.2)	
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Fig.	6	Numb-mediated	regulation	of	the	Hedgehog	pathway.	
Sonic	hedgehog	 (SHH)	binds	 to	 the	receptor	Patched	 (PTC)	and	 inhibits	 its	 repression	of	
Smoothened	(SMO)(1).	Activated	SMO	translocates	to	the	nucleus	and	triggers	the	nuclear	
activity	of	the	GLI	transcription	factors.	GLI	proteins	regulate	Hh	target	gene	expression,	
promoting	 tumor	 proliferation	 and	 survival	 (2).	A)	Numb	 activates	 Itch	 ubiquitin-ligase	
activity	 on	 GLI	 proteins,	 targeting	 them	 to	 proteasomal	 degradation	 (3).	 B)	 Numb	
downregulation	negatively	affects	Itch	activation,	leading	to	increased	GLI	protein	half-life	
and	increased	transcriptional	activation	of	Hh	target	genes.	Figure	adapted	from	46.	
	
The	 described	 mechanism	 highlighted	 a	 pro-differentiation,	 anti-proliferative	 effect	 of	
Numb	 in	 tumor	 cells	 due	 to	 suppression	 of	 functional	 Gli	 activity	 (Fig.	 6B).	 Aberrant	
activation	 of	 the	 Hh	 signaling	 can	 enhance	 survival	 and	 proliferation	 of	 cells,	 inducing	
tumorigenesis	 and	metastasis	 formation	 56–60.	 Aberrant	 activation	 of	 the	Hh	 pathway	 is	
indeed	 associated	 with	 different	 solid	 cancers	 57,58,59,61	 and	 can	 be	 induced	 by	 ligand-
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independent	constitutive	activation	or	hyper-expression	of	Hh	pathway	players	62.	Numb	
deregulation	is	an	additional	regulator	of	Hh	signaling	activation.	Therefore,	the	subversion	
of	 the	 Numb-Hh	 axis	 could	 be	 relevant	 to	 tumorigenesis.	 Moreover,	 since	 a	 signaling	
crosstalk	between	Notch	and	Hh	is	involved	in	normal	developmental	processes,	as	well	as	
in	tumorigenesis,	an	 interesting	scenario	emerges	 in	which	Numb	might	act	as	a	master	
regulator	 of	 two	 fundamental	 and	 intimately	 integrated	 morphogenetic	 systems.	 The	
obvious	consequence	of	this	is	a	profound	and	concomitant	alteration	of	these	mechanisms	
in	tumors	displaying	Numb	dysfunction	(see	paragraph	2.4). 
	
2.3.4 NUMB	AND	THE	p53-MDM2	CIRCUITRY	
A	previous	work	in	our	lab	has	demonstrated	the	involvement	of	Numb	in	the	regulation	of	
the	tumor	suppressor	p53,	by	the	ability	of	Numb	to	bind	and	inhibit	the	ubiquitin	ligase	
Mdm2	63.	This	has	profound	implications	in	BC	tumorigenesis,	where	a	reduction	of	the	p53	
activity	was	observed	in	Numb-deficient	BCs	63.	In	the	next	paragraphs	will	be	discussed	the	
key	role	that	p53	plays	into	the	cell	and	the	complex	circuitry	involved	in	its	regulation,	the	
alterations	of	this	pathway	in	cancers	and	what	is	known	about	the	function	of	Numb	in	the	
p53	regulation.	
				
2.3.4.1 THE	ROLE	OF	THE	TUMOR	SUPPRESSOR	p53	
While	the	tumor	suppression	function	of	p53	has	long	been	recognized,	the	mechanisms	
underlying	this	biological	role	and	its	regulation	are	still	under	intense	investigation.	p53	is	
known	as	the	“cellular	gatekeeper”	64	or	the	“guardian	of	the	genome”	65,	because	of	its	
central	role	 in	orchestrating	specific	cellular	responses	to	a	broad	range	of	stress	factors	
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encountered	 by	 cells	 66.	 p53	 acts	 like	 a	 cellular	 stress	 sensor	 that	 can	 be	 activated	 in	
response	 to	 different	 stimuli,	 such	 as	 DNA	 damage,	 hyper-proliferative	 signals	 as	
consequence	of	oncogene	activation,	hypoxia,	oxidative	 stress,	 ribonucleotide	depletion	
and	nutrient	 starvation	 67.	Many	of	 these	 stimuli	 are	encountered	by	 tumor	 cells	 in	 the	
tumor	microenvironment	and	are	therefore	important	for	triggering	p53	tumor	suppression	
function	 in	vivo.	Depending	on	the	type	of	stimulus,	p53	activation	can	 lead	to	different	
cellular	outcomes,	such	as	transient	cell	cycle	arrest,	senescence,	DNA	repair,	autophagy	or	
apoptosis	 66.	 As	 a	 transcription	 factor,	 p53	 can	 activate	 and	 repress	 a	 broad	 range	 of	
transcriptional	targets	that	mediate	these	different	cellular	outcomes.	The	fine	tuning	of	
the	activation/repression	of	p53	target	genes	according	to	the	cell’s	necessities	relies	on	a	
complicated	network	of	signaling	interactions.	
According	to	the	traditional	model,	p53	activity	under	basal	conditions	,or	induced	by	mild	
stress	or	DNA	damage,	elicits	a	protective	response	that	supports	cell	survival	and	promotes	
the	repair	of	genotoxic	damage	68.	Under	these	conditions,	p53	engages	an	entire	suite	of	
responses	that	contribute	to	the	inhibition	of	cell	proliferation	(temporary	induction	of	a	
G1	 block)	 and	 DNA	 repair.	 In	 contrast,	 high	 levels	 of	 sustained	 stress,	 accompanied	 by	
irreparable	 damage,	 induce	 the	 killer	 functions	 of	 p53	 that	 consist	 in	 p53-mediated	
activation	of	cell	death	or	senescence	68	(Fig.	7).	Both	these	response	modes	help	to	prevent	
progression	 towards	 malignancy,	 either	 by	 preventing	 the	 accumulation	 of	 oncogenic	
lesions	or	by	eradicating	damaged	cells.	
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Fig.	7	Mechanisms	of	p53	tumor	suppression.	
Under	normal	conditions,	p53	is	present	at	very	low	concentrations	in	the	cell,	while	under	
stress	conditions,	it	accumulates	and	acts	as	a	point	of	integration	of	signals	from	different	
stress	stimuli,	thereby	resulting	in	the	appropriate	biological	response.	Under	conditions	of	
low/transient	 stress	 and	 damage,	 p53	 has	 a	 protector	 activity	 supporting	 DNA	 repair,	
adaptation	and	survival	of	cells	(mechanisms	in	dark	blue),	thus	acting	in	tumor	prevention.	
Under	sustained	stress	conditions,	p53	has	a	killer	activity	that	drives	the	elimination	of	
cells	that	cannot	be	repaired	(mechanisms	in	light	blue)	leading	to	suppression	of	tumor	
growth.	 p53	 functional	 deregulation	 could	 disrupt	 both	 of	 these	 activities	 leading	 to	
tumorigenesis,	tumor	progression,	chemoresistance	or	aging.	Figure	adapted	from	68,69.	
	
	
The	emerging	role	of	p53	in	the	regulation	of	SC	homeostasis	introduces	another	layer	of	
complexity	 in	 p53-mediated	 tumor	 suppression,	 linked	 to	 its	 ability	 to	 regulate	 SC	 self-
renewal	by	ensuring	an	asymmetric	mode	of	division	(see	paragraph	2.4.1)	70.	 In	tumors	
where	p53	is	inactivated,	cancer	progression	is	associated	with	expansion	of	the	SC	pool	as	
result	of	increased	self-renewal,	a	symmetric	mode	of	cell	division,	and	reprogramming	of	
progenitors	to	a	SC-like	state	70,71.	
To	summarize,	with	the	characterization	of	the	multiple	roles	of	p53	it	has	become	clear	
that	this	protein	is	critical	for	the	regulation	of	almost	every	aspect	of	cell	behavior.	Being	a	
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highly	connected	node,	p53	could	be	seen	as	an	Achille's	heel:	the	most	effective	way	for	a	
cell	transformation	to	occur	is	to	destroy	the	network	by	attacking	its	hub	72.	Therefore,	it	
is	not	surprising	 that	a	growing	complexity	within	 the	p53	pathway	and	 its	 regulation	 is	
emerging,	as	described	in	the	next	paragraph	2.3.4.2.		
	
	
2.3.4.2 p53	 STRUCTURE	 AND	 MECHANISMS	 OF	
REGULATION		
Unraveling	the	structural	biology	of	p53	is	a	good	starting	point	to	understanding	its	func-
tional	complexity	and	to	developing	a	structure-guided	approach	to	rescuing	p53	function	
in	tumors.	The	p53	protein	is	composed	of	three	different	functional	domains	separated	by	
short	linker	regions	(Fig.	8):	
i)	The	N-terminal	transactivation	domain	(TAD,	residues	1-70),	which	activates	transcription	
and	regulates	p53	stability	and	activity	73.	The	transcriptional	co-activator	proteins	p300/	
CREB-binding	protein	(CBP)	and	the	p53	inhibitor	murine	double	minute	(Mdm2)	(see	par-
agraph	2.3.4.3,	2.3.4.4)	have	overlapping	binding	sites	within	the	TAD	of	p53	and	compete	
for	its	binding.	Phosphorylation	events,	triggered	by	DNA	damage,	at	p53	N-terminal	resi-
dues	(Thr18	and	Ser20)	decrease	its	affinity	for	Mdm2	and,	concomitantly	increase	its	bind-
ing	with	p300/CBP,	which	induce	the	transactivation	activity	of	p53	73.	In	the	absence	of	
Mdm2,	the	p53	TAD	is	intrinsically	disordered	and	it	has	been	proposed	that	it	has	a	flexible	
conformation	allowing	it	to	adapt	for	binding	with	multiple	proteins;	this	is	known	as	the	
“induced	fit	model”	73.		
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ii)	The	sequence-specific	DNA-binding	core	domain	(DBD,	residues	94-293),	which	consists	
of	secondary	structural	elements	able	to	establish	multiple	contacts	with	the	DNA	major	
and	minor	grooves.	This	central	region	of	p53	is	globular	in	shape	and	has	a	low	thermody-
namic	stability	that	confers	structural	plasticity	to	allow	both	the	binding	to	different	in-
teractors	and	affect	p53	susceptibility	to	deleterious	mutations	74.	These	mutations	have	
an	impact	on	the	p53-folded	status	and,	thus,	on	the	overall	protein	function.		
iii)	The	C-terminal	p53	tetramerization	domain	(TD,	residues	324-355)	allows	protein	inter-
actions	between	the	p53	monomer	subunits.	These	interactions	are	extensive	and	mainly	
hydrophobic	and	are	critical	for	both	proteins	folding	and	homotetramer	formation.	p53	
homotetramerization	allosterically	regulates	the	DNA	binding	activity	of	p53.	p53	tetram-
ers	display	a	higher	affinity	for	the	p53	DNA	response	sequence	than	p53	monomers	and,	
consequently,	shows	an	increased	ability	to	act	in	the	nucleus	as	a	transcriptional	regulator	
of	p53	target	genes	75.	Mutations	in	the	TD	impair	the	correct	formation	of	homotetramers,	
leading	to	dominant-negative	phenotypes	and	cellular	transformation.	
iv)	Two	linker	proline-rich	regions	(PRR)	spanning	residues	71-93	and	294-323.	The	first	PRR	
contributes	to	functional	activity	binding	to	SH3	proteins	and	facilitating	p53	folding.	This	
latter	function	is	also	maintained	by	the	second	PRR,	which	also	accommodates	the	differ-
ent	symmetries	of	the	flanking	domains	73.	
v)	C-terminal	basic	 region	 spanning	amino	acids	356-393,	which,	 as	 suggested	 from	 the	
name,	 is	 rich	 in	 basic	 residues.	 Its	 conformational	 flexibility	 allows	 the	 region	 to	 adopt	
alternative	 conformations	 and	 provides	 binding	 specificity.	Moreover,	 it	 is	 subjected	 to	
post-translational	 modifications	 (PTMs)	 that	 affect	 p53	 DNA-binding	 activity	 and	
transcriptional	activity	since	it	allows	the	recruitment	of	co-activators	involved	in	opening	
the	chromatin	structure	73.		
 33 
	
Fig.	8	Schematic	structure	of	p53	protein	highlighting	its	main	functional	domains.	
Three	main	domains	of	p53	(TAD,	red;	DBD,	green;	TD,	blue),	the	proline-rich	linker	regions	
(white)	and	the	C-terminal	basic	region	(white)	are	indicated.	Residue	numbers	indicate	the	
boundaries	 between	 these	 different	 structural	 elements.	 TAD:	 transcriptional	 activation	
domains;	DBD:	DNA	binding	domain;	TD:	transactivation	domain.	Figure	from	73.	
	
The	traditional	model	of	stress-induced	p53	activation	consists	of	three	rate	limiting	steps	
66:	i)	p53	stabilization	ii)	DNA	binding	and	iii)	transcriptional	activation	of	p53	target	genes	
(Fig.	9).	
i)	p53	stabilization.	The	tight	control	of	p53	levels	and	function	is	mainly	achieved	by	the	
regulation	of	its	turnover	by	ubiquitin-mediated	proteasomal	degradation.	Mdm2	has	been	
described	as	the	main	E3	ligase	that	mediates	the	ubiquitination	of	p53,	committing	it	to	
proteasomal	degradation	76,77.	Mdm2	can	also	directly	inhibit	p53	activity	by	binding	the	
p53	TAD.	Since	Mdm2	is	also	a	known	p53	transcriptional	target,	the	absolute	balance	of	
p53	and	Mdm2	in	the	cell	is	maintained	in	an	auto-regulatory	feedback	loop	between	these	
two	 proteins	 whose	 equilibrium	 is	 essential	 to	 preserve	 the	 necessary	 p53	 activity	 72.	
Multiple	layers	of	Mdm2	regulation	are	therefore	able	to	affect	p53	levels	and	stability.	In	
response	to	stress	signals,	p53	is	displaced	from	its	negative	regulator	Mdm2	and	in	that	
way	p53	is	stabilized.	A	growing	number	of	proteins	that	affect	the	levels,	 localization	or	
activity	of	MDM2	(MDMX,	ARF,	YY1,	HAUSP,	RASSF1A,	NUMB),	thus,	influencing	p53	levels	
have	been	identified.	In	addition,	Mdm2	activity	can	also	be	regulated	by	phosphorylation	
and	acetylation	at	different	sites,	resulting	in	its	activation	or	inhibition	depending	on	the	
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precise	 site	 and	 on	 the	 modifying	 kinase	 (ATM,	 cAbl)	 or	 acetylase	 (CBP/p300)	 (see	
paragraph	2.4.4.3)	66.	
In	the	same	way,	p53	activation	is	regulated	by	an	array	of	PTMs.	Regulatory	redundancy	
among	 p53	 PTMs	might	 ensure	 that	 p53	 is	 regulated	 appropriately	 in	 a	 tissue-specific	
manner	 in	 response	 to	different	 stimuli	and	different	 strength	of	 signals	 78.	Genetic	and	
biochemical	 studies	 emphasize	 the	 notion	 that	 p53	 stabilization	 in	 vivo	 requires	 a	
sophisticated	regulatory	network.	Different	kinases	(ATM,	ATR,	DNAPK,	CHK1,	CHK2)	can	
affect	the	p53-Mdm2	interaction	by	phosphorylating	N-terminal	TAD	of	p53	and	stabilizing	
the	 protein	 in	 response	 to	 various	 stress	 signals.	 Recent	 work	 has	 demonstrated	 that	
acetylation	of	p53	C-terminal	lysine	residues	by	CBP/p300	is	required	for	p53	stabilization	
since	 it	 blocks	 some	 of	 the	 major	Mdm2-targeted	 ubiquitination	 sites	 66.	 p53	 PTMs	 in	
concert	with	the	interaction	of	p53	with	a	wide	variety	of	protein	binding	partners,	help	to	
regulate	its	subcellular	localization,	stability	and	conformation,	ultimately	controlling	p53	
transcription-dependent	and	-independent	functions.	
	
ii)	DNA	binding.	The	second	step	in	the	regulation	of	p53	activation	is	at	the	level	of	binding	
to	the	DNA	consensus	sequence	of	specific	response	elements	within	promoters	of	target	
genes.	 p53	 binding	 to	 DNA	 occurs	 through	 the	 central	 conserved	 DBD	 that	 provides	
sequence	specificity.	The	p53	C-terminal	 region	recognizes	 instead	structural	 features	of	
target	 DNA	 and	 folds	 back	 acting	 as	 a	 negative	 modulator	 of	 DNA	 binding	 domain.	
Additional	 p53	 PTMs	 interfere	 with	 this	 folding	 and,	 at	 the	 same	 time,	 regulate	 the	
recruitment	 of	 other	 cofactors	 (coactivators	 or	 corepressors)	 to	 allow	 sequence-specific	
DNA	binding	66.	
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iii)	Transcriptional	activation	of	p53	target	genes.	The	third	step	in	the	regulation	of	p53	
activation	involves	the	recruitment	of	the	general	transcription	machinery	and	additional	
cofactors.	Different	p53	PTMs	are	recognized	by	transcription	factors	to	achieve	promoter	
specific	transactivation.	Evidence	suggests	that	both	Mdm2	and	its	homologue	MdmX	are	
generally	recruited	at	the	promoter	region	of	target	genes	and	inhibit	their	transcription	79.	
In	light	of	recent	studies,	it	appears	that	p53	activation	in	vivo	requires	the	release	from	this	
repression	state	mediated	by	MdmX	e	Mdm2	66.	Moreover,	the	timing	of	p53	acetylation	of	
different	 regions	 in	 the	 protein	 might	 be	 important	 for	 selection	 of	 target	 genes	 to	
transactivate.	Also	methylation,	sumoylation,	and	neddylation	also	occur	at	specific	sites	in	
p53	and	 the	many	possible	 combinations	of	PTMs	might	act	 like	a	barcode,	 resulting	 in	
specific	and	sometimes	contradictory	p53	responses	80.	The	exact	combination	of	recruited	
cofactors	and	p53	PTMs	is	likely	to	determine	the	activation	of	specific	sets	of	target	genes	
and	direct	specific	cellular	responses.	
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Fig.	9	Model	of	p53	activation	
p53	activation	 involves	three	key	steps:	1)	stabilization,	2)	anti-repression	 ,	3)	promoter-
specific	activation.	Details	are	discussed	in	the	main	text.	Figure	adapted	from	66.	
	
2.3.4.3 MDM2	BIOLOGY	
Under	physiological	conditions,	p53	protein	is	tightly	maintained	at	low	steady	state	levels	
since	high	levels	of	pro-apoptotic	and	anti-proliferative	p53	might	be	detrimental	for	nor-
mal	cell	growth	and	development.	Low	cellular	p53	 levels	 in	unstressed	cells	are	mainly	
maintained	by	Mdm2,	a	p53	target	gene	that	is	able,	in	turn,	to	quench	p53	activity.	Low	
levels	of	Mdm2	activity	promote	monoubiquitination	of	p53,	responsible	for	its	shuttling	
from	the	nucleus	to	the	cytoplasm.	High	levels	of	Mdm2	instead	induce	polyubiquitination	
of	p53	that	triggers	its	degradation	(Fig.	10).	Moreover,	Mdm2	is	able	to	inhibit	p53	trans-
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activation	of	 target	genes	both	by	preventing	p53	 interaction	with	coactivators	 (it	 com-
petes	 with	 p300	 binding	 to	 the	 p53	 N-terminal	 TAD)	 and	 recruiting	 transcriptional	 re-
pressors	81	(Fig.	10).	
	
	
Fig.	10	Mechanisms	of	Mdm2	regulation	on	p53.	
Several	stress	conditions	such	as	acute	DNA	damage	or	oncogene	activation	(by	stimulating	
ARF-mediated	Mdm2	inhibition)	induce	p53	activation.	Activated	p53	is	released	from	its	
negative	regulator	Mdm2.	Mdm2	physiologically	interacts	with	p53	promoting	its	ubiquiti-
nation	and	consequent	degradation,	favoring	p53	nuclear	export	and	blocking	p53	trans-
activation	activity	on	target	genes.	Transcription	of	these	genes	is	ultimately	important	for	
mediating	 tumor	 suppressor	 functions	of	p53.	Among	p53	 target	 genes,	p53	 stimulates	
Mdm2	transcription	forming		a	p53	/Mdm2	auto-regulatory	feedback	loop.	
Inhibitors	of	Mdm2	or	Mdm2/p53	interaction	should	stabilize	p53.	Figure	from	82.	
	
In	addition	to	this	well-characterized	function	of	Mdm2,	increasing	evidence	has	demon-
strated	several	p53-independent	roles	of	Mdm2.	In	fact,	Mdm2	is	able	to	regulate	several	
cellular	proteins,	and	is	thus	involved	in	pathways	ranging	from	DNA	repair	and	synthesis	
to	control	of	cell	 cycle	progression,	apoptosis,	cell	 fate,	differentiation,	cell	motility	and	
invasion	83.	The	mapping	of	Mdm2	structural	domains	has	helped	to	dissect	the	mecha-
nisms	underlying	its	biological	functions	and	its	expression	regulation.	
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Mdm2	contains	 four	 functionally	 independent	structural	domains:	 i)	an	N-terminal	p53-
binding	domain	(aa	18-111)	that	binds	the	p53	N-terminal	Box	I	domain,	ii)	a	central	region	
rich	in	acidic	amino	acids	also	referred	to	as	the	acidic	domain	(AD,	aa	237-288),	iii)	a	zinc-
finger	domain	(aa	289-331)	and	iv)	a	C-terminal	RING	finger	domain	(aa	436-482),	where	
the	E3-ubiquitin	ligase	activity	resides	84	(Fig.	11).	The	primary	amino	acid	sequence	of	the	
Mdm2	AD	is	evolutionarily	conserved	in	mammals	and	provides	the	binding	sites	for	many	
Mdm2	positive	regulators	(transcription	activator	YY1,	co-activator	p300)	and	negative	reg-
ulators	as	ADP	ribosylation	factor	(ARF),	Promyelocytic	leukemia	protein	(PML)	and	riboso-
mal	proteins,	Rb	85.	Moreover,	the	Mdm2	AD	is	involved	in	several	processes,	such	as	ubiq-
uitination-independent	inhibition	of	the	DNA-binding	function	of	p53	or	negative	regula-
tion	of	p300-mediated	p53	acetylation	and	other	p53-independent	functions	81.	
	
	
	
	
	
	
Fig.	11	Schematic	representation	of	the	full-length	Mdm2	structure.	
Mdm2	domains	include	the	N-terminal	p53-binding	domain	(yellow,	residues	18–101);	the	
centrally	located	acidic	domain	that	binds	ARF	and	is	involved	in	p53	ubiquitination	(green,	
residues	237–288);	and	the	zinc-finger	motif	(blue,	residues	289–330).	The	Mdm2	C-termi-
nal	contains	a	RING	domain	that	displays	E3-ubiquitin	ligase	activity	(orange,	residues	436–
482).	Numbers	indicates	amino	acid	residues	at	the	borders	between	these	domains.	NLS	
=	nuclear	localization	signal;	NES	=	nuclear	export	signal.	Figure	adapted	from	84	
	
Recent	evidence	highlights	 a	previously	unexpected	 role	of	 endogenous	Mdm2	 in	mito-
chondria	(mtMdm2)	that	is	independent	of	p53.	It	was	shown	that	Mdm2	is	actively	im-
ported	 into	mitochondria	and	 localizes	at	the	 level	of	the	mitochondrial	matrix	where	 it	
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appears	to	control	respiration	and	mitochondrial	dynamics	independently	of	p53	in	a	lung	
cancer	cell	line	model	system	86	.	High	levels	of	mtMdm2	prompt	an	increased	motility	in	
cancer	cells,	suggesting	an	additional	role	of	mtMdm2	in	tumorigenesis	86.	
	
Mdm2	gene	expression	is	regulated	by	two	transcriptional	promoter	elements:	P1,	where	
basal	transcription	is	initiated	and	P2,	which	is	activated	upon	p53-induced	transcription	87.	
Other	transcription	factors	(NF-kB,	IRF-8,	FliETS,	SP1),	pathways	(Rad-Raf-MEK-MAPK)	and	
several	microRNAs	(143,145,29,18b)	are	involved	in	modulation	of	Mdm2	mRNA	expres-
sion	and	protein	translation	81.	Moreover,	PTMs,	including	phosphorylation	of	Mdm2	pro-
tein	by	several	kinases,	can	affect	its	stability,	activity	and	localization	88,89.	Once	expressed,	
Mdm2	translocates	to	the	cytoplasm	where	it	mediates	the	proteasomal	degradation	of	
many	of	its	targets	81.		
	
An	enhanced	expression	of	Mdm2	is	tumorigenic,	thus,	establishing	it	as	an	oncoprotein.	
Indeed,	 amplification	 of	 the	MDM2	 gene	 is	 a	 common	 event	 occurring	 in	 over	 17%	 of	
tumors	 90.	 This	 event	 accounts	 for	 Mdm2	 overexpression	 and	 contributes	 to	 p53	
inactivation	 in	 many	 p53-WT	 tumors	 91–93.	 In	 human	 tumors,	 Mdm2	 overexpression	 is	
associated	with	poor	prognosis	and	correlates	with	more	aggressive	and	metastatic	tumor	
phenotypes,	especially	in	solid	tumors	81.			
	
	
2.3.4.4 REGULATION	OF	THE	p53-MDM2	PATHWAY	
Different	therapeutic	strategies	aim	to	overcome	p53	attenuation	in	cancer	cells.	One	pos-
sibility	is	to	rescue	p53	levels	by	directly	targeting	the	Mdm2-p53	interaction.	Thus,	there	
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have	been	several	studies	focused	on	characterizing	this	interaction	at	the	structural	and	
functional	level.	Although	the	main	interaction,	originally	mapped	between	N-terminal	do-
mains	of	p53	and	Mdm2	blocks	the	p53-mediated	transactivation	of	target	genes,	it	alone	
is	not	sufficient	to	promote	Mdm2-catalyzed	p53	ubiquitination	94.	A	second	interaction	
site	has	been	identified	between	a	specific	DNA-binding	site	in	the	p53	DBD	that	harbors	a	
ubiquitin	signal	(Box	V)	and	the	Mdm2	AD	and	part	of	the	zinc-finger	domain	95	(Fig.12).	
This	latter	region	is	located	between	residues	211	and	321	and	is	critical	for	Mdm2-medi-
ated	ubiquitin	ligase	activity	towards	p53	95.	In	particular,	deletion	of	Mdm2	residues	247-
258	and	270-274	was	shown	to	severely	impair	its	ability	to	ubiquitinate	p53	85.	Moreover,	
this	activity	can	be	affected	by	phosphorylation	events	at	multiple	sites	in	Mdm2.	Different	
kinases	(PLK1,	HGSk3,	GK2,	c-ABL)	target	Mdm2	residues	within	these	cluster	regions	(247-
258	and	270-274)	or	in	close	proximity	to	them,	thereby	modulating	Mdm2	E3-ligase	activ-
ity	85.		
Further	experimental	results	support	the	idea	that	the	N-terminal	domain	and	the	AD	of	
Mdm2	bind	to	p53	in	a	cooperative	way.	In	this	model,	the	interaction	between	the	p53	
Box	I	and	the	Mdm2	N-terminal	domain	acts	to	induce	conformational	changes	in	Mdm2	
that	facilitate	the	binding	between	the	p53	Box	V	and	the	Mdm2	AD	94	(Fig.	12).	
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Fig.	12	Dual	site	mechanism	of	Mdm2-p53	interaction.	 
The	p53	and	Mdm2	proteins	are	shown	in	schematic	modular	format.	Interaction	of	the	N-
terminal	TAD1	of	p53	with	the	N-terminal	hydrophobic	pocket	of	MDM2	leads	to	a	confor-
mational	shift	that	facilitates	the	association	between	the	acidic	domain	of	MDM2	with	the	
so-called	‘ubiquitylation	signal’	within	the	Box	V	region	of	p53.	This	brings	the	C-terminal	
domain	(CTD)	of	p53	into	contact	with	the	RING	domain	of	MDM2	together	with	the	E2	
ligase,	 leading	to	ubiquitylation	of	p53.	TAD1	and	TAD2	=	two	functional	portions	of	the	
transcriptional	activation	domains;	PRO=proline-rich	domain.	II,III,	IV,	V	=	highly	conserved	
Box	regions	of	the	p53	DNA	binding	domain.	Figure	adapted	from	96	
	
	
Currently,	the	vast	majority	of	the	inhibitors	were	screened	or	designed	in	order	to	bind	
the	N-terminal	regions	of	Mdm2	and	p53	(e.g.,	Nutlin	family	of	inhibitors	has	been	the	first	
to	be	characterized).	Further	characterization	of	the	second	structural	interaction	between	
the	p53	DBD	and	the	Mdm2	AD	could	be	extremely	helpful	for	designing	inhibitor	mole-
cules	that	are	able	to	modulate	this	second	interaction	surface	to	therapeutically	reactivate	
p53	tumor	suppressor	activity.		
	
There	is	also	a	wide	“supporting	cast”	of	interacting	factors	that	are	involved	at	multiple	
levels	 in	Mdm2-p53	regulation.	The	following	proteins	are	the	main	interactors	that	can	
affect	Mdm2	localization,	binding	and	expression,	reviewed	in	81:	
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- MdmX	shows	significant	homology	and	shares	domain	structural	architecture	with	
Mdm2	97.	It	inhibits	p53	transactivation	activity	but	does	not	directly	induce	p53	degrada-
tion	 since	 its	 RING	 domain	 lacks	 E3-ligase	 activity.	 However,	 by	 heterodimerizing	 with	
Mdm2,	MdmX	also	directly	contributes	to	p53	turnover	98.	
- ARF	interacts	with	Mdm2,	sequestering	it	into	the	nucleolus,	thereby,	indirectly	sta-
bilizing	p53	by	preventing	its	Mdm2-mediated	cytosolic	degradation	99.	A	similar	mecha-
nism	is	mediated	by	PML	that	confines	Mdm2	to	the	nuclear	compartment	100.	Nucleophos-
min	(NPM)	instead	competes	with	Mdm2	for	p53	binding,	thus	stabilizing	p53	101.		
- 14-3-3	is	a	p53	target	gene	that	stabilizes	p53	by	increasing	Mdm2	auto-ubiquitina-
tion	and	inhibits	Mdm2-mediated	p53	nuclear	export	to	the	cytoplasm	102	
- Ribosomal	proteins	bind	to	the	Mdm2	AD	inhibiting	 its	E3-ligase	activity	towards	
p53.	-Subset	of	Polycomb	proteins	bind	and	destabilize	Mdm2	leading	to	 increasing	p53	
stability	103.	
The	above-mentioned	interactors	could	be	indirect	targets	to	rescue	p53	levels	or	decrease	
Mdm2	activity	to	prevent	p53	degradation.	
	
2.3.4.5 p53	IN	CANCER	
The	prominent	role	of	p53	in	many	aspects	of	cell	physiology	makes	it	a	primary	target	for	
alterations	promoting	malignant	transformation.	p53	deficiency	can	enhance	the	initiation	
and	 progression	 of	 cancer.	 Tumors	 with	 p53	 dysfunction	 are	 characterized	 by	 genomic	
instability	 and	more	 aggressive	 features,	 such	 as	 increased	 invasiveness	 and	metastatic	
potential,	lack	of	cellular	differentiation,	increased	vascularization,	indefinite	proliferation	
and	resistance	to	anti-cancer	therapies	67.		
In	about	half	of	spontaneous	cancers,	p53	protein	does	not	function	correctly.	In	a	great	
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number	of	cases,	p53	dysfunction	 is	due	 to	mutations	of	 the	p53	 gene	or	 in	genes	 that	
encode	 for	 p53	 upstream	 or	 downstream	 regulatory	 proteins	 that	 interact	with	 p53	 or	
transmit	signal	information	to	and	from	p53.	Most	p53	mutations	are	missense	and	cluster	
in	86%	of	cases	in	the	p53	DBD	(Fig.	13).	Hotspot	mutations	involve	residues	important	for	
correct	architecture	folding	of	the	flexible	DNA	binding	surface	or	critical	for	contacts	with	
p53-responsive	 element	 on	 promoters	 of	 target	 genes.	 The	 functional	 impact	 of	 these	
mutations	is	dysregulated	p53	transactivation	activity.	Transcriptional	activity	requires	the	
formation	of	p53	tetramers	(dimers	of	dimers).	Incorporation	of	a	mutant	p53	monomer,	
due	 to	 mutation	 in	 a	 single	 p53	 allele,	 in	 these	 structures	 may	 preclude	 their	 activity	
resulting	in	a	dominant-negative	phenotype	104.	
	
In	some	human	cancers,	the	frequency	of	the	p53	mutations	is	not	as	high	as	in	the	vast	
majority	of	cancers.	In	breast	cancer,	p53	mutations	are	detected	in	only	20-30%	of	patients.	
However,	the	percentage	of	tumors	displaying	p53	dysfunction	is	higher,	due	to	the	fact	that	
p53	can	be	inactivated	also	by	indirect	mechanisms,	such	as	altered	expression	of	Mdm2	
(due	to	amplification	of	the	locus)	and	loss	of	ARF	protein	expression,	as	mentioned	above	
.	
Fig.	13	Hotspot	mutation	in	the	TP53	gene	in	human	cancer.	
Height	of	the	peaks	is	proportional	to	the	relative	frequency	of	cancer	associated	missense	
mutations	of	each	p53	residues	(see	figure	8	as	reference)	according	the	TP53	mutation	
database	of	the	Agency	for	Research	on	Cancer	105,104.	Figure	adapted	from	104.	
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From	a	therapeutic	perspective,	p53	reactivation	is	hailed	as	an	obvious	goal	to	halt	tumor	
progression.	The	emerging	 theme	 is	 that	p53	has	a	pivotal	 role	 in	maintaining	organism	
fitness	 through	 two	mechanisms:	 first,	 by	 supporting	 the	 adaptation	 and	 repair	 of	 cells	
under	conditions	of	stress	and	damage,	and	second,	by	driving	the	elimination	of	cells	that	
cannot	be	repaired	or	are	under	constant	stress	conditions	69.	Although	there	is	still	much	
to	learn,	experimental	evidence	clearly	indicates	that	manipulating	the	p53	pathway	could	
bring	considerable	therapeutic	benefits.		
	
The	goal	is	to	try	to	re-establish	the	growth	inhibitory	function	of	p53	in	cancer	cells	where	
it	is	impaired	or	defective.	The	main	approaches	(Fig.	14)		include	106:		
i) gene	therapy	consisting	of	adenoviral	delivery	of	p53	WT	(Ad-p53)	into	cancer	cells	
to	rescue	p53	activity.	In	vitro	and	in	vivo	studies	demonstrated	that	Ad-P53	delivery	cor-
relates	with	tumor	regression	in	several	cancer	contexts	including	head	and	neck	cancer	
107,lung	cancer	 108,	prostate	 109,	glioma	110.	This	 strategy	has	shown	a	satisfactory	safety	
profile	thus	promoting	its	testing	in	phase	I	to	IV	clinical	trials	for	the	treatment	of	different	
tumor	types,	such	as	recurrent	malignant	gliomas	111,	head	and	neck	cancer	112,	hepatocel-
lular	carcinoma	113,	and	significantly	 increased	patient	survival	when	combined	to	radio-
therapy.	
ii) inhibition	of	Mdm2	or	Mdm2-p53	 interaction	using	small	molecule	 inhibitors	 114,	
(see	paragraph	2.3.4.6),	such	as	Nutlin		115.	
iii) restoration	of	 the	p53	WT	conformation	 in	mutated	cases	 116.	Mutant	p53	often	
accumulates	in	cancer	cells	and	therefore	represents	a	tumor-specific	biomarker	117,118.	In	
silico	high-throughput	 screenings	of	 chemical	 libraries	and	computational	analyses	have	
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identified	several	small	molecules	that	are	able	to	restore	physiological	p53	WT	functions	
and	conformation,	leading	to	massive	apoptosis	in	tumor	cells	and	thus	antitumor	activity.	
These	 compounds	 include	 PRIMA-1,	 MIRA-3,	 STIMA-1,	 PhiKan083,	 ellipticine,	 P53R,	
NSC319726,	CP31398	[reviewed	in	106].	
iv) targeting	mutant	p53	to	degradation	119.	An	alternative	strategy	in	tumors	addicted	
to	mutant	p53,	 involves	 targeting	p53	mutants	 to	degradation	by	administration	of	p53	
siRNA	or	small	molecules	that	induce	degradation	of	mutant	p53	(e.g.,	HSP90	inhibitors,	
SAHA	inhibitor,	arsenic	trioxide)	120,121.	
v) p53-based	immunotherapy	(e.g.,	vaccines:	p53	SLP,	INGN25).	Mutant	p53	expres-
sion	in	cancer	cells	can	be	used	as	tumor-specific	antigen	to	target	with	immunotherapy.	
p53	vaccines	against	mutant	p53	synthetic	peptides	have	entered	phase	I/II	clinical	trials,	
and	were	well-tolerated	and	able	to	activate	a	specific	anti-mutant	p53	immune	response	
122.	
	
Considering	 the	above,	 it	 is	clear	 that	 the	evaluation	of	p53	status	 in	 tumors	 is	of	great	
importance	in	deciding	the	appropriate	treatment	strategy.	Many	p53	mutations	 lead	to	
abnormal	 p53	 nuclear	 accumulation118.	Mutant	 p53	 protein	 probably	 accumulates	 as	 a	
result	 of	 compromised	 p53-mediated	 transcription	 of	 its	modulator	Mdm2.	As	 a	 result,	
mutant	p53	has	a	longer	half-life	compared	to	the	relatively	unstable	WT	protein.	Based	on	
this	 observation,	 a	 large	 number	 of	 studies	 have	 used	 immunohistochemistry	 (IHC)	
detection	of	accumulated	p53	as	a	surrogate	marker	for	p53	mutational	status	123.	In	this	
IHC	analysis,	a	semi-quantitative	score	is	attributed	according	to	the	percentage	of	positive	
nuclear-stained	cells	in	the	analyzed	tissue	section	118,123.	Data	from	several	breast	cancer	
cohorts	 demonstrated	 that	 p53	 accumulation	 is	 an	 independent	 parameter	 of	 poor	
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prognosis	 124.	 It	has	emerged,	however,	 that	also	undetectable	p53	nuclear	staining	 is	a	
likely	 indicator	 of	 null-mutations	 in	 the	 p53	 gene	 and	 poor	 prognosis	 118.	 p53	 gene	
sequencing	clearly	remains	the	most	reliable	technique	to	assess	p53	mutational	status	in	
a	 tumor	 sample.	 However,	 its	 application	 is	 lab	 intensive	 and	 time-consuming,	 thus,	
currently	not	suitable	in	clinical	settings.		
	
 
	
	
Fig.	14	Multiple	strategies	to	reactivate	the	p53	pathway	in	cancer.		
According	to	the	mechanism	of	p53	dysfunction,	different	approaches	can	be	used	to	re-
store	p53	function	in	tumors	125–127	 ,	 in	order	to	halt	tumor	growth.	The	main	strategies	
used	to	directly	or	indirectly	recover	p53	tumor	suppressor	activity	include;	i)	direct	eleva-
tion	of	p53	protein	levels,	p53-based	immunotherapy;	ii)	inhibition	of	Mdm2	expression,	of	
its	ubiquitin	ligase	activity	or	of	the	Mdm2–p53	interaction;	iii)	restoration	of	mutant	p53	
(mut-p53)	 to	wild-type	p53	 (wt-p53)	 function	or	promotion	of	mut-p53	degradation;	 iv)	
modulation	of	Mdm2/Mdm2-p53	interactors.	RITA	=	Reactivation	of	p53	and	induction	of	
tumor	apoptosis.	Figure	adapted	from	81.		
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2.3.4.6 TARGETING	 OF	 THE	 p53-MDM2	 PATHWAY	 FOR	
CANCER	THERAPY		
The	MDM2-p53	pathway	has	been	widely	studied	and	presents	an	attractive	target	for	can-
cer	 therapy.	 Inhibition	of	Mdm2	or	of	 the	Mdm2-p53	 interaction	 represent	 indirect	ap-
proaches	to	re-establish	p53	function	and	are	thus	considered	as	viable	therapeutic	strat-
egies	to	negatively	affect	tumor	progression.	The	following	approaches	were	tested	in	vitro	
to	prove	their	efficacy	and	feasibility	and	some	of	them	are	proceeding	their	path	towards	
therapeutic	application	in	the	clinical	setting	81	(Fig.	14):	
i) Mdm2	inhibition.	This	strategy	exploits	silencing	techniques	using	antisense	oligo-
nucleotide	delivery,	Mdm2	ribozymes	or	aptamers.	All	these	techniques	showed	pro-apop-
totic	and	anti-proliferative	effects	in	vitro	in	a	panel	of	cancer	cell	lines	128	but,	only	recently,	
has	their	use	in	the	clinic	been	promoted	by	the	successful	smart	delivery	of	Mdm2	siRNA	
129,130.	
ii) Direct	inhibition	of	Mdm2-p53	binding.	Small	molecule	Mdm2	inhibitors	were	de-
signed	to	target	the	hydrophobic	pocket	on	the	surface	of	Mdm2	protein,	where	the	main	
residues	critical	for	p53	binding	are	present.	The	most	promising	candidates	came	from	the	
screening	of	chemical	 libraries	 to	 identify	molecules	 that	bind	the	N-terminus	of	Mdm2	
(e.g.,	Nutlin,	RG7112,	HCT116,	spiro-oxindoles,	isolindones,	chalcone,	MI219,	HLI98,	ben-
zodiazepinedione)	and	analogues	of	these	lead	compounds	are	being	developed	and	opti-
mized	for	clinical	use	114.	The	most	prominent	example	is	that	of	the	Nutlin	family	of	com-
pounds,	which,	in	p53	WT	tumors,	is	able	to	activate	tumor	suppressor	functions	of	p53	
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allowing	transactivation	of	downstream	target	genes	131.	Nutlin	has	been	proved	to	be	ef-
fective	 in	the	preclinical	setting,	and	a	related	compound,	RG7388	 is	better	tolerated	 in	
patients,	although	long-term	effects	in	a	clinical	setting	should	be	still	evaluated	132,133.	.		
The	aforementioned	compounds	only	weakly	inhibit	E3-ligase	activity.	They	likely	disrupt	
the	interaction	between	the	N-terminal	domains	of	Mdm2	and	p53,	but	are	unable	to	fully	
dissociate	the	complex,	since	a	second	Mdm2	AD-p53	Box	V	binding	persists.	Concerning	
this	issue,	an	alternative	approach	to	induce	p53	activation	involves	the	physical	or	allo-
steric	inhibition	of	Mdm2	E3-ligase	activity	by	targeting	this	second	Mdm2-p53	docking	site	
with	small	molecules	inhibitors	or	peptide	ligands	(e.g.,	ARF-mimicking	compounds)	134.	
	
Despite	the	intensive	efforts	aimed	at	identifying	or	synthetically	designing	novel	inhibitors	
targeting	the	Mdm2-p53	interaction,	no	such	drugs	have	been	approved	in	the	clinic.	How-
ever,	 some	 of	 these	 compounds	 (e.g.,	 RG7388,	 R05503781,	 SAR405838,	 CGM097,	MK-
8242)	are	already	being	tested	in	advanced	clinical	trials	and	appear	to	be	promising	for	
p53	WT	cancer	treatment	135.	
	
It	is	important	to	remember	that	multiple	levels	of	regulation	by	a	wide	and	dynamic	pro-
tein-interaction	network,	impose	restrictive	parameters	and	conditions	that	should	be	kept	
in	consideration	when	stratifying	patients	for	a	successful	precision	medicine.	In	this	con-
text,	exploiting	Numb	inhibition	of	the	Mdm2-p53	circuitry	for	the	rational	design	of	Numb	
mimetic	molecules	could	be	an	 interesting	parallel	strategy	to	reactivate	p53	in	p53	WT	
tumors.	
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2.3.4.7 THE	ROLE	OF	NUMB	IN	THE	REGULATION	OF	THE	
p53-MDM2	PATHWAY		
Previous	work	 from	our	 lab	has	highlighted	a	 tumor	 suppressor	 role	of	Numb	 in	breast	
cancer	related	to	its	sustainment	of	the	p53	pathway	under	physiological	conditions.	Numb	
enters	into	a	trimeric	complex	with	p53	and	Mdm2,	directly	interacting	with	both	proteins	
to	inhibit	Mdm2-mediated	ubiquitination	of	p53,	thereby	stabilizing	p53	protein	levels	63	
(Fig.	15).	
	
Fig.	15	Possible	model	of	NUMB	interaction	in	a	Numb/Hdm2/p53	tricomplex.		
A)	Mdm2	targets	p53	for	ubiquitination.	The	p53-Mdm2	interaction	is	mediated	by	at	least	
two	 different	 docking	 sites:	 1)	 between	 the	N-terminal	 BOX-I	 region	 of	 p53	 and	 the	N-
terminal	domain	of	HDM2;	2)	between	the	p53	DNA	binding	region	and	HDM2	acid	domain	
(AD).	B)	Possible	model	of	NUMB	action.	NUMB	prevents	the	physical	interaction	between	
p53	and	HDM2	AD,	by	intercalating	between	the	two	proteins.		
Figure	adapted	from	63	
Consequently	Numb-deficient	tumor	cells	(see	paragraph	2.4)	display	reduced	p53	levels	
and	activity,	and	impaired	ability	to	respond	to	genotoxic	treatment	and	to	efficiently	repair	
DNA	damage	63.	A	more	detailed	biochemical	and	structural	characterization	of	the	Numb-
Mdm2	 interaction	 from	our	 lab	has	 further	 illuminated	 the	mechanism	of	 the	action	of	
Numb	 on	 Mdm2	 136.	 In	 particular,	 a	 region	 encompassing	 the	 Numb	 exon	 3	 encoded	
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sequence	within	the	PTB	domain	(PTBi;	aa	54-91)	seems	to	be	necessary	and	sufficient	for	
high	affinity	binding	of	Numb	to	Mdm2.	Since	exon	3	is	alternatively	spliced,	this	region	is	
present	only	in	Numb	isoforms	1	and	2	(see	paragraph	2.2).	The	crystallographic	resolution	
of	the	Numb	PTBi	reveals	that	the	exon	3-containing	Numb	region	(11	aa)	is	arranged	as	a	
dynamic	 loop	 able	 to	 adopt	 at	 least	 three	 different	 conformations.	 This	 flexible	 loop	 is	
enriched	in	aromatic	and	positively	charged	amino	acids	136.	Nuclear	magnetic	resonance	
(NMR)	 chemical	 shifts	 and	 mutational	 analysis	 suggested	 that	 Numb	 PTBi	 residues	
contribute	 to	 the	 formation	 of	 a	 large	 hydrophobic	 and	 positively	 charged	 patch	 that	
dynamically	engages	an	 intrinsically	 flexible,	hydrophobic	and	negatively	charged	Mdm2	
region	at	the	level	of	its	AD	(aa	250-290),	giving	rise	to	a	“fuzzy”	complex	136	(Fig.	16).	 
Fig.	16	The	Ex3-encoded	sequence	represents	a	novel	surface	in	the	NUMB	PTB	domain	
dynamically	involved	in	MDM2	binding.	
A)	Ribbon	model	of	the	crystallographic	structure	of	Numb-PTBi	in	complex	with	a	GPpY	
phosphopeptide	 (violet).	 GPpY	 is	 a	 phosphopeptide	 that	 derives	 from	 a	 canonical	 PTB-
binding	 protein.	 The	 11	 aa	 exon3-encoded	 sequence	 is	 depicted	 in	 red.	 B)	 Schematic	
representation	 indicating	 that	 the	 PTBi:Mdm2	 interaction	 interface	 represents	 a	 fuzzy	
complex,	where	two	intrinsically	disordered	regions	in	both	binding	partners	interact	and	
retain	dynamic	and	intrinsic	disorder	in	the	complex.	The	Numb-Mdm2	interaction	is	based	
on	 multiple	 polar	 and	 hydrophobic	 interaction	 between	 the	 negatively	 charged	Mdm2	
acidic	domain	and	the	positively	charged	Numb	PTB	domain.	Figure	adapted	from	136	
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Interestingly,	as	previously	discussed,	the	Mdm2	AD	is	important	for	its	E3-ligase	activity	
and	is	also	targeted	by	other	Mdm2	inhibitors,	such	as	ARF.	The	Mdm2	AD	is	regulated	by	
different	PTMs,	 in	particular,	 phosphorylation	of	 different	 residues,	which	 contribute	 to	
maintain	 the	 interaction	with	p53	under	 ‘unstressed’	 conditions	when	 the	cell	needs	 to	
maintain	 low	 levels	 of	 p53.	 Phosphomimic	 mutants	 of	 Mdm2	 that	 mimic	 the	
phosphorylation	occurring	 in	vivo,	were	able	to	increase	the	binding	to	Numb,	indicating	
that	 probably	 also	 some	 PTMs	 might	 contribute	 to	 the	 Numb-Mdm2	 interaction.	 The	
crystallographic	 resolution	 of	 the	 Numb	 PTBi	 region	 might	 open	 the	 way	 to	 future	
therapeutic	interventions	in	breast	cancer,	envisioning	the	possibility	to	identify	new	small	
molecules	or	peptides	that	mimic	Numb	action	on	Mdm2	to	inhibit	its	E3-ligase	activity	and	
thus	rescue	p53	levels	in	Numb-deficient	tumors.	The	characterization	of	the	Numb-Mdm2	
interaction	and,	in	particular,	of	the	exclusive	role	of	the	exon	3-coded	region	of	Numb	in	
this	interaction,	prompted	us	to	investigate	whether	exon	3-containing	Numb	isoforms	have	
a	specific	role	in	p53	regulation,	as	will	be	described	in	the	results	section	of	this	thesis	(see	
paragraph	5.3).		
	
2.3.5 NUMB	IN	CELL	ADHESION,	CELL	MIGRATION	AND	
EPITHELIAL-TO-MESENCHYMAL	TRANSITION		
The	role	of	Numb	in	endocytosis	and	recycling	of	transmembrane	receptors	unveils	addi-
tional	functions	in	the	regulation	of	cell	adhesion.	Numb	was	indeed	reported	to	physically	
interact	with	the	E-cadherin/catenin	complex	at	the	level	of	cells	adherens	junctions	(AJs)	
137.	AJs	are	multi-protein	complexes	that	provide	a	strong	mechanical	attachment	between	
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adjacent	epithelial	cells,	and	are	thus,	involved	in	the	regulation	of	plasma	membrane	dy-
namics,	cell	shape	and	motility	138.	AJs	consist	of	the	transmembrane	E-cadherin	protein	
responsible	for	i)	trans-pairing	intercellular	contacts	on	opposing	cells	and	ii)	intracellular	
interactions	with	cytoplasmic	p120-catenin,	β-catenin	and	α-catenin	that	are	connected	to	
the	actin	cytoskeleton,	locally	regulating	its	dynamics	139.	In	this	context,	Numb	contributes	
to	continuous	internalization	and	recycling	at	plasma	membrane	of	E-cadherin-containing	
vesicles,	within	Rab11	containing	endosomes,	for	the	maintenance	of	AJ	stability	137.		
To	 acquire	migratory	 traits,	 cells	 need	 to	 undergo	 epithelial-to-mesenchymal	 transition	
(EMT).	EMT	is	a	process	in	which	epithelial	cells	acquire	pro-metastatic	migratory	traits	by	
expressing	mesenchymal	markers	while	losing	their	cell-cell	contacts	and	polarity.	Numb	
dysfunction,	by	ablating	 its	 role	 in	cell	adhesion	maintenance,	 triggers	 the	EMT	process	
connected	with	tumor	progression	and	metastasis	140.	
Another	role	of	Numb	is	in	cell-extracellular	matrix	adhesion	regulation,	controlling	integrin	
endocytosis.	Numb	is	able	to	control	the	directional	trafficking	of	 integrin	at	the	 leading	
edge	of	cell	protrusions	 in	migrating	cells.	Numb	binds	to	beta-integrins	and	 localizes	to	
clathrin-coated	 pits	 at	 the	 substratum-facing	 cell	 surface.	 These	 interactions	 allow	 the	
control	of	 integrin	endocytic	 trafficking,	 from	their	 internalization	 to	 their	 route	back	 to	
plasma	membrane	to	make	new	adhesion	sites	at	the	leading	front	28.	
Numb	is	also	involved	in	the	EMT	process	by	regulating	cell	polarity	in	epithelial	cells.	Cell	
polarity	 is	established	by	 the	asymmetrical	organization	of	 several	 cellular	components.	
Polarity	complex	proteins	(PAR)	are	involved	in	coordinating	this	process	and	have	a	role	
also	in	the	establishment	of	tight	junctions	(TJs).	TJs	seal	neighboring	epithelial	cells	thus	
functionally	separating	the	apico-basolateral	surfaces	and	limiting	liquid	flux	between	cel-
lular	interspace.	TJs	consist	of	a	network	of	transmembrane	proteins,	occludin	and	claudin,	
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and	the	cytoplasmic	scaffolding	proteins	ZO-1,-2,	and	-3	141,139.	By	interacting	and	affecting	
the	localization	of	PAR3	(members	of	PAR	polarity	complex)	it	seems	that	Numb	might	also	
be	involved	in	regulation	of	TJs	dynamics	2.	
Moreover,	Numb	seems	to	prevent	EMT	by	being	a	negative	regulator	of	Notch.	The	Notch	
signaling	cascade	promotes	EMT	by	inducing	Snail	and	Slug	that,	in	turn,	transcriptionally	
repressing	the	expression	of	E-cadherin	142,143.	
In	 the	context	of	 cancer,	 the	downmodulation	of	Numb	can	causally	drive	an	enhanced	
tumor	invasion	by	prompting	the	EMT	phenotype	142,143	.	Taken	together,	these	data	suggest	
a	role	of	Numb	in	driving	all	the	steps	of	the	EMT	process,	from	loss	of	cellular	polarity	and	
cell-cell	 contacts	 (dynamic	 remodulation	 of	 AJs	 and	 TJs),	 actin	 remodeling	 and	 cell-to-
extracellular	matrix	dynamics	for	cell	migration. 
	
2.3.6 INCREASING	 THE	 COMPLEXITY:	 THE	 ROLE	 OF	
NUMB	ISOFORMS		
Recent	 evidence	has	 highlighted	 another	 level	 of	 complexity	 in	 the	 regulation	of	Numb	
biochemical	 functions	 concerning	 the	 differential	 role	 of	 Numb	 isoforms.	 As	 previously	
described,	 there	 are	 four	main	 Numb	 isoforms	 in	mammals,	 resulting	 from	 alternative	
splicing	events	that	occur	at	the	level	of	exon	3	and	exon	9	of	the	NUMB	gene.	To	date,	the	
different	functional	roles	of	these	isoforms	is	not	fully	understood.	However,	some	studies	
have	focused	on	dissecting	the	role	of	the	exon	9	alternative	splicing	event	and	highlighted	
a	differential	role	of	Numb	isoforms	in	Notch	activation	19.	
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Numb	Ex9	alternative	splicing		
The	expression	of	exon	9-containing	isoforms	(1	and	3)	vs.	exon	9	lacking	isoforms	(2	and	4)	
is	developmentally	regulated	144.	Alternative	splicing	is	skewed	towards	isoforms	1	and	3	in	
progenitor	cells,	whereas	isoforms	2	and	4	are	predominantly	expressed	in	differentiated	
cells	145.	This	pattern	of	expression	is	observed	in	the	embryonic	mouse	brain	and	in	the	
developing	 pancreas	 and	 retina,	 where	 isoforms	 1	 and	 3	 are	 expressed	 in	 early	
developmental	 stages	 and	 decrease	 upon	 lineage	 differentiation.	 In	 mammalian	
neurogenesis,	this	pattern	is	compatible	with	distinct	Numb	isoform	functions	in	promoting	
either	neuronal	differentiation	(isoforms	2	and	4)	or	enhancing	cell	proliferation	(isoforms	
1	and	3)	20.	Neuronal	differentiation	implies	a	switch	in	Numb	isoform	expression	towards	
an	 increase	 in	 exon	 9-lacking	 isoforms	 2	 and	 4	 144.	 The	 mechanism	 underlying	 the	
differential	 effect	 of	 Numb	 isoforms	 1/3	 vs.	 2/4	 on	 the	 cell	 proliferation/differentiation	
balance	has	been	linked	to	the	Notch	signaling	regulation.	Indeed,	increased	expression	of	
exon	9-containing	isoforms	1	and	3	seems	to	result	in	enhanced	Notch	activation,	while	the	
prevalence	of	exon	9-lacking	isoforms	2	and	4	results	in	Notch	signaling	attenuation	144	(Fig.	
17)	However,	it	is	not	clear	how	Numb	isoforms	mediate	this	dual	and	opposite	effect	on	
Notch	signaling.	
Fig.	17	Numb	isoforms	structure	and	role	in	Notch	regulation.		
Numb	 isoform	1/3	activate	Notch	 signaling	 thus	affecting	 cell	proliferation,	while	Numb	
isoform	2/4	seem	to	negatively	impact	on	Notch	pathway	prompting	cell	differentiation.	
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Alternative	splicing	is	a	tightly	regulated	process	in	development,	as	well	as	in	adult	tissues,	
and	aberrant	alternative	splicing	has	been	proposed	to	influence	all	the	hallmarks	of	cancer	
146.	 The	 production	 and	 abundance	 of	 splice	 variants,	which	 exert	 sometimes	 opposing	
functions,	 is	 dynamically	 regulated	 in	 a	 temporal	 and	 spatial	 manner	 147.	 Notably,	
deregulation	of	the	alternative	splicing	of	Numb,	 leading	to	alterations	 in	Numb	isoform	
expression,	has	been	observed	in	different	cancers,	suggesting	a	role	of	aberrant	alternative	
splicing	 in	the	tumorigenic	processes.	 Indeed,	 increased	expression	of	exon	9-containing	
isoforms	have	been	observed	 in	breast,	 colon	and	 lung	cancer	 compared	 to	 the	normal	
tissue	counterpart	148,149,150.		
Some	alternative	splicing	factors	have	been	shown	to	be	involved	in	Numb	exon	9	splicing,	
such	as	Rbm10,	Rbm5,	Rbm6,	and	Rbfox3.	Rbm5	and	Rbm6	seem	to	promote	exon	9	inclu-
sion,	while	Rbm10	induces	exon	9	skipping	151.	By	regulating	the	ratio	of	Numb	isoforms,	
the	expression	levels	of	Rbm	proteins	can	affect	the	cell	proliferation	rate,	thus	recapitu-
lating	the	differential	function	of	Numb	isoforms	1/3	vs.	2/4	on	the	regulation	of	the	Notch	
signaling	pathway	151.	In	addition,	other	pre-mRNA	splicing	regulators	have	been	described	
to	affect	Numb	exon	9	alternative	splicing.	Rbfox3	promotes	exon	9	skipping	152	and	RBM4	
has	been	described	to	suppress	exon	9	inclusion,	while	promoting	the	retention	of	exon	3	
153.	Deregulation	of	the	Numb	splicing	pattern	due	to	mutations	or	altered	expression	of	
these	regulators	is	frequently	associated	with	cancer	progression.	
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Numb	Ex3	alternative	splicing	
In	contrast	to	Numb	exon	9	alternative	splicing,	little	is	known	about	the	functional	conse-
quences	of	Numb	exon	3	alternative	splicing.	Some	information	about	its	functional	conse-
quences	in	the	context	of	neurodegenerative	disease	has	emerged.	In	Alzheimer’s	disease,	
Numb	isoforms	differentially	affect	amyloid	precursor	protein	subcellular	trafficking	and	
processing	to	generate	amyloid	B	peptide,	the	main	component	of	neuritic	amyloid	plaques	
154.	In	neural	cells,	the	expression	of	exon	3-containing	isoforms	1/2	or	of	exon	3-lacking	
isoforms	3/4,	differentially	directs	sorting	of	amyloid	precursor	protein	towards	degrada-
tive	or	recycling	compartments,	respectively	155.	
Another	 strong	 indication	of	differential	 roles	of	exon	3-containing	vs.	 -lacking	 isoforms	
derives	 from	the	fact	 that	the	subcellular	 localization	of	 these	 isoforms	 is	different.	The	
Numb	PTB	domain,	which	presents	as	either	the	long	version	containing	the	exon	3	codified	
sequence	(PTBi)	or	the	short	version	lacking	the	exon	3	sequence	(PTBo)	(Fig.	3),	appears	
to	control	the	targeting	Numb	to	the	cortical	plasma	membrane.	In	particular,	exon	3-con-
taining	Numb	isoforms	1	and	2,	possessing	the	longer	PTBi	domain,	are	mainly	localized	at	
the	level	of	the	cell	membrane	probably	because	of	their	interaction	with	acidic	membrane	
phospholipids	(e.g.,	phosphoinositides,	PIP)	19.	In	contrast,	exon	3-lacking	Numb	isoforms	
3	and	4	are	mainly	distributed	in	the	cytoplasm.	The	region	encompassing	the	Numb	PTBi	
domain	is	rich	in	basic	residues,	which	might	explain	its	higher	binding	affinity	for	PIP	lipids	
compared	to	PTBo	156.		
It	is	not	clear	yet	the	precise	mechanism	that	regulates	the	subcellular	localization	of	Numb	
isoforms;	however,	it	is	known	that	Numb	phosphorylation	plays	a	role.	Numb	hyperphos-
phorylation	seems	to	disrupt	Numb	interactions	with	α-adaptin,	Eps15,	E-cadherin	and	in-
tegrin,	 thus,	 affecting	 its	 endocytic	 functions	 and	 its	 localization	 10,28,157.	 Numb	 cortical	
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plasma	membrane	localization	has	also	been	shown	to	be	dynamically	regulated	by	GPCR-
activated	phospholipid	hydrolysis	and	aPKC-dependent	phosphorylation	events	156.	aPKC	
activation	has	been	described	to	cause	redistribution	of	Numb	from	the	cortical	membrane	
to	the	cytosol	10,	but	nothing	has	been	described	so	far	concerning	isoform-specific	mech-
anisms	of	Numb	localization.	 
	
2.4 NUMB	AND	CANCER		
Numb	regulation	of	signaling	pathways	lies	at	the	heart	of	its	function	as	a	tumor	suppres-
sor	in	cancer	development	2.	The	tumor	suppressor	role	of	Numb	was	highlighted	in	several	
types	of	solid	tumors,	 including	breast	cancer,	 lung	cancer,	malignant	pleural	mesotheli-
oma	and	hepatocellular	carcinoma	2,158,63.	The	clinical	relevance	of	Numb	in	tumorigenesis	
can	be	appreciated	considering	that	 loss	of	Numb	protein	 is	detected	 in	around	30%	of	
breast	and	lung	tumors	(Numb-deficient)	and	it	is	correlated	with	poor	prognosis	(higher	
tumor	grade)	and	more	aggressive	neoplastic	disease	 44,63.	 The	 lack	of	mutations	 in	 the	
NUMB	gene	in	tumors	44,	excluded	this	alteration	as	causally	linked	to	loss	of	Numb	protein.	
Evidence	from	our	lab	demonstrated	that	Numb-deficient	breast	and	lung	tumors,	the	mo-
lecular	mechanism	responsible	for	loss	of	Numb	protein	is	due	to	enhanced	ubiquitination	
and	ensuing	proteasomal	degradation	of	the	protein.	Low	Numb	levels	in	primary	culture	
cells	from	Numb-deficient	tumors	can	be	rescued	by	treatment	with	the	proteasome	inhib-
itor	MG132,	resulting	in	a	growth	inhibitory	effect	44.	However,	loss	of	Numb	function	in	
tumors	is	not	only	due	to	enhanced	proteasomal	degradation	but	appears	to	involve	di-
verse	mechanisms	that	converge	on	Numb	deficiency.	A	recent	study	in	prostate	cancer	
 58 
highlighted	transcriptional	deregulation	of	the	NUMB	gene	as	an	additional	mechanism	un-
derlying	the	downregulation	of	Numb	159.	Downmodulation	of	Numb	mRNA	levels	in	these	
tumors	was	associated	with	an	advanced	tumor	stage	159.		
PTMs	of	Numb	protein	can	also	account	for	decreased	Numb	physiological	functions.	Numb	
phosphorylation	by	atypical	protein	kinase	C	(aPKC)	destabilizes	its	interaction	with	p53,	
thus,	enhancing	p53	proteolysis.	Consequently,	decreased	p53	protein	levels	and	activity	
result	in	pro-tumorigenic	phenotypes.	aPKC-mediated	Numb	phosphorylation,	also	alters	
the	subcellular	distribution	of	Numb	and	promotes	self-renewal	and	proliferation	of	tumor	
initiating	cells	(TIC),	thus,	playing	a	crucial	role	in	promoting	tumorigenesis	160.		
Several	lines	of	evidence	have	demonstrated	that	Numb	loss,	independent	of	the	mecha-
nism	underlying	its	deficiency,	can	confer	a	tumor	growth	advantage	by	two	main	mecha-
nisms:	i)	activation	of	Notch	and	ii)	decreased	levels	of	p53	(Fig.	18).	
i)	In	normal	breast	parenchyma,	the	Numb/Notch	circuitry	is	relevant	to	the	control	of	the	
proliferative/differentiative	 balance.	 Numb	 expression	 levels	 inversely	 correlate	 with	
Notch	 activation	 158.	 Numb	 loss-of-function	 phenocopies	 Notch	 gain-of-function	 and	 is	
linked	to	a	hyper-proliferative	phenotype.	Restoration	of	Numb	levels	by	overexpressing	
the	protein,	or	attenuation	of	Notch	activity	by	pharmacological	inhibition,	is	able	to	revert	
the	hyper-proliferative	status	of	Numb-deficient	breast	tumors	44.	
ii)	Ablation	of	Numb	induces	a	reduction	 in	p53	protein	 levels	and	activation	upon	DNA	
damage	63.	This	 is	 linked	to	 increased	resistance	of	Numb-deficient	tumors	to	genotoxic	
agents	 compared	 with	 Numb-proficient	 tumors	 63.	 Loss	 of	 Numb	 and	 consequent	
downmodulation	of	p53	has	been	associated	with	the	development	of	poorly	differentiated	
tumors,	impaired	mammary	gland	morphogenesis	in	mice,	and	increased	tumor	cell	prolif-
eration	161.	Restoration	of	Numb	levels	by	overexpressing	the	protein	or	pharmacological	
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inhibition	 of	Mdm2	 activity	 by	 Nutlin-3	 rescues	 p53	 levels	 and	 the	 chemosensitivity	 of	
Numb-deficient	tumor	cells	162.	
	
The	complete	elucidation	of	all	the	mechanisms	involved	in	Numb	deregulation	in	cancer	
is	crucial	for	the	identification	of	novel	therapeutic	targets	and	strategies	for	the	treatment	
of	the	Numb-deficient	tumors.		
	
	
	
Fig.	18	Numb	regulated	signaling	pathways	and	their	deregulation	in	cancer.		
On	 the	 left,	 Numb	 regulation	 on	 Integrin,	 adherens	 junction	 (AJs)	 dynamics	 and	 on	
downstream	 signaling	 pathways	 (p53,	 	 Notch,	 Hedgehog)	 and,	 on	 the	 right,	 their	
deregulation	upon	loss	of	Numb	in	cancer.	
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2.4.1 NUMB	 INVOLVEMENT	 IN	 CANCER:	 THE	 ROLE	 IN	
THE	 DETERMINATION	 AND	MAINTENANCE	 OF	 THE	 STEM	
CELL	COMPARTMENT	
The	physiological	maintenance	of	the	SC	compartment	is	ensured	by	the	ability	of	a	SCs	to	
perform	ACD.	Following	this	division	mode,	a	SC	generates	two	DCs	with	different	cell	fates:	
one	DC	retains	the	parental	SC	fate	and	withdraws	into	quiescence,	while	the	second	DC	
undergoes	 mitotic	 expansion	 and	 progressive	 lineage-specific	 differentiation.	 ACD	 thus	
ensures	the	preservation	of	the	SC	pool	while	allowing	the	proliferation	of	differentiated	
cells	 163.	 The	 correct	 execution	of	ACD	 likely	 represents	 a	mechanism	 to	prevent	 tumor	
development.	 This	 latter	 point	 is	 supported	 by	 evidence	 showing	 that	 uncontrolled	
symmetric	 division	 of	 SCs	 is	 associated	 with	 tumorigenesis	 70.	 The	 symmetric	 mode	 of	
division,	 indeed,	 gives	 rise	 to	 two	 DCs	 with	 identical	 SC	 fate,	 thereby	 expanding	 the	
population	of	pluripotent	cells,	thus,	facilitating	cancer	development.	
The	mode	of	SC	division	is	tightly	regulated	in	development	and	tissue	regeneration,	as	well	
as	in	adult	SC	homeostasis.	Intrinsic	and	extrinsic	determinants	can	have	an	impact	on	cell	
fate	choices.	These	determinants	consist	of	unequal	segregation	of	molecular	fate	proteins	
between	the	two	DCs	or	of	polarized	signaling	triggered	by	“niche”	local	microenvironment	
cues	or	by	neighboring	cells,	respectively	164.	
The	dual	role	of	Numb	in	the	inhibition	of	Notch	signaling	and	simultaneous	stabilization	of	
the	p53	pathway	has	been	linked	to	its	role	in	the	regulation	of	adult	SC	homeostasis.	Numb	
asymmetric	partitioning	at	SC	mitosis	causes	functional	asymmetry	of	the	Numb-p53	and	
Numb-Notch	circuitries	 that	 impart	distinct	developmental	and	proliferative	 fates	 to	 the	
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two	DCs	161.	In	the	mammary	gland,	retention	of	Numb	in	one	of	the	DCs	imposes	a	SC	fate.	
This	can	be	explained	because,	 in	this	cell,	Numb	positively	regulates	p53	activity,	which	
results	in	withdrawal	into	quiescence,	a	stemness	marker	161.	Thus,	differential	p53	activity	
in	the	two	DCs,	as	result	of	diverse	Numb	levels,	imposes	an	asymmetric	mode	of	SC	division	
161.		
In	 the	 progenitor	 daughter	 cell,	 Numb	 progressively	 re-accumulates	 and	 appears	 to	 be	
critical	 for	differentiation	and	 the	correct	maturation	of	progenitors	 (Fig.	19).	To	 resolve	
some	of	these	apparent	incongruences,	a	unifying	scenario	takes	into	account	the	role	of	
Numb	during	the	progressive	steps	of	lineage	specification.	In	immature	SC	division,	Numb	
seems	to	segregate	in	stem	daughter	cell,	while	as	maturation	proceeds,	instead,	the	re-
expression	of	Numb	confers	a	differentiative	fate	in	committed	progenitors	161.		
	
	
	
Fig.	19	Role	of	Numb	 in	 the	maintenance	of	 the	 stem	and	progenitor	 cell	pools	 in	 the	
mammary	epithelium.		
Left,	during	normal	mammary	stem	cell	mitosis,	ACD	prevail,	maintaining	the	stem	cell	pool	
and	gland	homeostasis.	 In	 stem	cells,	Numb	 (red	dots)	 is	 retained	 in	one	daughter	 cell,	
where	it	stabilizes	p53	(dark	green),	leading	to	quiescence	and	the	adoption	of	a	stem	cell	
fate.	In	progenitor	cells,	Numb	gets	re/accumulated	and	is	partitioned	equally	between	the	
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two	daughter	cells,	which	have	 identical	proliferative	and	developmental	characteristics.	
Right,	when	Numb	 function	 is	 lost,	p53	activity	 is	decreased	 favouring	expansion	of	 the	
stem	 cell	 pool	 due	 to	 SCD,	 and	dedifferentiation	of	 progenitors	 thus	 facilitating	 tumour	
formation.	Figure	adapted	from	165.	
	
Some	studies	have	investigated	the	effects	of	loss	of	Numb	in	cancer	63,44,161.	Loss	of	Numb	
expression	 and	 consequently	 of	 p53	 activity	 at	 the	 level	 of	 the	 SC	 compartment	 in	 the	
mammary	gland	results	in	a	skewing	in	the	mode	division	towards	a	symmetric	mode	and	
in	 the	 acquisition	 of	 unlimited	 self-renewal	 potential,	 causing	 the	 expansion	 of	 the	 SC	
population.	In	contrast,	at	the	level	of	the	progenitors,	loss	of	Numb	causes	the	activation	
of	the	EMT	program	associated	with	dedifferentiation	and	the	de	novo	acquisition	of	SC	
traits	161	(Fig.	19).	Together,	these	effects	result	in	abnormal	tissue	morphogenesis	and	the	
emergence	of	CSCs	161.		CSCs	from	Numb-deficient	breast	cancers	display	an	increased	self-
renewal	potential	compared	to	normal	mammary	SCs	or	Numb-proficient	CSCs	161	
The	effects	of	loss	of	Numb	have	also	been	shown	to	contribute	directly	to	breast	cancer	
tumorigenesis.	 The	 selective	 ablation	of	Numb	 in	 the	mouse	mammary	 gland	 results	 in	
morphological	 alterations	 and	 development	 of	 preneoplastic	 lesions.	 Thus,	 Numb	
regulation	of	p53	stability	 represents	physiologically	a	 tumor	suppressor	barrier	 that,	by	
maintaining	SC	homeostasis,	safeguards	against	their	uncontrolled	expansion.		
Notably,	the	restoration	of	the	Numb/p53	circuitry	in	Numb-deficient	tumors	can	override	
all	 the	phenotypes	 linked	 to	 the	dysregulated	p53	 levels	 and	 furthermore	 it	 appears	 to	
represent	an	effective	CSC	targeted	therapy	162.	Restoration	of	Numb	by	ectopic	expression	
in	primary	Numb-deficient	breast	cancer	cells	results	 in	a	reduction	of	their	tumorigenic	
potential	in	vivo	161	.	Moreover,	it	has	been	demonstrated	that	in	vivo	treatment	of	patient-
derived	xenografts	(PDX)	of	Numb-deficient	breast	cancer	with	the	Mdm2	inhibitor,	Nutlin-
3a,	a	Mdm2	 inhibitor,	 restores	p53	 levels	 in	 these	breast	 tumors	and	decrease	 the	 self-
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renewal	properties	of	their	CSCs	162.	Moreover,	upon	re-transplantation	of	MECs	derived	
from	Numb	deficient	PDX	treated	with	Nutlin-3a,	cells	are	able	to	induce	the	formation	of	
smaller	tumors	in	NOD/SCID	mice	compared	to	the	corresponding	not	treated	control	162.	
Moreover,	the	effect	of	Nutlin-3a	was	even	more	striking	when	combined	with	paclitaxel,	a	
standard-of-care	chemotherapy	drug	used	 in	treatment	of	many	cancer,	 including	breast	
cancer	 166;	 the	 combined	 treatment	 was	 shown	 to	 prevent	 tumor	 regrowth	 following	
interruption	of	chemotherapy	treatment	162.		
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3 AIM	OF	THE	PROJECT	
 
Since	the	discovery	of	the	tumor	suppressor	function	of	Numb	in	our	lab	in	2004	44,	addi-
tional	evidence	has	been	produced	supporting	the	role	of	Numb	in	the	tumorigenesis	pro-
cess	63,158,167.	The	first	molecular	pathway	that	was	discovered	to	be	deregulated	in	tumors	
upon	loss	of	Numb	was	the	Notch	pathway,	which	is	hyperactivated	when	Numb	is	lost	44.	
Subsequently,	it	was	discovered	that	Numb	is	also	able	to	regulate	the	p53	tumor	suppres-
sor	pathway	63,	whose	inactivation	is	one	of	the	most	frequent	events	in	human	cancers	
168.	
With	a	view	to	developing	therapeutic	strategies	for	Numb-deficient	tumors,	our	lab	has	
focused	efforts	on	how	to	interfere	with	mechanisms	acting	upstream	of	Numb	loss	(i.e.,	
on	the	machinery	promoting	Numb	degradation),	or	downstream,	in	particular,	at	the	level	
of	Notch	and	p53	signaling.	
With	regards	to	the	latter,	our	lab	has	performed	an	extensive	structural	study	to	elucidate	
the	mechanism	of	action	of	Numb	in	the	p53	pathway	and,	in	particular,	on	its	interaction	
with	Mdm2	136.	From	this	study,	it	emerged	that	a	region	of	Numb	encompassing	the	alter-
natively	spliced	exon	3	is	the	main	structural	determinant	mediating	the	interaction	with	
the	Mdm2	acidic	domain	and	the	consequent	inhibition	of	the	Mdm2	E3	ligase	activity136.	
Since	exon	3	is	present	in	Numb	isoforms	1	and	2,	and	not	in	isoforms	3	and	4,	this	finding	
raised	the	possibility	of	a	differential	role	of	Numb	isoforms	in	cancer.		
Thus,	the	founding	hypothesis	of	this	thesis,	is	that	the	exon	3-containing	Numb	isoforms	
1	and	2	are	responsible	for	the	p53	regulation	by	Numb	and	thus	they	might	play	a	role	in	
BC	tumorigenesis.		
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To	test	this	hypothesis,	we	first	tried	to	elucidate	whether	in	some	selected	breast	cell	lines,	
the	Numb	isoforms	1	and	2	have	specific	and	differential	roles	 in	the	control	of	the	p53	
pathway	and	consequently	on	regulation	of	p53-dependent	phenotypes,	such	as	the	re-
sponse	to	genotoxic	stress.	We	then	investigated	whether	the	deregulation	of	the	Numb	
isoforms	levels	is	an	event	present	in	primary	BCs	and	whether	the	alteration	of	the	alter-
native	splicing	of	Numb	might	predict	resistance	to	genotoxic	stress	and	differential	prog-
nostic	outcome	in		human	BCs.			
 
Together,	the	results	of	this	thesis	 	try	to	clarify	 if	the	deregulation	of	Numb	alternative	
splicing	could	be	a	new	pre-translational	mechanism	responsible	for	the	functional	loss	of	
Numb	in	some	BCs		paving	the	way	for	the		identification	of	novel	molecular	targets	for	the	
treatment	of	Numb-deficient	tumors.	
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4 MATERIALS	AND	METHODS	
	
	
4.1 CELL	CULTURE	PROCEDURES	AND	REAGENTS	
	
4.1.1 CELL	LINES		
We	used	the	following	human	cell	lines:	HEK-293	(from	embryonic	kidney),	and	two	breast	
cell	 lines	BT-474	 (ductal	 carcinoma)	and	MCF-10A	 (not-tumorigenic	mammary	epithelial	
cells),	all	from	the	American	Type	Culture	Collection	(ATCC). HEK-293	cells	were	cultured	in	
DMEM	medium	(Lonza)	supplemented	with	10%	South	American	fetal	bovine	serum	(FBS	
SA,	HyClone),	2	mM	L-glutamine	(Euroclone)	and	100	µg/mL	penicillin	and	streptomycin	
antibiotics	 (Sigma). BT-474	cells	were	cultured	 in	DMEM,	10%	FBS	North	American	fetal	
bovine	serum	(FBS	NA),	2	mM	L-	glutamine	and	100	µg/mL	penicillin	and	streptomycin	an-
tibiotics.	MCF-10A	cells	were	maintained	in	a	1:1	mixture	of	DMEM	and	Ham	F12	medium	
(Invitrogen)	 supplemented	 with	 5%	 horse	 serum	 (Invitrogen),	 10	 µg/ml	 human	 insulin	
(Boehringer-Mannhaim),	 0.5	 µg/ml	 hydrocortisone	 (Sigma),	 100	 ng/ml	 cholera	 toxin	
(Sigma),	100	µg/mL	penicillin	and	streptomycin	antibiotics	(Sigma)	and	2	mM	L-glutamine.	
20	ng/ml	human	epithelial	growth	 factor	 (hEGF,	Vinci-Biochem)	was	added	 freshly	each	
time.	
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4.1.2 PRIMARY	MAMMARY	EPITHELIAL	CELLS	(MECs)		
Human	primary	BC	epithelial	cells	were	isolated	from	tissue	biopsies	by	mechanical	disso-
ciation	and	enzymatic	digestion	with	200	U/ml	collagenase	type	1A	and	100	U/ml	of	hyalu-
ronidase	(both	from	Sigma),	 in	DMEM/F12	1:1	medium	supplemented	with	2	mM	gluta-
mine,	for	4-5	h	at	37°C	with	rotation.	Cell	suspensions	were	further	digested	in	0.05%	tryp-
sin-EDTA,	centrifuged	(80g,	5	min),	re-suspended	in	hypotonic	0.2%	NaCl	solution	to	lyse	
red	blood	cells	and	eventually	filtered	through	a	40	µm	cell	strainer	filter.	Flow-through	
cells	 were	 collected	 in	Mammary	 Epithelial	 Basal	Medium	 (MEBM).	 Serum-free	MEBM	
(Clonetics)	was	supplemented	with	5	µg/ml	insulin,	0.5	µg/ml	hydrocortisone,	1	U/ml	hep-
arin	(Wockhardt),	2	mM	glutamine	and	100	µg/mL	penicillin	and	streptomycin	antibiotics.	
The	complete	MEBM	medium	was	obtained	by	adding	EGF	 (20	ng/mL),	 FGF	 (20	ng/mL,	
Peprotech),	and	B-27	Supplement	(2%,	Gibco)	immediately	before	use.	The	complete	me-
dium	was	sterilized	by	filtering	through	a	0.2	µm	filter	before	using	 it	 to	resuspend	and	
plate	cells	on	six-well	plates.	Primary	cells	were	amplified	in	culture	for	only	7-10	days	to	
avoid	adaptation	to	cell	culture	conditions	and,	thus,	be	representative	of	the	primary	tu-
mor.	
	
4.1.3 PLASMIDS	AND	REAGENTS	
Nutlin-3a	(Cayman	Chemical)	and	MG-132	(Enzo	Life	Science)	were	used	at	10	μM.	Cisplatin	
was	used	at	different	concentrations	according	to	the	length	of	treatment	and	the	sensitiv-
ity	of	the	treated	cells.		
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Mammalian	expression	constructs	encoding	the	different	Numb	isoforms	were	engineered	
in	a	pcDNA	vector	in-frame	with	a	FLAG-tag	at	the	C-terminus.		The	mammalian	vector	for	
the	expression	of	Mdm2	was	a	kind	gift	from	Prof.	K.	Helin	(Biotech	Research	and	Innova-
tion	Centre,	Copenhagen,	Denmark).	
 
4.1.4 GENE	 EXPRESSION	 SILENCING	 BY	 siRNA	
TRANSFECTION	
Transient	silencing	of	specific	Numb	isoforms	was	achieved	by	transfecting	specific	prede-
signed	siRNAs	(see	Fig.	25	and	sequences	below).	A	non-targeting	universal	control	siRNA	
was	used	as	a	negative	control.	For	the	silencing	experiments	in	MCF-10A	cells,	delivery	of	
siRNA	oligos	was	achieved	using	Lipofectamine	RNAiMAX	(Invitrogen).	Briefly,	for	cells	cul-
tured	in	6-well	plates,	we	prepared	siRNA/Lipofectamine	RNAiMAX	complexes	by	diluting	
single	siRNA	oligos	(final	concentration	=	10	nM	in	2.5	ml	final	culture	volume)	and	5	μl	
Lipofectamine	RNAiMAX	 in	 500	μl	OPTIMEM.	The	mixture	was	 incubated	 for	 20	min	 at	
room	temperature	(RT).	Cells	were	plated	in	a	total	volume	of	2	ml	of	complete	medium	
without	 antibiotics	 and	 the	 siRNA/Lipofectamine	 RNAiMAX	 mixture	 was	 added	 to	 the	
plated	cells.	24	h	post-transfection,	we	replaced	the	medium	with	2	ml	of	complete	me-
dium.	Cells	were	harvested	72	h	post-transfection	for	IB,	RT-qPCR	or	IF	analysis.		
The	following	siRNA	oligos	were	used:	
i) Total	Numb	siRNA,	5’-CAGCCACUGAACAAGCAGA-3’	(GE	Healthcare);		
ii) ctrl	siRNA,	5’-AGACGAACAAGUCACCGAC-3’	(GE	Healthcare);		
iii) Numb	isoforms	1/2:	5’-AGGCUUCUUUGGAAAAACU-3’	(GE	Healthcare);		
iv) Numb	isoforms	3/4:	5’-AGAUUGAAAGCUACUGGAA-3’	(GE	Healthcare);		
v) p53	siRNA	VHS40367	(Invitrogen).	
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4.1.5 CELL	TRANSFECTION		
Cells	were	plated	in	10	cm	dish	the	day	before	transfection	to	reach	50-70%	confluency	the	
day	of	transfection.	DNA	/CaPO4	complexes	were	prepared	by	diluting	20μg	DNA	in	serum	
free	medium	(final	volume	=	500	μl)	and	CaCl2	in	final	concentration	of	0,25	M.	This	mixture	
was	added	drop	by	drop	in	a	second	tube	containing	2X	HBS	reagent.	After	incubating	5	
min	at	room	temperature	(RT),	the	resulting	1	ml	DNA/CaPO4	complex	mixture	was	added	
to	the	cell	culture	dish	drop	by	drop	and	incubated	for	15	h	in	a	CO2	incubator	at	37	°C.	
Cells	were	collected	and	analyzed	by	IB	after	48h.		
	
4.1.6 VIABILITY	ASSAY	
Primary	tumor	cells	derived	from	tissue	digestion	of	patient	BC	biopsy	samples	were	plated	
as	a	single	cell	suspension	in	6-well	plates	and	treated	with	cisplatin	(18	μg/ml)	for	9	h,	then	
released	for	72	h	in	cisplatin-free	medium	(plus	or	minus	10	µM	Nutlin-3a).	For	the	evalua-
tion	of	viability,	cells	were	stained	with	0.05%	crystal	violet	(DNA	intercalating	dye),	for	10	
min	and	then	extensively	washed	free	of	the	dye.	The	crystal	violet	retained	by	live	cells	
was	leached	in	acetic	acid	(10%)	and	the	dye	absorbance	(proportional	to	the	number	of	
living	cells)	was	read	at	595	nm.	
	
4.2 SELECTION	 OF	 BREAST	 CANCER	 PATIENTS	 AND	
STATISTICAL	ANALYSIS	
The	RT-qPCR	analysis	of	the	expression	levels	of	Numb	isoforms,	presented	in	Figures	32-
34,	was	performed	on	a	case-cohort	of	890	BC	FFPE	samples.	The	case-
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a	subcohort	of	672	patients	 randomly	selected	 from	the	consecutive	“IEO	cohort”	com-
posed	of	2453	BC	patients	(see	paragraph	5.6).	This	subcohort	(n=671)	 includes	585	pa-
tients	free	of	distant	metastasis	and	87	patients	who	instead	experienced	distant	relapse.	
We	verified	that	the	“subcohort”,	representing	~27%	of	the	entire	cohort,	was	representa-
tive	of	the	“IEO	cohort”	(see	Table	1).	No	significant	difference	was	scored	considering	pa-
tients’	features	between	the	subcohort	and	the	remaining	patients	not	included	in	the	sub-
cohort.	To	yield	the	final	case-cohort,	the	subcohort	was	enriched	with	all	the	remaining	
patients	from	the	“IEO	cohort”	who	experienced	distant	metastasis	within	10	years	of	fol-
low-up:	this	gave	an	additional	218	patients	for	whom	RNA	was	available.	Therefore,	the	
final	case-cohort	 included	305	patients	with	distant	metastasis	and	585	patients	 free	of	
distant	metastasis	at	10	years	after	the	excision	of	the	primary	tumor.	
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Table	1	Patient	clinical-pathological	characteristics	in	the	breast	cancer	cohorts	analyzed. 
Distribution	of	patient	clinical-pathological	characteristics	in	the	random	subcohort	(n=672)	
compared	with	the	entire	IEO	cohort	(All,	n=2453)	and	the	Not-in-subcohort	(n=1781)	a)	P-
value	derived	from	χ2	test;	b)	not	available	c)	perivascular	invasion	d)	estrogen	receptor	e)	
progesterone	receptor	f)	P-value	derived	from		t-test	
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The	association	between	Numb	mRNA	levels	(quintile	groups)	and	the	risk	of	distant	me-
tastasis	at	10	years	post-surgery	was	evaluated	with	the	univariate	and	multivariable	“pseu-
dolikelihood”	modification	of	Cox	proportional	hazards	regression	model.	These	analyses	
were	performed	using	widely	available	software	 (e.g.,	 the	cch	 function	 in	 the	R	survival	
package).	All	p-values	are	2-sided	with	a	significance	level	of	0.05. 
	
4.3 PROTEIN	PROCEDURES	
	
4.3.1 CELL	LYSIS		
Adherent	cells	were	rinsed	twice	with	phosphate	buffer	saline	(PBS	1X)	and	lysed	directly	
in	the	cell	culture	plate	in	ice-cold	RIPA	lysis	buffer	[50	mM	Tris-HCl	(pH	7.5),	150	mM	NaCl,	
1	mM	EDTA,	1%	NP40,	0.5%	sodium	deoxycholate,	0.1%	sodium	dodecyl	sulphate,	protease	
inhibitor	cocktail	(Calbiochem,	added	freshly	each	time;	1:200)	by	scraping	directly	on	the	
plate	using	a	cell	scraper.	The	volume	of	lysis	buffer	was	proportional	to	the	number	of	cells	
being	lysed	(around	300	μl/10	cm	dish	or	50	μl/well	of	a	six	well	plate).	Cell	lysates	were	
then	incubated	for	30	min	on	ice	and	then	clarified	by	centrifugation	at	13000	rpm	at	4°C	
for	30	min.	The	supernatant	was	transferred	to	a	new	collection	tube	and	the	protein	con-
centration	was	quantified	using	the	Bradford	assay	(Biorad),	according	standard	procedure.	
BSA	calibration	curves	were	used	as	standard	reference	for	protein	quantification.	Laemmli	
sample	buffer	4x	[250	mM	Tris-HCl,	40%	glycerol,	8%	SDS,	0.4%	Bromophenol	blue]	supple-
mented	with	β-mercaptoethanol	 (120	µ/ml)	was	added	to	 the	 lysate	and	samples	were	
boiled	at	95°C	for	10	min	before	loading	into	a	sodium	dodecyl	sulphate	(SDS)	polyacryla-
mide	gel.		
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4.3.2 SDS	 POLYACRYLAMIDE	 GEL	 ELECTROPHORESIS	
(SDS-PAGE)	AND	IMMUNOBLOTTING	
Desired	amounts	of	protein	were	loaded	on	polyacrylamide	SDS	denaturing	gels	(Mini-PRO-
TEAN	and	Criterion	Tris-Glycine	Precast	Gels).	Electrophoresis	was	performed	in	Running	
buffer	1X	(Running	buffer	10X:	250	mM	Tris-HCl,	192	mM	Glycine,	1%	SDS)	at	200V.	The	
electrophoretic	transfer	of	proteins	from	polyacrylamide	gels	to	nitrocellulose	membrane	
was	achieved	by	Trans-Blot	Turbo	semi-dry	transfer	system	optimized	for	mixed	molecular	
weight	transfer	(2.5	A,	25	V,	12	min).	
Following	transfer,	the	membrane	was	blocked	1	h	(or	overnight)	in	5%	non-fat	dry	milk	in	
Tris-buffered	saline	(25	mM	Tris-HCl	pH	7.4,	137	mM	NaCl,	2.7	mM	KCl)	supplemented	with		
0.1%	Tween	(TBS-T)	and	then	incubated	with	primary	antibodies	diluted	in	5%	milk	in	TBS-
T,	for	1	h	at	RT,	or	at	4°C	overnight,	followed	by	3	washes	in	TBS-T	of	10	min	each.	The	
membrane	was	 then	 incubated	with	 different	 horseradish	 peroxidase	 (HRP)-conjugated	
secondary	antibody	(AbII)	diluted	in	5%	milk	in	TBS-T	for	45	min	and	washed	again	3	times	
in	TBS-T,	10	min	each	wash.	The	ECL	(enhanced	chemiluminescence)	method	(Amersham)	
was	used	to	reveal	proteins	on	Amersham	Hyperfilm	(GE	Healthcare).	
The	 following	 primary	 antibodies	were	 used	 for	 immunoblotting	 (IB)	 :	 anti-Total	 Numb	
monoclonal	antibody	(generated	in-house	against	amino	acids	537–551	of	human	Numb	
63);	anti-Numb	1/2	polyclonal	antibody	(generated	in-house	against	amino	acids	66-80	of	
human	Numb	 isoform-1);	anti-Mdm2	OP46	(EMD	Millipore);	anti-p53	DO-1	and	FL-2393	
(Santa	Cruz	Biotechnology);	anti-phospho-p53–Ser	15	and	anti-FLAG	(2368;	Cell	Signaling);	
anti-Vinculin	(V9131,	Sigma).	
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4.3.3 PROTEIN	ASSAYS	
	
4.3.3.1 IMMUNOPRECIPITATION	
For	 co-immunoprecipitation	 experiments,	 HEK-293	 cells	 overexpressing	 Numb-flagged	
isoforms	were	lysed	in	JS	buffer	[50	mM	Hepes	pH	7.5,	150	mM	NaCl,	10%	Glycerol,	1%	
Triton	X100,	1.5	mM	MgCl2,	5	mM	EGTA,	1:200	Protease	inhibitor	cocktail	added	just	be-
fore	use].	Total	lysate	of	HEK-293	cells	was	incubated	with	anti-FLAG	M2-agarose	Affinity	
Gel	(Sigma)	resin	in	JS	lysis	buffer	for	2	h	with	rotation	at	4°C.	This	resin	consists	of	murine	
IgG1	anti-FLAG	covalently	attached	to	agarose.	Beads	were	pulled	down	by	centrifugation	
at	2000	rpm	for	2	min	and	washed	three	times	in	JS	buffer.	Supernatant	was	collected	be-
fore	washing	steps.	Immunoprecipitated	proteins	were	eluted	in	Laemmli	loading	buffer,	
boiled	for	10	min	at	95°C,	centrifuged	for	1	min	and	analyzed	by	IB.	
	
4.3.3.2 IMMUNOFLUORESCENCE	
For	immunofluorescence	(IF)	experiments,	cells,	plated	on	glass	coverslips,	were	washed	
twice	with	PBS,	fixed	by	incubating	with	4%	paraformaldehyde	for	10	min,	washed	again	
with	PBS	1X	and	permeabilized	in	PBS	0.1%	Triton	X-100	for	10	min	at	RT.	To	avoid	non-
specific	binding	of	the	antibodies,	coverslips	were	incubated	for	1	h	with	goat	serum	as	a	
blocking	reagent.	Cells	were	then	incubated	with	primary	antibody	(anti-phospho-histone	
H2AX	(Ser	139);	Upstate)	diluted	in	BSA	3%	/	PBS	1X,	washed	three	times	in	BSA	1%	/	PBS	
1X	 and	 then	 a	 secondary	 fluorochrome-conjugated	 (Cy3)	 antibody	 (Jackson	 Immu-
noResearch	Laboratory)	was	applied	for	45	min	in	the	dark.	Cells	were	washed	again	three	
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times	in	PBS	1X	before	proceeding	with	2	min	DAPI	staining	(for	nuclear	visualization)	fol-
lowed	by	two	additional	washing	steps.	Coverslips	were	mounted	in	glycerol	mounting	me-
dium	and	observed	under	a	white-field	microscope	(Olympus)	using	a	20X	0.75	NA	objec-
tive	equipped	with	a	digital	camera	for	collection	of	cells	and	tissue	section	images.	Digital	
images	were	computer	processed	using	Fiji/ImageJ	imaging	software	(National	Institute	of	
Health)	and	Photoshop	(Adobe).		
	
4.3.3.3 IHC	 CHARACTERIZATION	 OF	 p53	 MUTATIONAL	
STATUS	ON	BC	SAMPLES	
p53	functionality	is	often	compromised	in	cancer,	by	direct	mutations	of	the	p53	gene	or	
indirect	mechanisms	 (see	paragraph	2.3.4.5).	To	evaluate	 the	p53	status	of	 the	BC	FFPE	
cohort	analyzed	in	Fig.	33-34,	we	took	advantage	of	IHC	analysis,	that	is	largely	recognized	
as	a	surrogate	method	for	determining	the	p53	mutational	status	123,118.when	sequencing	
is	not	possible	or	 it	 is	too	time-	and	cost-consuming	due	to	the	high	number	of	patients	
analyzed.	The	p53	IHC	analysis	was	performed	on	the	entire	consecutive	cohort	of	2453	BC	
cases	 collected	 at	 the	 European	 Institute	 of	 Oncology	 (IEO,	 Milan)	 via	 standardized	
operative	procedures,	from	BC	patients	who	underwent	surgery	between	years	1997	and	
2000	 (the	 “IEO	 cohort”).	 Informed	 consent	 was	 obtained	 for	 use	 of	 all	 clinical	 data	
connected	with	the	related	tissue	sample.		
3-μm	thick	sections	prepared	from	formalin-fixed	paraffin-embedded	(FFPE)	tissue	micro-
array	(TMA)	blocks	were	deparaffinized,	pre-treated	with	the	Epitope	Retrieval	Solution	2	
(pH	9)	at	100°C	for	20	min	and	then	incubated	for	30	min	with	the	primary	antibody	(p53	
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DO-1,	Santa	Cruz	Biotechnology)	at	a	final	concentration	of	40	ng/ml.	p53	IHCs	were	pro-
cessed	in	a	Bond	Max	Automated	Immunohistochemistry	Vision	Biosystem	(Leica	Microsys-
tems	GmbH,	Wetzlar,	Germany)	using	the	Bond	PolymerRefine	Detection	Kit	(DS9800,	Leika	
Biosystems).	 TMA	 slides	 were	 scanned	 exploiting	 Aperio	 ScanScope	 system	 (Leika	 Mi-
crosystems)	and	then	analyzed	by	a	pathologist.	For	each	sample,	the	percentage	of	cells	
with	p53-positive	nuclei	was	scored	on	a	total	of	500	cells	counted.	Patients	were	classified	
according	to	the	percentage	of	p53-positive	nuclei	into	three	groups:		
i)	0-1	(0-1%	positive	nuclei),	indicative	of	loss	of	p53	protein	due	to	missense	mutations	or	
mutations	at	the	level	of	the	p53	promoter	118;	
ii)	2-79	(2-79%	positive	nuclei),	representative	of	p53	WT	levels	of	p53;	
iii)	80+	(over	80%	positive	nuclei),	indicative	of	possible	p53	missense	mutations	(generally	
involving	the	DNA-binding	domain	of	p53),	leading	to	p53	accumulation,	as	reported	124	123.	
This	accumulation	is	probably	due	to	mechanisms,	such	as	the	loss	of	the	ubiquitin-ligase	
Mdm2,	due	to	the	impairment	of	the	transcriptional	p53	activity	(Mdm2	is	also	one	of	the	
p53	target	genes	169,170).	
We	evaluated	 the	 cumulative	 occurrence	of	 distant	metastasis	 or	 death	 from	BC	 in	 the	
entire	cohort	of	BC	patients,	clustered	into	the	three	p53	IHC	groups.	Patients	classified	as	
80+	and	0-1	displayed	a	worse	prognosis	compared	to	the	2-79%	class	of	presumptive	p53	
WT	samples,	as	expected	for	BCs	with	an	alteration	of	the	p53	pathway,	suggesting	that	p53	
IHC	 can	 be	 used	 as	 a	 surrogate	 to	 evaluate	 the	 p53	 mutational	 status	 (Fig.	 20A).	
Furthermore,	the	percentage	of	p53	presumptive	mutated	samples	(groups	“0-1”	and	“80+	
combined)	in	the	cohort	(considering	the	samples	with	an	available	p53	IHC	classification)	
is	~20%,	in	accordance	with	the	published	data	reported	on	the	incidence	of	p53	mutations	
in	BC	171,172	(Fig.	20B).	
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Fig.	20	Prognostic	relevance	of	p53	status	evaluated	by	IHC	in	the	IEO	cohort	of	BCs.		
A)	The	entire	cohort	of	2453	BC	patients	was	analyzed	and	semi-quantitatively	categorized	
into	three	groups	based	on	the	percentage	of	p53	nuclear	stained	cells:	0-1%	(0-1	group,	
indicative	of	complete	loss	of	p53),	2%-79%	(2-79	group,	indicative	of	WT	p53)	and	>80%	
(80+	group,	indicative	of	p53	missense	mutations).	Cumulative	incidence	of	distant	metas-
tasis	or	death	from	BC	is	shown	for	each	group.	The	hazard	ratios	(HR)	comparing	the	dif-
ferent	p53	groups	(with	P-values)	is	shown	and	was	estimated	with	a	univariate	Cox	pro-
portional	hazards	model.	95%	Cl	=	confidence	interval.	B)	Distribution	of	the	2453	BC	pa-
tients	into	the	p53	IHC	groups.	N:	number	of	patients;	“N.	events”:	number	of	patients	with	
distant	metastasis;	NA:	p53	IHC	not	available.	Data	published	in	136	
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4.4 NUCLEIC	ACID	TECHNIQUES	
 
 
4.4.1 mRNA	PURIFICATION	AND	cDNA	SYNTHESIS	
Total	RNA	including	small	RNAs	was	extracted	from	FFPE	tumor	sections	included	in	the	
case-cohort,	using	the	AllPrep	DNA/RNA	FFPE	Kit	(Qiagen).	Patient	samples	were	processed	
using	 on	 column	 semi-automated	 DNA/RNA	 purification	 including	 a	 RNasi-free	 DNase	
treatment,	exploiting	QIacube	technology	according	manufacturer’s	instructions.	Two	hun-
dred	nanograms	of	purified	total	RNA	(measured	using	the	NanoDrop	ND-1000	Spectro-
photometer)	were	used	for	first	strand	cDNA	synthesis	by	Superscript	VILO	cDNA	Synthesis	
Kit	(Thermo	Fisher	Scientific)	following	the	relative	protocol	scaled	to	a	final	reaction	vol-
ume	of	10	µl.	The	reaction	mix	was	incubated	according	to	the	following	thermal	condi-
tions:	25°C	10	min,	42°C	60	min	and	85°C	5	min.	
	
4.4.2 GENE	PREAMPLIFICATION	AND	RT-qPCR	ANALYSIS		
The	RT-qPCR	screening	was	performed	for	 the	analysis	of	 the	relative	mRNA	expression	
levels	of	total	Numb,	Numb	1/2,	Numb	3/4,	Numb	1/3,	Numb	2/4,	Gapdh,	Gusb,	Hprt1,	
Tbp,	using	the	specific	TaqMan	Gene	Expression	Assays.	In	brief,	total	Numb	primers	were	
chosen	to	amplify	a	portion	of	Numb	protein	(spanning	Numb	exon	5-6	boundary)	common	
to	all	Numb	isoforms	(see	Fig.	21,	A	assay).	Hydrolysis	probes	spanning	exon	boundaries	
were	designed	to	specifically	detect	and	amplify	Numb	isoforms	in	which	an	exon	skipping	
event	occurs.	Otherwise	either	one	primer	or	the	probe	were	designed	partially	on	the	exon	
in	order	to	detect	the	exon	inclusion	event	(see	Fig.	30	for	details).	
Inventoried	TaqMan	gene	expression	assays	used	for	the	RT-qPCR	screening	were:	
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Hs01105433_m1	 for	 ‘NUMB	 TOT’	 (NUMB	 isoform-1:	 NM_001005743.1,	 -2:	
NM_001005744.1,	 -3:	NM_003744.5	and	 -4:	NM_001005745.1),	Hs01105434	 for	NUMB	
1/3,	 Hs02800695_m1	 (HPRT1),	 Hs03929097_g1	 (GAPDH),	 Hs99999908_m1	 (GUSB),	
Hs01060665_g1	 (ACTB),	 Hs00963534_m1	 (ALAS1)	 and	 Hs00427621_m1	 (TBP)	 all	 pur-
chased	from	Thermo	Fisher	Scientific.	
The	custom	TaqMan	gene	expression	assays	to	detect	NUMB	1/2	(forw.GATGAATCAAGAG-
GAATGCACATC;	 rev.	 TGAAGAACTTCCTTTCAGCTTTCAA;	 probe:	 TGAAGATGCTGTAAAAAG)	
and	 NUMB	 2/4	 forw.	 TGGCACCACAATCTCCTACCT;	 rev.	 AGGCAGCACCAGAAGATTGAC;	
probe:	CCAAGGGACCGAGTGG)	were	designed	using	the	Primer	Express	Software	V3.0	and	
purchased	from	Thermo	Fisher	Scientific.	The	custom	TaqMan	assay	to	detect	NUMB	3/4	
(forw.	 GAATGCACATCTGTGAAG;	 rev.	 ACTGCTTTAACTGCTTTC;	 probe:	 TTCCAG-
TAGCTTTCAATCTTTT)	was	from	Bio-Rad	Laboratories.	
Ten	cycles	of	pre-amplification	of	cDNA	were	performed	before	RT-qPCR	amplification,	us-
ing	a	pooled	mix	of	the	aforementioned	Taqman	gene	expression	assay	(0.2X	each	assays)	
and	TaqMan	Preamp	Master	Mix	(Thermo	Fisher	Scientific),	according	to	the	following	con-
ditions	(95°C	10	min,	10	cycles:	95°C	15	sec,	58°C	4	min).	The	preamplified	reaction	mix	
(final	volume	50	µl)	was	diluted	1:5	before	quantitative	PCR	amplification	(5	µl	were	used	
for	each	RT-qPCR	reaction).	
RT-qPCR	was	performed	in	a	volume	of	10	µl	in	384-well	plate,	analyzing	each	target	gene	
as	technical	triplicates	according	to	the	following	thermal	cycling	conditions:	polymerase	
activation	1	cycle	at	95°C	for	10	min	followed	by	40	cycles:	95°C	15	sec,	55°C	1	min,	on	the	
Roche	LightCycler®	480	Real-Time	PCR	System.	The	RT-qPCR	output	data	 for	each	gene	
were	analyzed	calculating	the	average	Cq	(AVG	Cq)	of	the	triplicate	values	when	the	stand-
ard	deviation	was	<	0.4,	or	excluding	the	outlier	value	when	the	standard	deviation	was	≥	
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0.4.	AVG	Cq	data	were	normalized	on	the	geomean	of	4	housekeeping	genes	(Hprt1,	Gapdh,	
Gusb,	Tbp).	The	normalized	Cq	(Cq	normalized)	of	each	target	gene	was	calculated	using	
the	following	formula:		
Cq	normalized	=	AVG	Cq	-	SF;		
where:	SF	is	the	difference	between	the	AVG	Cq	value	of	reference	genes	for	each	patient	
and	a	constant	reference	value	K;	K	represents	the	mean	of	the	AVG	Cq	of	the	4	reference	
genes	calculated	across	all	samples	(K	=	24.148).	This	normalization	strategy	allows	the	re-
tention	of	information	about	the	abundance	of	the	original	transcript,	as	measured	by	RT-
qPCR	(i.e.,	in	Cq	scale),	which	is	conversely	lost	when	using	the	more	classical	ΔCq	method.	
We	defined	Cq	=	35	as	the	limit	of	detection	and	Cq	values	beyond	this	limit	were	set	to	35.	
Normalized	data	were	then	processed	for	statistical	analysis.	
For	gene	expression	analysis	and	p53	sequencing	on	primary	breast	tumors	the	DNA/RNA	
was	extracted	using	the	AllPrep	DNA/RNA	Mini	Kit	automated	on	QIAcube	(QIAGEN).	500	
ng	of	RNA	was	retrotranscribed	in	a	reaction	volume	of	20	µl	as	described	before.	ΔΔCt	
method	was	used	to	calculate	relative	fold-changes	normalized	against	5	reference	genes	
(Gusb,	Hprt1,	Tbp,	Alas1,	Actb).	
	
4.4.3 DIGITAL	PCR	
We	performed	ONE	STEP	Droplet	Digital	PCR	(ddPCR)	on	BC	FFPE	samples.	For	droplet	gen-
eration,	we	placed	150	ng	DNA/well	for	each	sample	and	the	appropriate	ddPCR	master	
mix	(ONE	STEP	supermix	or	ddPCR	buffer	control)	and	the	required	assay,	diluted	in	20	µl	
of	final	volume	in	the	middle	row	of	droplet	generator	cartridge	(already	preloaded	in	the	
DG8	cartridge	holder)	while	70	µl	of	droplet	generation	oil	were	loaded	into	the	bottom	
well.	The	prepared	cartridge	holder,	placed	within	a	Q-100	droplet	generator,	allowed	the	
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sample	to	be	partitioned	in	20,000	nanoliter-sized	droplets	for	each	sample.	40	µl	of	wa-
ter/oil	emulsion	droplet	for	each	sample	were	transferred	from	the	top	well	of	the	cartridge	
into	a	96-well	PCR	plate.	The	PCR	plate	was	placed	in	a	thermal	cycler	using	the	following	
thermal	cycling	protocol:	57°C	30	min,	95°C	5	min,	40	cycles	(each:	94°C	30	sec,	57°C	1	min,	
98°C	10	min).	Completed	the	PCR	amplification,	the	plate	was	placed	inside	a	QX100	drop-
let	reader.	Plate	layout	was	set	up	according	experimental	design	using	QuantaSoft	soft-
ware.	After	QX100	droplet	reader	finished	interrogating	all	well	plate,	this	software	was	
also	used	to	analyzed	data	in	each	well	reporting	as	output	the	concentration	(copies/µl)	
of	the	related	target	within	the	sample.	Data	were	normalized	on	the	relative	quantification	
of	one	of	 the	samples.	The	 following	assays	were	used	 (see	Fig.	21):	A	 (Hs01105431),	B	
(Hs01105433_m1),C	 (forward	 primer:	 GCGGTCAAAGGAGCAAAACA;	 reverse	 primer:	
GGGACCTTTGGGATTAGTGAAAA;	probe:	ACTTTGTCTCCTGATTAGTAC	).	
	
4.4.4 DNA	 POLYMERASE-MEDIATED	 PCR	
AMPLIFICATION	AND	AGAROSE	GEL	ELECTROPHORESIS		
We	extracted	DNA	and	RNA	from	two	distinct	pools	of	primary	normal	breast	cells	(3	sam-
ples	each),	from	MCF-10A	non-tumorigenic	breast	epithelial	cells	and	from	seven	primary	
BC	samples	using	the	AllPrep	DNA/RNA	Mini	kit	(Qiagen).	Retro	transcription	of	0.5	µg	RNA	
in	20	µl	of	final	volume	was	performed	using	the	Superscript	VILO	standard	protocol.	Once	
retrotranscribed,	2	µl	of	reaction	volume	were	used	for	PCR	amplification	using	the	follow-
ing	primers	(Fig.	22A):	
Forw.	gcttcccggttaagtaccttggc;	Rev.	tatgaccggcctggaagagac		
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PCR	was	performed	using	GoTaq	DNA	polymerase	(Promega)	according	to	manufacturer’s	
guidelines	and	the	thermal	cycling	protocol	was	adapted	according	to	primer	set	melting	
temperatures	 (Tm).	 Initial	 denaturation	95°C	2	min,	35	 cycles	 (each	 cycle:	denaturation	
95°C	1	min,	annealing	62°C	1	min,	extension	72°C	3	min).	After	amplification,	15	µl	of	PCR	
products	mixed	with	6X	Blue/orange	 loading	dye	 (Promega)	were	directly	 loaded,	along	
with	DNA	marker	(1	Kb	DNA	ladder,	Promega)	into	the	wells	of	a	1%	agarose	gel	in	1X	Tris-
Acetate	EDTA	buffer	(from	50X	TAE:	250	mM	Tris-HCl,	192	mM	Glycine,	2	M	Tris,	1	M	acetic	
acid,	10	mM	EDTA	pH	8)	and	separated	by	gel	electrophoresis.	Gel	Red	(Biotium)	was	added	
1:10000	to	agarose	as	tracking	fluorescent	nucleic	acid	dye	to	visualize	PCR	products	during	
electrophoresis	separation.	DNA	bands	were	visualized	under	a	UV	lamp.	
	
4.4.5 p53	GENE	SEQUENCING	
For	p53	mutational	status	analysis	of	primary	BCs,	the	p53	gene	(NM_000546.4,	10	coding	
exons)	was	sequenced	according	to	standard	procedure.	DNA	was	extracted	through	the	
AllPrep	DNA/RNA	FFPE	Kit	(Qiagen)	from	the	FFPE	BC	samples,	as	described	above	(para-
graph	4.4.1),	and	the	p53	gene	was	PCR	amplified	using	specific	PCR	primers	that	cover	the	
entire	p53	coding	sequence	and	all	exon-intron	boundaries.	Every	forward	and	reverse	pri-
mer	had	a	5'	universal	tail	(PE-21	forward;	M13	reverse).	The	strategy	allows	sequencing	
all	 the	different	amplified	 fragments	with	only	2	 sequencing	primers	 that	 recognize	 the	
universal	tail	sequences	of	PCR	primers.	The	primers	were	designed	with	a	similar	Tm,	so	
that	all	the	different	regions	could	be	amplified	simultaneously	in	isothermal	conditions.	
The	PCR	products	were	purified	with	EXO-SAP	enzymes,	sequenced	with	BigDye	chemistry	
v3.1	and	run	onto	a	3730xl	Sequencer	(Applied	Biosystems).	Data	were	analyzed	with	Mu-
tation	Surveyor	(SoftGenetics).	
 83 
	
5 RESULTS	
 
5.1 EVALUATION	 OF	 THE	 EXPRESSION	 OF	 NUMB	
ISOFORMS	IN	BREAST	CELL	LINES	
	
The	 aim	 of	 this	 thesis	was	 to	 elucidate	 the	 role	 of	 the	 different	 Numb	 isoforms	 in	 the	
regulation	of	p53	and	their	relevance	and	contribution	to	breast	carcinogenesis.	We	used	
two	 different	 human	 breast	 cell	 lines	 as	model	 system	 to	 evaluate	 the	 Numb	 isoforms	
expression:	the	non-transformed	mammary	epithelial	immortalized	cell	line,	MCF-10A,	and	
the	tumor	BT-474	cell	line	derived	from	a	ductal	carcinoma.	
These	cell	lines	are	both	p53-WT	and	represent	breast	cell	line	displaying	an	intermediate-
high	level	of	Numb	expression	compared	to	a	panel	of	breast	cell	lines	analyzed	in	the	lab	
(not	shown).	
As	a	starting	point,	we	evaluated	the	abundance	of	all	Numb	isoforms	in	these	cell	model	
systems.	Nine	different	 splice	variants	of	Numb	have	been	 reported	 (Fig.	21A),	but	only	
isoforms	1	to	4	have	been	described	in	detail	in	the	literature	since	they	are	expressed	in	
many	different	tissues.	To	evaluate	the	levels	of	expression	of	the	Numb	isoforms,	we	used	
digital	PCR	and	three	different	sets	of	Taqman	assays	able	to	recognize	specific	sets	of	Numb	
isoforms:	Assay	‘A’	specific	for	Numb	isoforms	1	to	8	designed	across	the	coding	exons	5-6;	
Assay	‘B’	recognizing	Numb	isoforms	1,	2,	3,	4	and	9	designed	across	the	boundary	of	exons	
7-8;	Assay	‘C’	recognizing	all	nine	isoforms	designed	across	exon	10	(Fig.	21A).	The	digital	
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PCR	analysis	was	performed	on	two	different	amounts	of	cDNA	retrotranscribed	from	RNA	
extracted	from	the	two	cell	lines	(Fig.	21B).	
Fig.	21	Numb	isoforms	1,	2,	3	and	4	are	the	most	abundant	in	the	breast	cell	lines	MCF-
10A	and	BT-474.		
A)	Schematic	representation	of	all	nine	Numb	isoforms	described	as	products	of	alternative	
splicing	 events	 of	 the	 gene.	 Colored	 rectangles	 highlight	 the	 regions	 amplified	 by	 the	
Taqman	assays	(A,	B,	C)	used	in	the	digital	PCR	analysis.	The	coding	exons	are	numbered	in	
red	and	their	length	in	bp	is	indicated	in	black	inside	the	exon	box.	B)	Digital	PCR	analysis	
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was	performed	on	mRNA	isolated	from	MCF-10A	and	BT-474	cells,	using	the	Taqman	assays	
indicated	in	A.	The	results	show	the	number	of	copies/µl	of	each	set	of	isoforms	detected	
by	the	different	assays.	Two	quantities	of	cDNA	for	each	cell	line	was	analyzed	as	indicated	
(ng).	Results	derive	from	a	single	experiment.	
	
In	both	cell	 lines,	 the	number	of	the	molecules	of	 isoforms	1	to	8	 (assay	A)	 is	similar	or	
slightly	higher	than	the	number	of	the	molecules	of	all	isoforms	1	to	9	(assay	C)	in	the	same	
cell	line,	indicating	that	isoform	9	is	not	present	or	is	expressed	in	negligible	amounts	(Fig.	
21B).	Considering	that	also	the	number	of	molecules	recognized	by	assay	B	(Numb	1,	2,	3,	
4	and	9)	is	similar	to	the	number	of	the	molecules	identified	by	the	other	two	assays	in	each	
cell	line	(Fig.	21B),	we	can	conclude	that	the	isoforms	1	to	4	are	the	main	Numb	isoforms	
expressed	in	these	breast	cell	lines,	consistent	with	the	literature.	
To	confirm	the	predominant	expression	of	Numb	isoforms	1	to	4	in	human	breast	tissue,	
we	amplified	the	cDNA	retrotranscribed	from	RNA	extracted	from	primary	human	normal	
and	tumor	breast	tissue,	using	primers	designed	to	amplify	Numb	isoforms	1	to	8	(Fig.	22A).	
The	 PCR	 products	 were	 analyzed	 on	 an	 agarose	 gel	 to	 discriminate	 the	 length	 of	 the	
amplified	DNA	 (Fig.	 22B).	 In	all	 the	 samples,	we	observed	 two	main	bands	>1000	bp	 in	
length	likely	corresponding	to	Numb	isoforms	1	to	4.	Considering	the	very	similar	sizes	of	
isoforms	1	and	3	and	of	isoforms	2	and	4	it	was	not	possible	to	distinguish	between	these	
pairs.	 Indeed,	 in	 MCF-10A	 cells,	 in	 which	 we	 have	 confirmed	 at	 the	 protein	 level	 the	
expression	of	isoforms	1	to	4	(see	Fig.	25C),	we	only	observed	two	main	bands	in	the	PCR	
reaction.	
In	addition	 to	 the	 two	main	bands,	other	 faint	 smaller	bands	were	visible.	These	bands	
might	indicate	the	expression	at	very	low	levels	of	other	Numb	isoforms	(5	to	9)	or	they	
might	represent	incomplete	or	non-specific	products	from	the	PCR	reaction	(Fig.	22B).	
To	summarize,	these	results	suggest	that	the	four	main	Numb	isoforms	(1	to	4)	represent	
the	most	abundant	isoforms	in	tumor	and	normal	breast	cells.	Although,	we	cannot	exclude	
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that	there	might	be	some	breast	tumors	displaying	an	enrichment	of	other	Numb	isoforms,	
we	decided	to	focus	our	study	only	on	the	four	major	Numb	isoforms.	
	
	
Fig.	22	Numb	isoforms	1,	2,	3	and	4	are	the	most	abundant	in	normal	and	cancer	primary	
breast	cells.		
A)	 Schematic	 representation	 of	 exon	 composition	 of	 all	 nine	 Numb	 isoforms,	 with	 the	
positions	 of	 the	 forward	 (fw)	 and	 reverse	 (rv)	 primers	 (red	 arrows)	 used	 for	 the	 PCR	
amplification	shown	in	B.	The	corresponding	length	(bp)	of	the	PCR	products	is	shown	on	
the	right	in	blue.	The	ten	Numb	exons	(numbered	in	red)	and	their	corresponding	size	in	bp	
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(indicated	in	black	inside	the	exon	boxes	of	isoform	1)	are	shown.	B)	Gel	electrophoresis	of	
the	PCR	products	resulting	from	the	reaction	with	primers	shown	in	(A)	on	cDNA	derived	
from	MCF-10A	cells	and	from	primary	normal	breast	cells	(samples	1	and	2;	each	sample	
was	a	mix	of	cells	derived	from	three	different	patients)	and	from	primary	breast	tumor	
cells	(samples	3	to	7	derived	from	individual	tumors).	Reference	DNA	lengths	(bp)	are	shown	
on	the	left.	
	
5.2 ONLY	PTBi-CONTAINING	NUMB	 ISOFORMS	ARE	ABLE	
TO	EFFICIENTLY	BIND	MDM2	
Numb	physiologically	 binds	 to	 and	 inhibits	Mdm2,	 thereby,	 preventing	Mdm2-mediated	
ubiquitination	 of	 p53	 and	 stabilizing	 the	 p53	 tumor	 suppressor	 protein	 63.	 Recent	
biochemical	 and	 structural	 studies	 performed	 in	 our	 laboratory	 on	 the	 Numb-Mdm2	
interaction	surface	have	demonstrated	that	only	the	long	version	of	the	Numb	PTB	domain	
containing	the	stretch	of	11	aa	coded	by	exon	3	(PTBi),	which	is	present	in	isoforms	1	and	
2,	is	able	to	bind	to	Mdm2	in	vitro	136.In	contrast,	the	short	version	of	PTB	lacking	the	11	aa	
sequence	(PTBo)	and	present	in	isoforms	3	and	4,	is	not	able	to	bind	Mdm2	136.	Starting	
from	these	results,	we	reasoned	that	only	the	two	PTBi-containing	Numb	isoforms	1	and	2	
should	be	able	to	directly	bind	Mdm2	 in	vivo,	and,	thus,	to	inhibit	p53	ubiquitination.	To	
test	this	hypothesis,	we	performed	co-immunoprecipitation	experiments	to	investigate	the	
physical	 interaction	of	the	Numb	isoforms	with	Mdm2.	To	overcome	the	problem	of	 low	
basal	 protein	 expression	 and/or	 the	 poor	 affinity	 of	 commercially	 available	 antibodies,	
which	often	hinder	co-immunoprecipitation	experiments,	we	exogenously	expressed	FLAG-
tagged	Numb	isoforms	and	WT	Mdm2	in	the	human	embryonic	kidney	cell	line,	HEK-293,	
which	 is	 known	 for	 its	 high	 transfection	 efficiency.	 We	 performed	 an	 anti-FLAG	
immunoprecipitation	 experiment	 and	 analyzed	 the	 immunoprecipitated	 proteins	 by	
immunoblotting	 (IB)	 with	 anti-FLAG	 and	 anti-Mdm2	 antibodies.	 Results	 revealed	 that	
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Mdm2	 co-immunoprecipitates	 preferentially	 with	 Numb	 isoforms	 1	 and	 2,	 despite	 all	
isoforms	being	expressed	and	immunoprecipitated	at	very	similar	levels	(Fig.	23).		
	
Fig.	23	PTBi-containing	Numb	isoforms	1	and	2	are	able	to	bind	strongly	to	Mdm2.		
Lysates	of	HEK-293	cells	transfected	with	the	FLAG-tagged	human	Numb	isoforms	1	to	4	
and	 with	 WT	 Mdm2	 were	 immunoprecipitated	 (IP)	 with	 the	 anti-FLAG	 antibody	 and	
immunoblotted	 (IB)	as	 indicated.	Total	 lysate	was	0.005%	of	 the	 IP.	Reference	molecular	
weight	(MW)	markers	are	indicated	on	the	right.	s.e.=short	exposure;	l.e.=long	exposure.	
Data	published	in	136.	
 
 
In	 the	 IB,	 we	 observed	 a	 doublet	 for	Mdm2	with	 a	MW	 of	 ~90	 kDa,	 compared	with	 a	
theoretical	MW	of	55	kDa.	While	the	slower	migration	of	Mdm2	in	polyacrylamide	gels	has	
been	already	described,	we	do	not	know	exactly	the	nature	of	the	doublet,	although	it	is	
probably	 due	 to	 a	 post-translational	 modification	 (PTM)	 of	 the	 protein.	 However,	 we	
demonstrated	that	the	Mdm2	antibody	used	is	specific	for	the	protein,	by	interfering	Mdm2	
expression	 in	HEK-293	 cells	with	 siRNA	oligos	 specific	 for	Mdm2	and	 verifying	 in	 IB	 the	
disappearance	of	the	band	upon	silencing	(fig.	24).		
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Fig.	24	Specificity	of	anti-Mdm2	primary	antibody	tested	by	IB	
Lysate	 of	 Hek-293	 cells	 transfected	 with	 Mdm2	 siRNA	 oligo	 (10nM),	 Ctr	 siRNA	 or	 not	
transfected	 cells	 (NT)	 were	 analyzed	 by	 IB	 with	 the	 antibodies	 indicated	 on	 the	 right.	
Vinculin	was	used	as	a	loading	control.	
	
5.3 ONLY	PTBi-CONTAINING	NUMB	 ISOFORMS	ARE	ABLE	
TO	REGULATE	P53	PROTEIN	LEVELS		
	
Numb	is	able	to	protect	the	tumor	suppressor	p53	by	inhibiting	its	ubiquitination	by	Mdm2	
and	consequently	its	degradation	63		(see		paragraph	2.3.4.7).	Considering	that	we	observed	
that	only	Numb	isoforms	1	and	2	bind	strongly	to	Mdm2,	we	tested	the	possibility	that	only	
these	isoforms	might	specifically	be	responsible	for	p53	regulation.	We	decided	to	test	the	
effects	 of	Numb	 silencing	 on	 p53	 protein	 levels	 in	 the	MCF-10A	 cell	 line,	 by	 selectively	
silencing	 Numb	 isoforms	 1	 and	 2,	 isoforms	 3	 and	 4,	 and	 all	 isoforms	 as	 a	 control.	We	
designed	siRNA	oligos	specific	for	each	set	of	Numb	isoforms,	exploiting	the	presence	or	
not	of	exon	3	(Fig.	25A-B	for	details).	After	72	h	from	transfection	of	MCF-10A	cells	with	the	
siRNA	oligos,	we	assessed	p53	protein	levels	by	IB.	We	observed	a	marked	reduction	in	p53	
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levels	upon	depletion	of	Numb	isoforms	1	and	2,	or	of	total	Numb	as	control,	while	no	effect	
was	observed	following	depletion	of	Numb	isoforms	3	and	4	(Fig.	25C).		
	
	
Fig.	25	Only	PTBi-containing	Numb	isoforms	are	able	to	regulate	p53	levels	
A)	Localization	of	siRNA	target	sequences	at	different	positions	along	Numb	mRNA.	The	
siRNA	oligo	to	interfere	the	expression	of	all	Numb	isoforms	(siRNA	TOT,	green)	was	de-
signed	in	a	common	region	of	all	the	four	main	Numb	isoforms.	The	siRNA	targeting	Numb	
isoforms	1/2	 (siRNA	1/2,	 red)	 recognizes	a	 region	within	exon	3,	 retained	specifically	 in	
Numb	isoforms	1/2,	while	the	siRNA	recognizing	Numb	isoforms	3/4	(siRNA	3/4,	black)	was	
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designed	in	a	region	spanning	the	exon	2	and	4	boundary	that	is	created	when	the	exon	3	
skipping	event	occurs.	B)	Efficiency	of	the	interference	of	Numb	isoforms	in	MCF-10A	cells.	
MCF-10A	cells	were	transfected	with	siRNA	oligos	(10	nM)	specific	for	total	Numb	(Tot),	
Numb	1/2	or	Numb	3/4,	as	indicated.	After	72	h,	cells	were	lysed	and	analyzed	by	RT-qPCR	
to	assess	the	efficiency	of	Numb	isoform	silencing.	Each	target	was	analyzed	in	triplicate	
and	the	mean	+	standard	deviation	(sd)	is	shown.	Results	were	normalized	for	each	target	
on	Numb	mRNA	levels	of	control	siRNA	(Ctr)	 transfected	cells.	C)	An	aliquot	of	the	cells	
transfected	as	described	in	B)		were	lysed	and	subjected	to	IB	with	the	indicated	antibodies	
shown	on	the	right.	Control	(Ctr)	siRNA	was	used	as	a	reference	for	basal	Numb	expression.	
Vinculin	was	used	as	a	loading	control.	Numb	protein	appears	as	a	doublet	(upper	band:	
Numb	1	and	3,	72	and	71	kDa	 respectively;	 lower	band:	Numb	2	and	4,	66	and	65	kDa	
,respectively).		
Data	published	in		136	
	
The	efficiency	of	the	siRNA	silencing	was	confirmed	by	RT-qPCR	by	using	Taqman	assays	
designed	to	detect	specifically	the	PTBi-containing	or	-lacking	isoforms	(Fig.	25B).		
We	concluded	that	the	Numb	isoforms	have	different	roles	in	p53	regulation,	with	the	PTBi-
containing	isoforms	(1	and	2)	being	specifically	required	for	p53	stabilization,	in	accordance	
with	their	exclusive	ability	to	bind	the	E3-ligase	Mdm2	(Fig.	23	).	
	
5.4 PTBi-CONTAINING	NUMB	ISOFORMS	AFFECT	THE	P53-
DEPENDENT	RESPONSE	TO	GENOTOXIC	STRESS		
 
In	MCF-10A	cells,	loss	of	Numb	results	in	an	impairment	of	p53	activation	in	response	to	
genotoxic	stress	63,	as	a	consequence	of	the	exaggerated	Mdm2-mediated	degradation	of	
p53	itself	44.	To	verify	whether	the	regulation	of	this	p53	function	is	Numb	isoform-specific,	
we	repeated	the	experiment	of	selective	ablation	of	the	Numb	isoforms	in	MCF-10A	cells,	
and,	72	h	after	transfection,	we	treated	cells	with	increasing	doses	of	cisplatin	for	16	h	(Fig.	
26A).	Cisplatin	acts	as	a	genotoxic	drug	able	to	trigger	p53	activation	in	response	to	DNA	
damage,	as	assessed	by	the	increasing	levels	of	p53,	both	as	total	protein	and	as	the	serine	
15-phoshorylated	activated	form	(Fig.	26A,	Ctr	samples).	The	silencing	of	total	Numb	and	
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Numb	PTBi-containing	isoforms	1	and	2	(see	Fig.	26B	for	silencing	efficiency),	significantly	
reduced	 the	 upregulation	 of	 total	 and	 activated	 p53	 upon	 cisplatin	 treatment,	 as	 also	
confirmed	by	the	reduction	of	the	p53	transcriptional	target,	Mdm2	170,173.	In	contrast,	no	
effect	was	observed	upon	silencing	the	PTBo-containing	Numb	isoforms	3	and	4	(Fig.	26A).		
Based	on	this	result,	we	reasoned	that	an	alteration	of	Numb	isoform	1/2	levels	would	affect	
p53-mediated	functional	responses,	such	as	DNA	damage	repair.	To	test	this,	we	focused	
on	the	known	marker	of	DNA	damage	–	phosphorylation	of	serine	139	of	histone	H2AFX	(γ-
H2AX)	 –	 and	 the	 number	 of	 foci	 positive	 for	 this	marker;	 the	 persistence	 of	 these	 foci	
indicates	that	DNA	damage	has	not	been	repaired	174,175.	MCF-10A	cells	were	silenced	for	
total	Numb	or	for	specific	isoforms	(1/2	and	3/4)	and	then	treated	for	15	h	with	cisplatin	or	
vehicle	in	the	untreated	control	sample.	Cisplatin	was	then	washed	out	and	cells	cultured	
in	fresh	medium	for	a	further	24	hours	to	allow	DNA	repair.	The	untreated	samples,	and	
cisplatin-treated	samples,	before	and	after	washout,	were	analyzed	for	the	number	of	γ-
H2AX	foci	by	IF	(Fig.	27).	As	expected,	after	cisplatin	treatment,	we	observed	an	increase	in	
the	percentage	of	the	cells	with	>10	γ-H2AX	foci	in	all	samples	indicative	of	DNA	damage.	
Upon	washout,	this	DNA	damage	was	repaired	only	in	Ctr	siRNA	or	Numb	3/4	interfered	
samples,	evidenced	by	a	reduction	in	the	percentage	of	the	cells	with	>10	γ-H2AX	foci	(Fig.	
27A).	In	contrast,	cells	silenced	for	total	Numb	or	Numb	isoforms	1/2	did	not	display	DNA	
repair,	with	the	percentage	of	the	cells	with	>10	γ-H2AX	foci	remaining	equivalent	to	that	
observed	in	p53	silenced	cells	(Fig.	27A).	These	data	indicate	that	loss	of	p53,	induced	by	
the	p53	siRNA	or	as	consequence	of	Numb	1/2	silencing,	impairs	the	ability	of	the	cells	to	
repair	DNA	damage	 (Fig.	27	A-B),	 thus	confirming	 the	 role	of	Numb	 isoforms	1/2	 in	 the	
regulation	of	p53	levels	and	activity	and,	consequently,	of	p53-mediated	responses	in	the	
cell.		
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Fig.	26	PTBi-containing	Numb	isoforms	are	able	to	regulate	the	p53	response	to	genotoxic	
stress.	
A)	MCF-10A	cells	silenced	for	the	indicated	Numb	isoforms	(or	with	Ctr	siRNA)	were	treated	
with	increasing	doses	of	cisplatin	for	16	h.	IB	was	performed	using	the	antibodies	indicated	
on	the	right.	p53-pSer15	represents	the	activated	form	of	p53	phosphorylated	on	Ser15.	
Vinculin	was	used	as	a	loading	control.	MW	markers	are	shown	on	the	left.	B)	The	efficiency	
of	Numb	isoform	silencing	in	the	MCF-10A	cells	described	in	A	was	assessed	by	RT-qPCR	
analysis.	Data	represent	the	mean	+	sd	of	technical	triplicates,	normalized	to	the	Ctr	siRNA		
for	each	assay.		
Data	published	in	136.	
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Fig.	27	Numb	PTBi-containing	isoforms	regulate	p53-mediated	DNA	damage	repair	upon	
genotoxic	stress.	
A)	MCF-10A	cells	were	silenced	for	Numb	isoform	expression	as	indicated	in	the	legend	on	
the	right.	Negative	controls	were	transfected	with	siRNA	(Ctr),	while	positive	controls	were	
transfected	with	p53	targeting	siRNAs.	Silenced	cells	were	treated	72	h	after	transfection	
with	vehicle	alone	(Not	treated),	or	cisplatin	(12	µg/ml)	for	15	h	before	washing	out	drug	
and	 culturing	 in	 fresh	medium	 for	 a	 further	 24	 h	 to	 allow	DNA	 repair.	 Cells	were	 then	
analyzed	before	(Cisplatin)	and	after	(Cisplatin	+	24	h	release)	washout	by	IF	using	an	anti-
phosphorylated	 γ-H2AX	 antibody.	 For	 each	 condition,	 ten	 random	 fields	 were	 analyzed	
(from	two	independent	experiments),	counting	the	number	of	γH2AX	foci/cell.	In	each	field,	
we	 calculated	 the	percentage	of	 cells	 displaying	0-1,	 2-10,	 >10	 γH2AX	 foci/nucleus.	 The	
graph	reports	the	mean	+	sd	of	these	percentages	calculated	for	each	condition.	*=	P-value	
£0.01	compared	with	Ctr-siRNA	in	each	group.	B)	Representative	panels	showing	IF	staining	
with	anti-phosphorylated	γ-H2AX	 (red)	and	DAPI	 (blue)	on	 the	MCF-10A	cells	used	 in	A,	
interfered	as	indicated	on	the	right.	Bar=50	µM.	
Data	published	in	136.	
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5.5 LOW	LEVELS	OF	PTBi-CONTAINING	NUMB	 ISOFORMS	
PREDICT	 RESISTANCE	 TO	 GENOTOXIC	 TREATMENT	 IN	
PRIMARY	BCs.	
	
The	previous	result	indicates	that	the	ablation	of	Numb	isoforms	1	and	2	in	MCF-10A	cells	
leads	to	an	impaired	p53-dependent	response	to	genotoxic	stress.	We	reasoned	that	also	
primary	 BCs	 deficient	 in	 Numb	 1/2	 expression	 should	 display	 increased	 resistance	 to	
genotoxic	 stress.	 To	 investigate	 this	 possibility,	 we	 employed	 13	 primary	 mammary	
epithelial	cell	(MEC)	samples	derived	from	breast	tumors	with	a	p53-WT	sequence.	For	each	
sample,	we	evaluated	the	relative	mRNA	levels	of	total	Numb,	Numb	1/2	and	Numb	3/4	
(Fig.	28).			
Cells	were	 treated	with	 cisplatin	 (Fig.	 29A)	or	 cisplatin	plus	Nutlin-3a	 (Fig.	 29B)	 for	 9	h,	
released	 for	 72	 h	 in	 fresh	medium	 and	 then	 analyzed	 for	 their	 viability	 (Fig.	 29A-B).	 A	
significant	 inverse	 correlation	between	 the	mRNA	 levels	 of	Numb	 isoforms	1/2	 and	 cell	
viability	was	observed,	while	no	evident	correlation	could	be	evidenced	with	 the	mRNA	
levels	 of	 Numb	 isoforms	 3/4	 and	 total	 Numb	 (Fig.	 29C).	 To	 understand	 whether	 the	
increased	resistance	to	cisplatin	treatment	in	Numb	1/2-low	BCs	was	due	to	a	lack	of	p53	
response,	we	treated	in	parallel	the	cells	with	Nutlin-3a,	a	known	inhibitor	of	the	Mdm2-
p53	interaction,	in	order	to	restore	p53	levels	independently	of	Numb	levels.	The	treatment	
was	able	to	rescue	sensitivity	to	cisplatin	in	Numb	1/2-low	cells	(Fig	29D),	suggesting	that	
the	effect	 is	mediated	by	p53.	 To	exclude	a	 toxic	effect	of	Nutlin-3a,	we	also	 treated	 in	
parallel	 three	 BCs	 with	 only	 Nutlin-3a,	 and	 observed	 only	 a	 slight	 decrease	 of	 the	 cell	
viability	(Fig.	29B).	
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In	conclusion,	we	demonstrated	that	low	mRNA	levels	of	PTBi-containing	Numb	isoforms	
(1/2)	are	linked	to	increased	resistance	to	genotoxic	treatments	in	primary	BC	cells,	likely	
due	to	the	low	levels	of	p53	in	these	tumors.	
Fig.	28	RT-qPCR	analysis	of	the	mRNA	levels	of	total	Numb,	Numb	1/2	or	Numb	3/4	in	13	
primary	breast	tumors.		
MEC	=	mammary	epithelial	cells.	Data	are	expressed	as	mean	+	sd	of	a	technical	triplicate	
normalized	on	mRNA	levels	MCF-10A	cells	(=	1;	not	shown).	Data	published	in	136.	
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Fig.	29	The	response	of	primary	BC	cells	to	genotoxic	treatment	correlates	with	the	mRNA	
levels	of	Numb	1/2.	
A-B)	Viability	of	the	13	primary	BC	samples	described	in	Fig.	28,	after	9	h	of	treatment	with	
18	μg/ml	 cisplatin	 alone	 (A)	or	 in	 combination	with	10	μM	Nutlin-3a	 (B,	 black	bars),	 or	
Nutlin-3	alone	(B,	red	bars),	and	72	h	of	release	in	fresh	medium.	Data	are	from	a	single	
experiment.	C)	Correlation	between	cisplatin	sensitivity	and	Numb	isoform	expression.	The	
cell	viability	of	the	13	primary	BC	samples	treated	with	cisplatin	alone	after	release	in	fresh	
medium	is	reported	as	a	function	of	the	mRNA	levels	of	Numb	isoforms	1/2	(top),	Numb	
isoforms	 3/4	 (middle)	 or	 total	 Numb	 (bottom,	 Numb-TOT),	 determined	 in	 Fig.	 28.	 R=	
Pearson	 correlation	 coefficient	 and	 relative	p-value	 (P)	 determined	using	 the	 two	 tailed	
Student’s	t	test	are	shown.	D)	Viability	of	primary	BC	cells,	as	a	function	of	Numb	1/2	mRNA	
levels,	 after	 treatment	 with	 cisplatin	 (Cispl)	 or	 cisplatin+Nultin-3a	 (Cispl+Nutl).	 The	 13	
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primary	 BC	 cells	 analyzed	 in	 Fig.	 28	were	 grouped	 according	 to	 the	 level	 of	 Numb	 1/2	
expression	(low,	intermediate	or	high)	defined	as	tertiles	of	expression.	The	data	are	shown	
as	the	average	value	within	these	three	groups	+	sd.	P-values	were	determined	using	two	
tailed	Student’s	 t	 test	 	comparing	to	cisplatin	alone	 in	each	group.	*	=	P	<	0.01.	NS,	not	
significant.	Data	published	in	136.	
	
	
	
5.6 NUMB	ISOFORMS	PREDICT	PROGNOSTIC	OUTCOME	IN	
HUMAN	BCs	
		
We	 reasoned	 that	 low	 mRNA	 levels	 of	 Numb	 isoforms	 1	 and	 2	 in	 BCs,	 in	 addition	 to	
conferring	 resistance	 to	 genotoxic	 agents,	might	 also	 lead	 to	 a	more	 aggressive	disease	
phenotype	and	potentially	drive	a	worse	prognostic	outcome.	This	scenario	would	be	in	line	
with	our	previous	observation	that	low	levels	of	total	Numb	protein	predict	poor	prognosis	
63.	Therefore,	we	decided	to	perform	a	large-scale	screening	of	a	retrospective	case-cohort	
of	 890	 formalin-fixed	 paraffin-embedded	 (FFPE)	 patients	 to	 investigate	 the	 correlation	
between	Numb	 isoform	expression	 and	 clinical	 outcome.	 This	 case-cohort	was	 selected	
from	a	consecutive	cohort	of	2453	BC	FFPE	samples	collected	at	 the	 IEO	between	years	
1997-2000;	the	“IEO	cohort”	and	with	at	least	10	years	of	complete	follow-up	information		
after	surgical	resection	of	primary	BC.		The	clinical	endpoint	was	distant	metastasis,	defined	
as	the	time	from	removal	of	primary	tumor	to	the	appearance	of	distant	metastasis	or	death	
from	BC	as	first	event.	Details	of	the	case-cohort	selection	are	given	in	the	Materials	and	
Methods	 paragraph	 4.2.	 The	 final	 case-cohort	 was	 comprised	 of	 305	 patients	 who	
experienced	distant	metastasis	and	585	patients	that	were	free	of	distant	metastasis	at	10	
years	of	follow	up.	Clinical-pathological	parameters	of	the	“IEO	cohort”	and	the	selected	
case-cohort	are	shown	on	Table	1,	paragraph	4.2.	
To	measure	Numb	isoform	expression	in	the	FFPE	BC	samples	of	the	case-cohort,	we	used	
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RT-qPCR.	Before	performing	this	analysis,	we	assessed	the	specificity	of	the	Taqman	assays	
used	for	Numb	isoform	identification	and	the	potential	bias	introduced	by	the	cDNA	pre-
amplification	step	of	the	RT-qPCR	procedure.	We	used	different	Taqman	assays	specific	for	
the	 detection	 of	 PTBi-containing	 Numb	 isoforms	 (1/2),	 PTBo-containing	 Numb	 isoforms	
(3/4),	exon	9-containing	Numb	isoforms	(1/3)	and	exon	9-lacking	Numb	isoforms	(2/4)	(Fig.	
30A).	RT-qPCR	reactions	performed	using	plasmids	encoding	the	single	Numb	isoforms	as	
templates,	verified	the	specificity	of	these	Taqman	assays	(Fig.	30B).	
	
 
Fig.	 30	 Analysis	 of	 the	 specificity	 of	 the	 Taqman	 assays	 used	 for	 Numb	 isoform	
amplification		
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A)	Schematic	representation	of	target	sequences	recognized	by	Taqman	assays	on	Numb	
mRNA.	 Taqman	 assays	were	 designed	 for	 the	 specific	 detection	 of	 the	 different	 Numb	
isoforms	resulting	from	the	exon	3	(dark	orange)	and	exon	9	(dark	blue)	alternative	splicing	
events.	A	zoom	of	the	exon	3	region	(left)	and	the	exon	9	region	(right)	is	depicted	to	show	
the	positions	of	the	Taqman	assays	for	the	specific	amplification	of	Numb	isoforms	1/2	or	
3/4	(left),	or	Numb	isoforms	1/3	or	2/4	(right).	Forward	primer	(F)	and	reverse	primer	(R)	
localization	is	indicated	by	the	arrows	and	the	position	of	the	probe	is	identified	by	dotted	
lines.	Tot=	Total	Numb,	1/2	=	Numb	isoforms	1	and	2,	3/4	=	Numb	isoforms	3	and	4,	1/3	=	
Numb	isoforms	1	and	3,	2/4	=	Numb	isoforms	2	and	4.	B)	The	specificity	of	the	indicated	
Taqman	assays	(total:	Numb	all,	Numb	1/2,	Numb	3/4,	Numb	1/3,	Numb	2/4)	was	tested	
by	RT-qPCR	analysis	of	pcDNA	vectors	encoding	the	different	Numb	isoforms	(1,	2,	3,	4).	
Empty	pcDNA	(Ctr)	was	used	as	a	negative	control.	The	analysis	was	performed	in	triplicate	
(values	represent	the	mean	+	sd)	using	0.1	pg	of	each	vector.		Data	published	in	136.	
	
	
To	evaluate	the	possible	bias	introduced	by	the	pre-amplification	of	the	cDNA	during	the	
RT-qPCR	 procedure,	 we	 compared	 this	 method	 with	 digital	 PCR.	 This	 latter	 approach	
allowed	 us	 to	 quantify	 the	 amplified	 copies	 in	 absence	 of	 a	 pre-amplification	 step.	We	
extracted	RNA	from	five	FFPE	samples	prepared	from	breast	tumors	and	retrotranscribed	
to	cDNA.	The	RT-qPCR	analysis	(after	cDNA	pre-amplification)	and	the	digital	PCR	analysis	
were	 performed	 in	 parallel.	 Comparing	 these	 two	 techniques,	 the	 trend	 in	 the	 relative	
expression	 levels	 of	 Numb	 isoforms	 was	 maintained	 in	 all	 samples,	 albeit	 with	 some	
quantitative	differences	(Fig.	31).	These	results	confirm	that	the	pre-amplification	step	does	
not	appear	to	affect	the	overall	accuracy	of	the	RT-qPCR	analysis.		
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Fig.	31	Comparison	of	relative	expression	levels	of	Numb	isoforms	detected	by	digital	PCR	
and	RT-qPCR	on	mRNA	extracted	from	FFPE	samples	of	BCs. 
A)	 Relative	 number	 of	 molecules	 of	 the	 Numb	 isoforms,	 or	 total	 Numb	 (Numb	 TOT)	
indicated	on	x-axis,	detected	by	digital	PCR	analysis	on	cDNA	retrotranscribed	from	RNA	
extracted	from	5	FFPE	BC	samples	(1	to	5),	relative	to	sample	1	(assigning	value=1	to	the	
molecule	numbers	of	this	sample).	B)	The	same	samples	as	in	A	were	analyzed	by	RT-qPCR	
after	pre-amplification	of	 the	cDNA.	The	relative	mRNA	expression	 levels,	normalized	 to	
sample	1,	are	shown.	Data	are	expressed	as	the	mean	±	sd	of	technical	triplicate	values.	
	
	
Having	verified	 the	 technical	 set-up	of	 the	assay,	we	proceeded	with	 the	analysis	of	 the	
case-cohort	of	890	BC	patients.	RNA	extracted	from	each	sample	was	retrotranscribed,	pre-
amplified	and	analyzed	for	the	expression	of	total	Numb,	Numb	isoforms	1/2	vs.	3/4,	and	
Numb	 isoforms	 1/3	 vs.	 2/4	 (see	 paragraph	 4.4.2	 for	 details).	 Patients	were	 stratified	 as	
“LOW”	(the	lowest	quintile	of	expression)	and	“HIGH”	(all	the	rest	of	the	quintiles)	for	each	
Numb	category	(Fig.	32-34).		
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We	next	correlated	Numb	status	(LOW	vs.	HIGH)	for	each	Numb	category	(Total,	Numb	1/2,	
Numb	 3/4,	 Numb	 1/3,	 Numb	 2/4)	 with	 the	 prognosis	 of	 BC	 patients	 (Fig.	 32-34).	 The	
prognostic	endpoint	of	the	analysis	was	the	cumulative	incidence	of	distant	relapse	up	to	
10	year	after	the	surgical	removal	of	the	primary	tumor.		
	
	 Concerning	the	analysis	relative	to	the	total	Numb	category,	“LOW”	patients	dis-
played	a	significative	higher	risk	of	distant	relapse	occurrence,	compared	to	the	“HIGH”	
group	(Fig.	32):	in	univariate	analysis	the	HR	=2.22,	p-value	=	<	0.01;	in	multivariable	anal-
ysis	adjusted	for	for	tumor	grade,	Ki-67,	tumor	size,	number	of	positive	lymph	nodes,	age	
at	surgery,	ERBB2	status	and	estrogen/progesterone	receptor	status,	the	HR=1.75,	p-value	
=	0.002.		This	data	is	in	accordance	with	our	previous	results	indicating	that	loss	of	Numb	
protein,	via	hyper-degradation,	correlates	with	poor	prognosis	in	BC	63,44.	Our	results	sug-
gest	that	loss	of	Numb	mRNA	expression	is	an	independent	predictor	of	risk	of	distant	re-
lapse	and can	be	due	in	some	BCs		to	additional	mechanisms	acting	at	the	pre-translational	
level. 
Fig.	32	Low	Total-Numb	status	correlates	with	higher	risk	of	distant	relapse.	
Cumulative	 incidence	of	distant	relapse	 in	a	case-cohort	of	890	BC	patients	according	to	
their	expression	level	of	total	Numb	mRNA	(Numb	TOT).	Univariate	Hazard	ratio	(HR)	was	
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calculated	 using	 univariate	 Cox	 proportional	 hazards	 regression	 model.	 Low,	 lowest	
expression	 quintile:	 High,	 remaining	 four	 quintiles.	 HR=hazard	 ratio;	 P=	 p-value.	 In	 the	
entire	case-cohort	(N=890),	multivariable	analyses	were	adjusted	for	Grade,	Ki-67,	tumor	
size,	 number	 of	 positive	 lymph	 nodes,	 age	 at	 surgery,	 ERBB2	 status	 and	
estrogen/progesterone	receptor	status.	
	
Regarding	the	analysis	of	the	mRNA	levels	of	Numb	isoforms	that	differ	for	the	presence	of	
the	exon	3	sequence	(PTBi-containing	Numb	1/2	vs.	PTBo-containing	Numb	3/4),	we	found	
that	a	“LOW”	Numb	1/2	status	predicts	poor	prognosis	in	a	univariate	analysis	of	the	entire	
cohort:	HR=1.56	,	p=0.01	(Fig.	33A).	When	BCs	were	stratified	according	to	their	p53	status	
(WT	vs.	mutated,	see	Materials	and	Methods,	paragraph	4.3.3.3	for	details),	the	correlation	
with	 Numb	 1/2	 status	 in	 the	 univariate	 analysis	 was	 maintained	 only	 in	 the	 p53-WT	
subgroup	of	patients	(HR=1.72	,	p=0.01),	while	it	disappeared	in	the	mutated	p53	subgroup	
(p53	mut)		(Fig.	33B).	The	significance	of	the	correlation,	in	the	entire	cohort	and	in	the	p53-
WT	subgroup,	was	lost	in	multivariable	analysis	adjusted	for	tumor	grade,	Ki-67,	tumor	size,	
number	of	positive	lymph	nodes,	age	at	surgery,	ERBB2	status	and	estrogen/progesterone	
receptor	status	(Fig.	33B).	However,	when	we	considered	only	the	luminal	subtype	of	BCs,	
which	represents	almost	70%	of	all	BCs	and	are	enriched	in	p53-WT	tumors	176,	a	low	Numb	
1/2	 status	 emerged	 as	 an	 independent	 predictor	 of	 risk	 of	 disease	 recurrence,	 in	
multivariable	analysis,	both	in	the	entire	luminal	subcohort	(HR=1.54	,	p=0.03)	and	in	the	
p53-WT	luminal-subcohort	(HR=1.59	,	p=0.05).	These	findings	are	in	accordance	with	our	
results	 indicating	 an	 increased	 resistance	 to	 genotoxic	 treatments	 in	 the	 primary	 BCs	
displaying	 low	Numb	1/2	 levels	 (Fig.	29),	and	 	argue	that	also	 in	 real	cancers	 the	 tumor	
suppressor	function	of	Numb	1/2	is	directly	linked	to	its	regulation	of	p53.	
In	contrast,	Numb	3/4	expression	levels	did	not	correlate	with	disease	outcome	in	any	case	
(Fig.	33	A,B).		
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	Fig.	33	Expression	of	Numb	1/2	is	an	independent	predictor	of	prognosis	in	luminal-type	
BCs	with	a	p53-WT	status.	
A)	Cumulative	 incidence	of	distant	 relapse	 in	a	case-cohort	of	890	BC	patients	stratified	
according	to	the	mRNA	expression	levels	of	the	indicated	Numb	isoforms.	Group:	Low	(red,	
lowest	quintile	of	expression)	and	High	(black,	remaining	four	quintiles).	Hazard	ratios	(HR)	
nad	P-values	are	shown.	B)	Hazard	ratio	(HR)	of	distant	relapse	(with	corresponding	P-values)	
of	low	vs.	high	Numb	1/2	or	Numb	3/4	patients	in	the	entire	case-cohort	(N=890)	or	in	the	
luminal	subtype	of	BC	(N=666),	further	stratified	for	p53	mutational	status	(WT	or	mutated).	
Univariate	 and	multivariable	 analyses	 are	 calculated	using	 the	Cox	proportional	 hazards	
regression	model.	In	the	entire	case-cohort	(N=890),	multivariable	analyses	were	adjusted	
for	Grade,	Ki-67,	tumor	size,	number	of	positive	lymph	nodes,	age	at	surgery,	ERBB2	status	
and	estrogen/progesterone	 receptor	 status,	while	 in	 the	 luminal	 subtype	of	BC	 (N=666)	
multivariable	analyses	were	adjusted	for	Grade,	Ki-67,	tumor	size,	number	of	positive	lymph	
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nodes	and	age	at	surgery.		Data	published	in	136	
	
	 Finally,	from	the	univariate	analysis	of	the	mRNA	levels	of	Numb	isoforms	that	differ	
for	the	presence	of	the	exon	9	sequence	(Numb	1/3	vs.	2/4),	we	found	that	a	“LOW”	status	
of	both	Numb	1/3	and	Numb	2/4	was	associated	with	a	significant	increase	in	the	incidence	
of	 distant	 relapse,	 both	 in	 the	 entire	 case-cohort	 and	 in	 the	p53-WT	 subgroup	 (for	 low	
Numb	2/4	in	p53-WT	subgroup	there	is	only	a	clear	tendency	but	not	significative)	(Fig.	34).	
However,	in	multivariable	analysis	only	the	Numb	1/3	results	as	independent	predictor	of	
distant	metastasis	occurrence	(Fig.	34B),	both	in	the	entire	case-cohort	and	in	the	p53-WT	
subgroup	(see	discussion).	
	
In	conclusion,	we	found	that	low	mRNA	levels	of	total	Numb	or	Numb	1/2	isoforms,	Numb	
1/3	and	2/4	are	 indicative	of	poor	prognosis	 in	BCs,	whereas	no	 correlation	 came	 from	
Numb	3/4	status.	The	result	was	further	evidenced	in	the	p53-WT	patients,	indicating	an	
effect	 mediated	 principally	 by	 the	 downregulation	 of	 the	 p53	 pathway	 by	 Numb	 1/2	
isoforms.	
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Fig.	34	Low	levels	of	Numb	isoforms	1/3	and	of	Numb	isoforms	2/4	correlate	with	adverse	
prognosis.	
A)	Cumulative	incidence	of	distant	metastasis	in	a	case-cohort	of	890	BC	patients	clustered	
in	two	groups	according	to	the	mRNA	expression	levels	of	the	indicated	Numb	isoforms.	
Group:	Low	(red,	lowest	quintile	of	expression)	and	High	(black,	remaining	four	quintiles).		
Hazard	ratios	and	P-values	are	shown.		
B)	Hazard	ratios	(HR)	of	risk	of	distant	metastasis	(with	corresponding	P-values)	in	low	vs.	
high	Numb	1/3	or	Numb	2/4	patients	in	the	entire	case-cohort	(N=890),	further	stratified	
for	p53	mutational	status	(WT	or	Mut).	Univariate	and	multivariable	analyses	are	calculated	
using	the	Cox	proportional	hazards	regression	model	Multivariable	analyses	were	adjusted	
as	described	in	fig.	32.			
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6 DISCUSSION	
 
	
6.1 THE	ROLE	OF	NUMB	ISOFORMS	IN	THE	REGULATION	OF	
THE	p53	PATHWAY.	
An	organized	picture	of	cancer	hallmarks	was	proposed	in	2000	by	Hanahan	and	Warburg	
in	their	widely	cited	review	177.	The	overwhelming	complexity	of	cancer	biology	was	sys-
tematically	simplified	in	a	few	major	cancer	properties.	They	include	sustaining	prolifera-
tive	signaling,	resisting	cell	death,	evading	growth	suppressors,	enabling	replicative	immor-
tality,	inducing	angiogenesis,	and	activating	invasion	and	metastasis	178.	In	addition	to	these	
established	hallmarks,	coordinated,	aberrant	alternative	splicing	is	emerging	as	a	common	
driver	of	carcinogenesis	and	tumor	progression,	thus,	justifying	its	consideration	as	one	of	
the	cancer	hallmarks	179.	The	vast	majority	of	human	genes,	perhaps	over	94%,	are	alterna-
tively	spliced.	Cancer-associated	genes	can	be	expressed	as	splice	variants	that	either	favor	
or	 counteract	 cancer	 cell	 development.	 Thus,	 deregulation	 of	 alternative	 splicing	 could	
drive	 the	 switch	 towards	 the	 inappropriate	 expression	 of	 multiple	 oncogenic	 splice	
isoforms	147,179.	
Numb	is	among	the	genes	that	encode	for	different	isoform	variants,	deriving	from	
alternative	splicing	events	occurring	at	the	level	of	exon	3	and	exon	9	during	Numb	pre-
mRNA	maturation.	To	date	little	is	known	about	the	specific	roles	of	these	isoforms	(see	
paragraph	2.3.6).	The	interest	of	our	lab	in	Numb	started	from	the	discovery	of	its	tumor	
suppressor	role	 in	breast	cancer	44,	where	loss	of	Numb	was	detected	in	around	30%	of	
cases,	 correlating	with	poor	 prognostic	 outcome	 44,63.	More	 recently,	we	demonstrated	
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how	the	role	of	Numb	in	the	regulation	of	the	Mdm2-p53	circuitry	contributes	to	its	tumor	
suppressor	function	63,	leading	to	p53	downregulation	upon	loss	of	Numb.	In	particular,	a	
detailed	structural	and	biochemical	characterization	of	the	Numb-Mdm2	binding	interface,	
highlighted	a	critical	role	of	a	short	region	of	Numb,	including	the	exon	3-coded	sequence,	
in	the	inhibition	of	the	Mdm2	ubiquitin-ligase	activity	on	p53	136.	As	result	of	alternative	
splicing	 events,	 the	Numb	exon	3	 region	 is	 included	 in	 two	out	 of	 four	Numb	 isoforms	
(Numb	1/2)	suggesting	a	Numb	isoform-specific	role	in	Mdm2-p53	circuitry	regulation.		
In	 this	 thesis,	we	demonstrated	that	only	Numb	 isoforms	1/2	are	 indeed	able	 to	
efficiently	bind	to	Mdm2,	thereby	stabilizing	p53	protein	levels,	as	indicated	by	the	reduc-
tion	of	the	p53	 levels	observed	upon	Numb	1/2	silencing	 in	human	mammary	epithelial	
cells.	
	
p53	tumor	suppressor	function	guarantees	the	ability	of	the	cell	to	respond	to	gen-
otoxic	damage	by	activating	p53-dependent	DNA	repair	or	apoptosis	of	damaged	cells.	Loss	
of	Numb	isoforms	1/2	is	able	to	functionally	mimic	p53	dysregulation,	resulting	in	increased	
resistance	of	cells	to	DNA	damage	stimuli	and	persistence	of	unrepaired	DNA	lesions,	while	
no	effect	was	induced	by	loss	of	Numb	isoforms	3/4,	highlighting	the	importance	of	exon	3	
in	the	p53-dependent	DNA	damage	response.		
We	reasoned	that	levels	of	the	Numb	isoforms	could	therefore	have	an	impact	on	
breast	cancer	sensitivity	to	genotoxic	treatment.	In	this	regard,	analyzing	different	p53-WT	
primary	breast	tumors,	we	found	that	low	Numb	1/2	expression	was	associated	with	an	
increased	resistance	to	genotoxic	agents.	Moreover,	Numb	1/2-low	BCs	can	be	re-sensi-
tized	to	treatment	by	rescuing	p53	levels	with	Nutlin-3a	(an	inhibitor	of	Mdm2).	Of	note,	
Nutlin-3a	is	also	able	to	revert	CSC	expansion	associated	with	Numb-deficient	breast	cancer	
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162.	These	observations	not	only	confirm	the	role	of	Numb	1/2	in	p53	regulation,	but	open	
the	way	to	a	possible	therapeutic	strategy	for	overcoming	resistance	to	chemotherapy	and	
preventing	CSC-driven	tumor	relapse	of	Numb	1/2-low	BCs.	The	extensive	mapping	study	
of	the	Numb-Mdm2	interaction	136	could	be	exploited	for	the	design	of	molecules	that,	by	
mimicking	 the	 Numb	 exon	 3-encoded	 surface	 on	 Mdm2	 could	 rescue	 p53	 function	 in	
Numb-deficient	tumors.	
	
6.2 PROGNOSTIC	 VALUE	 AND	 RELEVANCE	 OF	 THE	 NUMB	
ISOFORM	EXPRESSION	IN	BREAST	TUMORIGENESIS.	
Low	Numb	1/2	expression	levels,	which	confers	resistance	of	BC	cells	to	chemotherapeutic	
treatment,	is	linked	to	a	more	aggressive	disease	and	poor	prognosis,	as	emerged	from	our	
screening	on	a	case-cohort	of	890	BC	patients.	Interestingly,	by	stratifying	patients	accord-
ing	to	p53	mutational	status,	we	were	able	to	unmask	the	prognostic	role	of	low	Numb	1/2	
specifically	 in	p53-WT	BCs.	These	 results	 further	 support	 the	 idea	 that	 the	 relevance	of	
Numb	1/2	 isoform	expression	 in	BC	 is	mainly	attributable	 to	 the	 regulation	of	p53.	 It	 is	
plausible	that	in	tumors	where	p53	is	already	deregulated	or	not	functional	(due	to	muta-
tions	of	the	gene	for	instance),	the	downmodulation	of	Numb	1/2	levels	would	not	provide	
an	additional	growth	advantage	or	contribute	significantly	to	the	adverse	prognostic	out-
come.	These	results	are	particularly	interesting	since	BCs,	compared	to	other	tumors,	dis-
play	a	relatively	lower	p53	mutation	rate	172,	in	particular,	among	luminal	subtype	cases,	
which	are	described	to	be	largely	p53-WT	176.		
In	luminal	BCs,	or	more	widely	in	p53-WT	BCs,	p53	dysfunction	might	depend	on	indirect	
mechanisms	that	lead	to	p53	inactivation.	Among	these	mechanisms,	loss	of	ARF	(Mdm2	
inhibitor)	180	and	MDM2	gene	amplification	181	result	in	decreased	p53	activity.	However,	
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these	alterations	are	infrequent	in	BC,	being	detected	in	20%	and	10%	of	tumor	cases,	re-
spectively	182,183.	 In	this	thesis,	we	propose	that	the	altered	alternative	splicing	of	Numb	
exon	3,	might	be	an	additional	mechanism	impacting	on	p53	stability	in	p53-WT	BCs.	In-
deed,	a	low	Numb	1/2	expression	has	an	even	stronger	prognostic	value	in	luminal	BCs	and	
emerges	as	an	independent	predictor	of	poor	prognosis	in	these	tumors.	
	
A	more	 complex	 scenario	 emerged	 from	 the	 analysis	 of	 the	mRNA	 levels	 of	 the	Numb	
isoforms	in	the	BC	case	cohort.	In	particular,	in	tumors	displaying	low	levels	of	all	the	Numb	
isoforms	(Numb	total	low),	we	observed	a	worse	prognosis,	with	an	effect	even	stronger	
than	we	found	in	Numb	1/2	low	BCs.			
Until	now,	the	best	characterized	mechanism	underlying	the	alteration	of	Numb	expression	
in	 Numb-deficient	 BCs	 has	 been	 represented	 by	 post-translational	 events	 causing	 en-
hanced	 ubiquitination,	 and	 ensuing	 proteasomal	 degradation,	 of	 the	 Numb	 protein	 44.	
However,	our	results	demonstrate	that	also	pre-translational	deregulation	of	Numb	might	
be	an	additional	mechanism	responsible	for	loss	of	Numb	in	some	BCs.	In	order	to	better	
stratify	the	BC	patients	according	the	mechanism	responsible	of	Numb	deficiency	we	are	
planning	to	characterize	the	case-cohort	by	IHC	for	the	expression	of	Numb	protein.	The	
combined	analysis	of	Numb	mRNA	and	protein	levels	will	provide	a	more	complete	scenario	
about	the	alteration	present	in	the	Numb	deficient	patients,	thus	accordingly	directing	a	
more	precise	targeted	therapeutic	approach.	
	
To	complete	the	picture,	we	also	observed	a	worse	prognosis	in	BC	patients	display-
ing	low	expression	levels	of	Numb	1/3	and	Numb	2/4	(with	or	without	the	region	coded	by	
exon	9,	respectively),	while	no	significant	effect	was	found	for	low	levels	of	Numb	3/4	(the	
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isoforms	without	the	exon	3	coded	region).	It	is	likely	that	the	prognostic-predictive	effect	
for	Numb	1/3	and	2/4	is	driven	by	loss	of	Numb	1	or	2	respectively,	having	demonstrated	
their	relevance	in	p53	regulation.		
Low	Numb	1/3	emerges	in	particular	as	an	independent	predictor	of	prognosis	in	the	anal-
ysis	of	the	entire	case-cohort	and	specifically	in	the	p53-WT	subgroup	of	patients.	This	re-
sult	is	prompting	us	to	further	investigate	the	role	of	the	single	Numb	isoforms	in	BC.		It	is	
clear	 that	 the	 impact	on	 the	 tumorigenesis	 (and	 consequently	on	 the	prognosis)	of	 the	
Numb	isoforms	might	derive	from	a	combination	of	the	multiple	pathways	regulated	by	
Numb	and	for	a	fully	comprehension	of	the	prognostic	values	of	the	Numb	isoforms	will	be	
necessary	to	better	elucidate	the	precise	contribution	of	each	individual	Numb	isoform	to	
cellular	processes.	For	instance	some	studies	have	highlighted	a	differential	role	of	Numb	
1/3	vs.	Numb	2/4	in	Notch	signaling	regulation,	in	particular	in	the	neuronal	lineage	20	and	
further	investigations	are	necessary	to	uncover	possible	isoform-specific	functions	in	other	
Numb-regulated	pathways,	such	as	Hedgehog	signaling.	The	impact	on	tumorigenesis	and	
prognosis	could	be	ascribable	to	the	balance	of	the	different	pro-	e	anti-tumorigenic	path-
ways	controlled	by	the	single	Numb	isoforms.	In	this	regard,	it	is	interesting	to	remark	how	
the	loss	of	all	the	Numb	isoforms	(observed	with	the	total	Numb	mRNA	levels)	showed	the	
strongest	predictive	value	of	poor	prognosis	in	BCs.		
	
In	the	near	future,	we	are	planning	to	further	characterize	the	function	of	Numb	isoforms	
1	to	4,	individually,	having	demonstrated	that	they	are	the	main	Numb	isoforms	present	in	
breast	cells.	To	this	purpose,	we	have	set	up	an	‘artificial’	Numb-deficient	cellular	model	
system,	MCF-10A	cells	stably	silenced	for	Numb,	in	which	we	plan	to	re-express	each	single	
isoform	to	study	their	specific	contribution	to	signaling	pathways	epistatically	controlled	by	
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Numb	(e.g.,	Notch,	Hedgehog,	p53)	and	phenotypes	involved	in	tumor	progression,	such	as	
proliferation,	response	to	genotoxic	stress,	stem	cell	homeostasis	and	migration.	
Moreover,	it	will	be	interesting	to	understand	how	and	whether	the	different	subcellular	
localizations	of	the	Numb	isoforms,	that	has	been	observed	in	some	cellular	systems19,156,	
might	be	linked	to	their	role	in	controlling	different	pathways	and	whether	also	the	endo-
cytosis	participates	in	the	regulation	of	p53,	considering	that	Numb	has	been	described	as	
an	endocytic	protein	21,2 .	
	
6.3 THE	MULTIPLE	WAYS	LEADING	TO	NUMB	DYSFUNCTION	
IN	 TUMORS	 AND	 THE	 POSSIBLE	 THERAPEUTIC	
INTERVENTIONS.	
The	scenario	that	is	emerging	to	explain	Numb	deficiency	in	BC	seems	to	be	complex	and	
to	involve	multiple	layers	of	deregulation.	The	deregulation	of	Numb	stability	by	post-trans-
lational	ubiquitination	and	degradation	is	only	one	of	the	possible	mechanisms	responsible	
for	Numb	deficiency.	In	this	context,	an	obvious	possibility	is	that	the	genetic	lesion	respon-
sible	for	the	excessive	Numb	degradation	leads	to	the	enhanced	activity	of	an	E3	ligase,	
reduced	activity	of	a	deubiquitinating	enzyme	(DUB),	or	to	the	deregulation	of	signaling	
molecules	regulating	the	ubiquitination	machinery,	e.g.,	kinases,	phosphatases,	and	ned-
dylating	 enzymes.	 Consistent	with	 this	 hypothesis,	 different	 E3-ligases,	 such	 as	 LNX	 184,	
Siah-1	185,	Mdm2	186	and	NAK	serine/threonine	kinase	187	have	been	associated	with	the	
modulation	of	Numb	levels.	Whatever	the	case,	the	therapeutic	restoration	of	Numb	func-
tion	might	in	principle	be	achieved	by	pharmacologically	inhibiting	the	enzyme(s)	respon-
sible	for	its	degradation.	
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The	 current	 study	defines	new	 layers	 in	 the	 regulation	of	Numb	 functions.	We	demon-
strated	that	also	upstream	mechanisms	related	to	pre-translational	deregulation	could	be	
associated	with	loss	of	all	or	some	specific	Numb	isoforms	in	BCs,	thus,	affecting	BC	aggres-
siveness.	Low	Numb	total	mRNA	levels	could	be	dictated	by	different	mechanisms	ranging	
from	deregulation	of	the	transcription	machinery	to	the	oncogenic	activity	of	some	miRNA,	
such	as,	miR-146a	and	miR-34,	which	have	been	described	to	target	Numb	and	suppress	its	
expression	188,189.	The	relevance	of	Numb	transcriptional	deregulation	has	emerged	also	
recently	in	the	prostate	cancer	context,	where	Numb	mRNA	downregulation	is	negatively	
associated	with	prostate	cancer	progression	159.		
The	elucidation	of	the	transcription	factors	or	miRNAs	involved	in	the	pre-translational	reg-
ulation	of	Numb	might	pave	the	way	to	the	identification	of	new	therapeutic	targets	for	
restoring	Numb	levels	in	Numb-deficient	tumors.	In	particular,	we	plan	to	evaluate	whether	
miR-146a,	miR-34	and	other	miRNA	candidates	predicted	to	target	Numb	mRNA,	display	a	
differential	expression	in	a	panel	of	breast	tumors	expressing	low	or	high	mRNA	levels	of	
total	Numb.	
	
Concerning	the	alterations	 in	Numb	alternative	splicing,	our	findings	are	consistent	with	
the	aforementioned	role	of	the	aberrant	functionality	of	the	splicing	machinery	in	onco-
genesis	and	are	prompting	us	to	investigate	the	biological	mechanisms	regulating	the	bal-
ance	of	Numb	isoforms.	Although	some	splicing	factors,	such	as	RBM	4/5/6/10	have	been	
implicated	in	regulation	of	Numb	exon	9	AS	151,153,	the	investigation	remains	open,	in	par-
ticular,	for	the	discovery	of	regulators	that	dictate	the	Numb	exon	3	AS,	with	the	conse-
quent	impact	on	the	p53	regulation.		
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Together	the	results	of	this	thesis	depict	a	more	complex	scenario	to	explain	the	loss	of	
Numb	function	 in	BCs,	where	probably	multiple	mechanisms,	ranging	from	proteasomal	
hyperdegradation	 to	 deregulated	 Numb	 mRNA	 transcription	 and	 alternative	 splicing,		
might	be	responsible	for	the	altered	Numb-regulated	pathways	observed	in	these	BCs,	such	
as	p53	and	Notch	signaling.	The	identification	of	all	the	molecular	players	involved	will	be	
important	to	find	new	possible	therapeutic	strategies	for	the	treatment	of	the	Numb-defi-
cient	BCs.	
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